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I. RESUMEN 
INTRODUCCIÓN: 
 
La anemia de Fanconi (AF) es una enfermedad compleja y muy heterogénea, que se 
describió por primera vez en 1927. La característica principal de esta enfermedad es el 
fallo de médula ósea. La AF se caracteriza también por anomalías en el desarrollo y por 
una alta predisposición a la aparición de tumores hematológicos, principalmente 
leucemia mieloide crónica, y también sólidos, particularmente carcinoma escamoso de 
cabeza y cuello y ano-genital (Howlett et al. (2005); (Kee and D'Andrea, 2012).  
 
La AF está causada por mutaciones en cualquiera de los 16 genes AF descritos hasta la 
fecha, (FANCA, B, C, D1/BRCA2, D2, E, F, G, I/BRIP1, J, L, M, N/PALB2, O/RAD51C, P/SLX4 y 
Q/XPF), los cuales siguen un patrón de herencia autosómica recesiva, a excepción del gen 
FANCB, cuya herencia está ligada al sexo. Estos genes participan en la ruta AF/BRCA, la 
cual se divide en tres complejos: el complejo  formado por las proteínas del “core” de AF; 
el complejo ID; y un tercer complejo que actúa por debajo de los dos complejos 
anteriores. Esta ruta está implicada en la regulación de la reparación del ADN, y es 
esencial para la reparación de los entrecruzamientos en las cadenas del DNA producidos 
por agentes entrecruzantes (Adam et al., 2003; Fanconi anaemia/Breast cancer, 1996; 
Kee and D'Andrea, 2010; Meetei et al., 2004; Meetei et al., 2005; Smogorzewska et al., 
2007; Strathdee et al., 1992).  
 
La severidad de la enfermedad es variable en función del gen AF mutado, así como 
también del tipo de mutación y del propio paciente. El gen que es responsable de la 
enfermedad en la mayor parte de los pacientes AF es FANCA, que participa en el primer 
complejo de la ruta. Mutaciones en genes como FANCD1/BRCA2, localizado por debajo de 
los dos primeros complejos de la ruta, implican una mayor severidad de la enfermedad, 
muy probablemente porque la proteína BRCA2 está implicada en la reparación del ADN 
mediante recombinación homóloga directa (HDR).  
 
A nivel celular, las células afectadas por AF presentan un fenotipo característico. Así, estas 
células son hipersensibles a una variedad de agentes endógenos (aldehídos, oxígeno, 
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citoquinas inflamatorias), y también exógenos (agentes entrecruzantes del ADN, 
radiaciones ionizantes…). Existe controversia sobre si este fenotipo es consecuencia de la 
inestabilidad genómica de las células AF, de deficiencias en el sistema de reparación del 
ADN  o de desequilibrios del metabolismo del oxígeno, aunque probablemente sea una 
combinación de todos estos mecanismos lo que determina el fenotipo de AF (Pagano et 
al., 2013); (Pallardo et al., 2010). 
 
En la actualidad, el único tratamiento curativo para el fallo de médula ósea de pacientes 
AF, es el trasplante de células madre hematopoyéticas a partir de un donante compatible 
sano o portador de la enfermedad. En el caso de los pacientes AF, la complejidad de estos 
trasplantes es mayor a la que tiene lugar en otro tipo de pacientes, debido a la 
hipersensibilidad de las células y tejidos de los pacientes AF a los agentes utilizados para 
su acondicionamiento pretrasplante. Una opción terapéutica para pacientes con AF que 
no dispongan de un donante adecuado, sería la terapia génica  (Rio et al., 2008). La 
principal población celular afectada en esta enfermedad es la de las células madre 
hematopoyéticas (CMHs). Por tanto, la introducción de una copia correcta del gen AF 
defectivo en las CMHs del paciente daría a estas células una ventaja proliferativa sobre las 
CMHs no transducidas. De este modo, la transducción de las CMHs del paciente con el 
vector terapéutico podría dar lugar a CMHs libres de enfermedad, y finalmente a células 
hematopoyéticas diferenciadas que repoblarían el sistema hematopoyético del paciente, 
resolviendo por tanto, el fallo de médula ósea.  
 
El desarrollo de estrategias de terapia génica requiere cierto número de CMHs de partida 
para ser transducidas con el vector terapéutico. Se contempla que ésta será una de las 
limitaciones para que la terapia génica convencional pueda ser utilizada en un elevado 
número de pacientes con AF. Ello deriva de la observación de que una vez desarrollado el 
fallo de médula ósea, el número de CMHs presentes en la médula ósea es muy reducido, 
y en general de mala calidad.  
 
Como alternativa a la utilización de CMHs para la terapia génica de la AF, en el año 2006 
se abrió un amplio horizonte de oportunidades gracias al desarrollo de la tecnología de 
reprogramación celular. Con ello era posible obtener células con pluripotencia inducida 
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(iPSCs) a partir de células adultas diferenciadas mediante la transducción de unos pocos 
genes (Yamanaka and Takahashi, 2006). Esta tecnología constituye una fuente de células 
muy prometedora en enfermedades que cursan con fallo de médula ósea, puesto que 
facilitaría la generación de un elevado número de CMHs autólogas corregidas 
genéticamente, que se podrían utilizar para la reinfusión del paciente. En este sentido, en 
un trabajo previo desarrollado por nuestro laboratorio, en colaboración con el Centro de 
Medicina Regenerativa de Barcelona y la Universidad Autónoma de Barcelona, se 
demostró la posibilidad de obtener in vitro progenitores hematopoyéticos libres de 
enfermedad procedentes fibroblastos reprogramados de la piel de pacientes con 
mutaciones en los genes FANCA y FANCD2 (Raya et al., 2009). 
A diferencia de lo que ocurre con estos genes, BRCA2 es uno de los genes AF localizados 
aguas abajo en la ruta AF/BRCA, y cuya deficiencia da lugar a un fenotipo más severo de la 
enfermedad. En el año 2000 se generó un modelo de ratón con mutaciones hipomórficas 
en el gen Brca2/Fancd1. Este modelo, caracterizado en nuestro laboratorio (Navarro et 
al., 2006), es uno de los que mejor reproduce el fenotipo hematopoyético característico 
de la FA, y ha constituido el modelo experimental con el que hemos desarrollado una 
gran parte del trabajo que se presenta. 
 
 
 
JUSTIFICACIÓN Y OBJETIVOS: 
 
Puesto que hasta la realización de nuestro trabajo se desconocía cuál era la relevancia del 
gen Brca2 en reprogramación celular, el primer objetivo de esta Tesis fue investigar 
comparativamente la relevancia de dicho gen, frente a Fanca, en el proceso de 
reprogramación celular. Para ello utilizamos células adultas y embrionarias procedentes 
de los modelos de ratón Brca2 y Fanca-/-.  En segundo lugar nos propusimos 
desarrollar un protocolo combinado de terapia génica y reprogramación celular para la 
generación de iPSCs corregidas genéticamente, las cuales serían sometidas a un proceso 
de diferenciación hematopoyética, con objeto de generar una fuente abundante de CMHs 
libres de la enfermedad. Por último nos propusimos explorar la posibilidad de utilizar 
estas células diferenciadas para corregir los defectos hematopoyéticos que caracterizan a 
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los ratones Brca2Δ27/Δ27 mediante trasplante de las mismas en ratones afectados por la 
enfermedad.  
 
RESUMEN DE RESULTADOS: 
La generación de iPSCs mediante la transducción de células Fanca-/- y Brca2Δ27/Δ27 con 
vectores gamma retrovirales portadores de cuatro factores de reprogramación mostró 
que los genes Fanca y Brca2 juegan un papel importante en el proceso de 
reprogramación de fibroblastos adultos. Sin embargo, Brca2 mostró un papel mucho más 
crítico que Fanca en tal proceso, puesto que la deficiencia de Brca2 no permitió la 
activación de los genes endógenos de pluripotencia, ni por tanto, la obtención de células 
con características de iPSCs. 
La corrección del defecto genético en fibroblastos embrionarios de ratones Brca2Δ27/Δ27, 
seguido de su transducción con un vector lentiviral de reprogramación  policistrónico y 
escindible permitió la reprogramación eficaz de células sin mutaciones en genes AF o de 
células con mutaciones en el gen Fanca, pero no de células Brca2Δ27/Δ27.  
El análisis de formación de focos de reparación de la proteína RAD51 después de la 
transducción con el vector de reprogramación de células sin mutaciones en genes AF o 
con mutaciones en el gen Fanca, demostró la activación del proceso de HDR durante el 
proceso de reprogramación celular. Sin embargo, en células Brca2Δ27/Δ27 la formación de 
focos de RAD51 no se vio aumentada durante la reprogramación celular. Estos resultados 
explican el papel crítico que juega tanto la proteína BRCA2 como el proceso de HDR 
durante la reprogramación celular. 
Puesto que durante la reprogramación de células Brca2Δ27/Δ27 se produjo un incremento 
en la apoptosis temprana y tardía de estas células, proponemos que la inducción de tales 
efectos serían responsables, al menos en parte, de la muy baja eficiencia de 
reprogramación que caracteriza a estas células.  
Las caracterización molecular y funcional de iPSCs procedentes de fibroblastos 
embrionarios de genotipo Brca2Δ27/Δ27 corregidos genéticamente permitió observar que 
estas células cumplían la mayor parte de los criterios para ser considerados “bona fide- 
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iPSCs”, aunque no fueron capaces de generar teratomas tras su implantación subcutánea 
en ratones inmunodeficientes. La escisión completa del casete de reprogramación 
permitió, sin embargo, la generación de teratomas con células diferenciadas a las tres 
capas embrionarias y en consecuencia la obtención de células iPSC completamente 
reprogramadas (“bona fide-iPSCs”). Las  iPSCs de genotipo Brca2Δ27/Δ27 corregidas 
genéticamente expresaban el ARNm de BRCA2, eran capaces de traslocar la proteína 
RAD51 a los foci de reparación del ADN y además eran resistentes a concentraciones de 
mitomicina C que resultaban altamente tóxicas en células AF.  
La caracterización de la ploidía y cariotipo de estas iPSCs mostró que a pase 17, 
únicamente dos clones mantenían un contenido de ADN diploide y un cariotipo normal. 
Tras la escisión del vector de reprogramación, un subclón que fue seleccionado por 
mantener un cariotipo normal también mostró inestabilidad genética a la vista de las 
alteraciones observadas en estudios de hibridación genómica comparada. El origen de 
estas anomalías no pudo ser determinado, ya que pudo deberse tanto al proceso de 
reprogramación, como al mantenimiento en cultivo durante largos periodos o al proceso 
de escisión del provirus reprogramador. 
Finalmente, la diferenciación hematopoyética de iPSCs de genotipo Brca2Δ27/Δ27 
corregidas genéticamente mediante diferentes aproximaciones experimentales descritas 
en la literatura, permitió la producción de células que expresaban marcadores 
característicos de células hematopoyéticas. No obstante, esta diferenciación resultó 
modesta, y el trasplante de estas células en ratones Brca2Δ27/Δ27 no consiguió reconstituir 
su sistema hematopoyético. 
 
CONCLUSIONES DERIVADAS DE ESTE TRABAJO: 
 
A la vista del trabajo realizado podemos decir que la ruta FA/BRCA juega un papel 
importante en el proceso de reprogramación celular, siendo BRCA2 una proteína crítica 
para la generación de células con pluripotencia inducida. Nuestros resultados también 
demostraron que durante la reprogramación celular se produce la activación de 
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reparación la del ADN mediante recombinación homóloga directa, lo que se midió 
mediante el reclutamiento de la proteína RAD51 a los foci de reparación del ADN en 
respuesta a la reprogramación. 
El incremento en la apoptosis detectado durante los primeros estadios de la 
reprogramación celular podría  ser responsable de la limitada reprogramación en células 
Brca2Δ27/Δ27. La complementación génica de las células Brca2Δ27/Δ27  con el vector portador 
del gen terapéutico, restauró la capacidad de éstas para reclutar la proteína RAD51 a los 
foci y permitió la reprogramación de estas células.  
La transducción de fibroblastos Brca2Δ27/Δ27 corregidos genéticamente con cuatro 
vectores retrovirales portadores de los genes de reprogramación no permitió la 
generación de iPSCs que cumplieran todos los criterios de reprogramación. Sin embargo, 
la utilización de un vector lentiviral de reprogramación policistrónico, seguido de la 
completa escisión del provirus reprogramador permitió generar iPSCs bona fide sin 
fenotipo FA. 
Finalmente, los protocolos de diferenciación hematopoyética in vitro basados en la 
transducción con HOXB4, seguido de la generación de cuerpos embrionarios y co-cultivo 
sobre estromas hematopoyéticos permitió una diferenciación modesta de iPSC 
cBrca2Δ27/Δ27 hacia el sistema hematopoyético. Estas células no fueron capaces de injertar 
en ratones Brca2Δ27/Δ27 irradiados, lo que indica una generación deficiente de células 
hematopoyéticas repobladoras en estos cultivos.  
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II. SUMMARY 
INTRODUCTION: 
Fanconi anemia (FA) is a complex and heterogeneous disease that was described for the 
first time in 1927. It is characterized by developmental abnormalities, cancer 
predisposition and bone marrow failure (BMF), being the BMF the most frequent cause of 
death of these patients.  
 
FA is caused by mutations in any of the 16 FA genes described so far (FANC-A, B, C, 
D1/BRCA2, D2, E, F, G, I/BRIP1, J, L, M, N/PALB2, O/RAD51C, P/SLX4, Q/XPF). All of them 
except FANCB follow an autosomal recessive inheritance (Adam et al., 2003; Fanconi 
anaemia/Breast cancer, 1996; Meetei et al., 2004; Meetei et al., 2005; Smogorzewska et 
al., 2007; Strathdee et al., 1992). These genes participate in the FA/BRCA pathway, that 
regulates several DNA repair pathways and is essential to resolve DNA interstrand-
crosslinks (ICLs) produced by ICL agents (Kee and D'Andrea, 2010). This pathway is 
composed of three different complexes, the “core complex”, the “I-D complex” and 
“downstream proteins”. 
 
The severity of the disease varies depending on the mutation. FANCA is the most 
frequently mutated FA gene, and participates in the first complex of the pathway. 
Mutations in genes such as FANCD1/BRCA2, localized in the third complex, result in a 
stronger severity of the disease, most probably because BRCA2 directly participates in the 
homology directed DNA repair (HDR).  
 
At a cellular level, FA cells have a characteristic response to certain endogenous 
(aldehydes, oxygen, inflammatory cytokines) and/or exogenous (ICL-agents, ionizing 
radiation…) agents. There is controversy about what causes the FA phenotype. While 
some authors support the idea that the phenotype of these cells is consequence of a 
defective ICL-DNA damage repair system that leads to the accumulation of genomic 
instability and damaged DNA, others relate the FA phenotype to an increased oxidative 
stress and imbalances in the oxygen metabolism. It is not clear yet what causes the FA 
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phenotype but most probably a combination of both mechanisms will be responsible for 
it.  
 
There are several palliative treatments for the hematopoietic affectation of FA patients, 
mainly based on the use of androgens and growth factors. The only current curative 
treatment for the BMF of FA patients is the hematopoietic stem cell transplantation 
(HSCT) from a compatible donor. This approach is limited to FA patients with an HLA-
compatible donor and has particular difficulties compared to transplants in other patients 
due to sensitivity of FA cells to conditioning regimes used for HSCT. 
 
Gene therapy is one of the most promising new therapeutic approaches to overcome the 
BMF in FA in patients without an HLA-identical donor (Rio et al., 2008). The insertion of a 
correct copy of the defective gene in the affected cells (HSCs) by gene therapy would give 
them a proliferative advantage over the defective cells. Thus, the transduction of a small 
number of HSCs with the therapeutic vector could give rise to disease-free HSCs, and thus 
to the whole progeny of differentiated cells that would restore the hematopoietic system 
(Qasim et al., 2007).  The development of gene therapy strategies requires a minimum 
number of cells to be transduced with the therapeutic vector. This is one of the handicaps 
of conventional FA gene therapy, because once the BMF has been developed, the number 
and quality of HSCs in the bone marrow is markedly reduced. For this reason, the 
possibility of having an unlimited source of HSCs to perform gene therapy in BMF diseases 
would be of marked relevance.  
In 2006, a new horizon to the field of gene cell therapy opened was opened thanks to the 
development of the cell reprogramming technology (Yamanaka and Takahashi, 2006). 
This technology would allow the generation of high numbers of gene-corrected 
autologous iPSC-derived HSCs to infuse them into patients suffering from BMF 
syndromes.   
 
In this respect, a previous work carried out by our laboratory, in collaboration with the 
Centre of Regenerative Medicine in Barcelona and with the Autonomous University of 
Bacelona, demonstrated the possibility of generating disease-free hematopoietic 
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progenitors from reprogrammed skin fibroblasts obtained from patients with mutations 
in FANCA and FANCD2 (Raya et al., 2009). 
In contrast to proteins encoded by these genes, BRCA2 is localized downstream in the 
FA/BRCA pathway, and its deficiency gives rise to a disease with a more severe phenotype 
compared to patients with mutations in other FA genes. In 2002 (McAllister et al., 2002a),  
K. McAllister developed a mouse model with hypomorphic mutations in Brca2/Fanc1 
gene. This model was characterized in our laboratory (Navarro et al., 2006) and is one of 
the models that best reproduces the hematopoietic phenotype characteristic of FA. This 
experimental model (Brca2) has been used along the present work.  
 
OBJECTIVES: 
Until our work was developed, the relevance of Brca2 in cell reprogramming was 
unknown. For this reason, the first objective of this thesis was to investigate the 
relevance of Brca2, compared with Fanca, in the cell reprogramming process required to 
generate iPSCs. For this purpose, cells from Fanca-/- and Brca2 mouse models were 
used. Our next purpose consisted on the development of a combined gene therapy and 
cellular reprogramming protocol that would result in the generation of gene-corrected 
Brca2 iPSCs. These cells would be then differentiated towards the hematopoietic 
system aiming to generate large numbers of disease-free HSCs. Lastly, we explored the 
possibility of using these cells to correct the hematopoietic defects that characterize 
Brca2mice 
 
RESULTS: 
The  reprogramming of uncorrected and gene-corrected Fanca-/- and Brca2Δ27/Δ27 
fibroblasts gamma-retroviral vectors individually harbouring the Oct-4, Sox2, Klf-4 and c-
myc showed that Fanca and Brca2 genes play important roles in cell reprogramming. 
Brca2 was, however, markedly more critical in cell reprogramming as no activation of the 
endogenous pluripotency genes could be reproducibly detected in Brca2Δ27/Δ27cells. 
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Additionally, our data showed that reprogramming by this method of gene-corrected 
Brca2 fibroblasts did not generate “bona fide” iPSCs. 
 On the other hand, reprogramming of gene-corrected Brca2Δ27/Δ27 fibroblasts with a 
polycistronic lentiviral vector, significantly increased the reprogramming efficiency 
compared with the results obtained with individual gamma-retroviral vectors. 
The analysis of RAD51 foci formation in wild-type cells and also in Fanca-/- cells during the 
cell reprogramming process demonstrated the activation of homology directed repair 
(HRD) in both cell types. However, this mechanism was not activated during 
reprogramming of Brca2Δ27/Δ27 cells. Additionally, apoptosis studies in Brca2Δ27/Δ27 cells 
revealed an increase in early and late apoptosis in these cells during the reprogramming 
process, accounting for the extremely low efficiency of reprogramming of these cells. 
Gene-corrected cBrca2Δ27/Δ27 iPSCs fulfilled most of the criteria to be “bona fide” iPSCs, 
but they were not able to form teratomas. The excision of the reprogramming cassette, 
facilitated however, the generation of teratomas and, in consequence the generation of 
“bona fide” iPSCs. These corrected Brca2Δ27/Δ27 iPSCs expressed hBRCA2 mRNA, were 
capable of translocating RAD51 to DNA repair foci, and were resistant to MMC 
concentrations that resulted toxic in FA cells. 
The characterization of ploidy and karyotype of corrected cBrca2Δ27/Δ27 iPSCs revealed 
that by passage 17 only two clones had a diploid DNA content and normal karyotype. 
After the excision of the reprogramming vector, only one sub-clone conserved a normal 
karyotype, but it also showed genomic instability as deduced from comparative genomic 
hybridization studies. 
Finally, the hematopoietic differentiation of corrected cBrca2Δ27/Δ27 iPSCs allowed the 
production of cells that expressed markers characteristic of hematopoietic system. This 
hematopoietic differentiation was, however, very modest, and the transplantation of the 
iPSC-derived cells did not engraft into Brca2Δ27/Δ27 mice.  
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CONCLUSIONS: 
The FANCA/BRCA pathway plays an important role in the process of cell reprogramming, 
being Brca2 critical for the generation of iPSCs. Furthermore, the process of cell 
reprogramming activates the homology directed DNA repair, measured by the 
recruitment of RAD51 to DNA repair foci, in response to cell reprogramming. It was 
observed that increased apoptosis during the first stages of cell reprogramming could 
account for the limited reprogramming of Brca2Δ27/Δ27cells.  
 
The complementation of Brca2Δ27/Δ27 cells restored the capacity of these cells to recruit 
RAD51 to DNA repair foci and allowed the reprogramming of these cells. The transduction 
of genetically-corrected Brca2Δ27/Δ27 fibroblasts with four gamma-retroviral vectors was 
unable to generate bona fide iPSCs. On the other hand, the reprogramming of genetically 
corrected Brca2Δ27/Δ27 firboblasts with a polycistronic lentiviral reprogramming vector 
restored the FA/BRCA pathway and generated bona fide iPSCs after the complete excision 
of the reprogramming cassette.  
 
In vitro hematopoietic differentiation protocols based on iPSC transduction with HOXB4, 
followed by embryo body generation and co-cultures over hematopoietic stromas, 
modestly differentiated cBrca2Δ27/Δ27 iPSCs towards the hematopoietic system and these 
cells were not able to engraft into irradiated Brca2Δ27/Δ27 mice, indicating a deficient 
generation of hematopoietic repopulating cells in these cultures.   
 
Taken together, the results presented in this manuscript show the critical role of BRCA2 in 
cell reprogramming and reveal the current advances and limitations of cell 
reprogramming approaches to be used in hematopoietic cell therapy. 
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III. INTRODUCTION 
A. FANCONI ANEMIA 
 
1. GENERAL CHARACTERISTICS OF FANCONI 
ANEMIA 
 
Fanconi anemia (FA) was first described in 1927 by a Swiss pediatrician named Guido Fanconi. It is 
a highly heterogeneous genomic instability syndrome characterized by developmental 
abnormalities, bone marrow failure (BMF) and cancer predisposition.  BMF appears in virtually all 
Fanconi anemia patients and in about 50% of these patients it appears during the first decade of 
life. 
 
FA patients are particularly sensitive to suffer from myelodysplastic syndrome (MDS), acute 
myeloid leukemia (AML) and squamous cell carcinoma (SCC) in head, neck and oral cavities due to 
the genomic instability of the cells (Howlett et al. (2005). It has recently been reported that 
specific chromosomal abnormalities are frequently observed in FA patients with MDS or AML 
(e.g., gain of 1q23-32, 3q26), suggesting that these abnormalities can be used as predictive 
markers (Kee and D'Andrea, 2012). 
 
FA is caused by mutations in any of the 16 genes described so far (FANC-A, B, C, D1/BRCA2, D2, E, 
F, G, I/BRIP1, J, L, M, N/PALB2, O/RAD51C, P/SLX4, Q/XPF), from which 16 complementation 
groups have been identified (Table 1). All of them follow an autosomal recessive inheritance 
except FANCB, whose inheritance is linked to the X chromosome (Adam et al., 2003; Fanconi 
anaemia/Breast cancer, 1996; Meetei et al., 2004; Meetei et al., 2005; Smogorzewska et al., 2007; 
Strathdee et al., 1992). The genetic products of these genes function in a pathway known as the 
FA/BRCA pathway, a common DNA repair pathway that cooperates with other DNA repair 
proteins to resolve DNA interstrand-crosslinks (ICLs) during replication (Kee and D'Andrea, 2010). 
 
At a cellular level, FA affected cells present a high percentage of chromosomal aberrations and 
hypersensitivity to DNA interstrand-crosslinking agents that can be caused by endogenous 
sources, such as aldehydes generated as products of cellular metabolism or exogenous agents, 
such as cysplatin, mitomycin C (MMC), diepoxybutane (DEB), etc. ICLs are the most deleterious 
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DNA lesions that block DNA replication and transcription (Howlett et al., 2005; Kee and D'Andrea, 
2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. FANCONI ANEMIA/BRCA PATHWAY 
As previously commented, FA proteins function in the FA/BRCA pathway, a complex pathway that 
regulates the repair of DNA interstrand-crosslinks (ICLs). The proteins that form this pathway are 
classified in three groups depending on their localization; the “core complex”, the “ID-Complex” 
or “downstream proteins”. 
 
2.1 PATHWAYS INVOLVED IN DNA DOUBLE STRAND 
BREAKS REPAIR AND DNA INTERSTRAND-CROSSLINKS 
(ICLs)  
When there is a lesion in the DNA or under conditions of replicative stress, the replication fork 
stalls after finding a defective template and starts the replication mechanism dependent on 
homology directed repair (HDR) that has to be extremely well coordinated to maintain the 
Table 1. Fanconi anemia genes. The table shows the Fanconi anemia genes and corresponding proteins, with 
their position in the FA pathway. The core complex is the one located at the beginning of the pathway. This 
complex activates the ID-complex. The ID-complex is composed by two genes, FANCI and FANCD2 and when 
ubiquitinated it becomes active. Downstream proteins form the third complex have an essential role in DNA 
repair by homology directed repair (HDR).  
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integrity of the genome (Howlett et al., 2005). The ability to sense and respond to these events is 
critical for cell survival (Smogorzewska et al., 2007). 
 
Non homologous end joining (NHEJ) and HDR are the two major mechanisms by which double 
strand breaks (DSB) are repaired in mammalian cells (Xia et al., 2001). When there is a DSB during 
the S-phase of the cell cycle, NHEJ and HDR DNA repair pathways compete to overcome the 
damage. In contrast, when the DSB takes place in other phases of the cell cycle, the system tends 
to repair the DSB by NHEJ (Figure 1).  
 
The ICL damage leads to a DSB in one sister chromatid of the DNA whose repair requires the 
coordination of multiple DNA repair processes needed to cut out the ICL. The only error-free 
mechanism by which DSB derived from an ICL can be repaired is HDR. It goes through previous 
steps that involve nucleotide excision repair (NER) and translesion synthesis (TLS) ending up in the 
HDR process that is the one that finally resolves the DSB (Figure 2). 
 
- Nonhomologous end joining -NHEJ- 
This is an efficient and rapid DSB repair process that does not require a homologous template. It is 
the preferred pathway in mammals in most of the phases of the cell cycle except in the S phase 
when it competes with other DNA repair mechanisms. NHEJ is error-prone, because it works 
ligating two broken DSB ends without a template and often the sequence changes at the site 
where the DNA broke (Kee and D'Andrea, 2012). This mechanism starts by the high affinity 
binding of the heterodimer KU70/KU80 to the ends of the broken DNA to stabilize it. Then, this 
complex recruits DNA-PKc that is the catalytic subunit of a DNA dependent kinase to process the 
DNA ends by phosphorylation. Finally the DNA ligase IV XRCC4 is the enzyme that ligates the two 
DNA ends to complete the repair of the damaged DNA (Figure 1). 
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- Nucleotide excision repair (NER)  
The nucleotide excision repair is the preferred DNA repair mechanism of lesions caused by ultra-
violet radiation (UV) in cells that are actively dividing. Briefly, this DNA repair pathway consists of 
recognizing both sides of the DNA lesion. Then, an incision in the DNA occurs and the damaged 
DNA strand is degraded by an endonuclease and the remaining fragment is eliminated by an 
exonuclease enzyme (de Laat et al., 1999). 
 
- Translesion synthesis (TLS) 
After ICL unhooking, the lesion in the DNA needs to be bypassed by a specialized low fidelity 
translesion synthesis polymerase that is recruited to the lesion by a post-translational 
modification of a polymerase processivity factor activated after the cell replication arrest. This 
polymerase extends the master strand, that is then used as a template for HDR, to restore the 
replication fork and make it functional again because it is able to restore distorted bases and also 
mismathches in base pairs (Chang and Cimprich, 2009). TLS is a damage tolerance process, 
essential in ICL repair because it prevents a prolonged replication fork stall that would result in 
DSB and ensures that the cells replicate, although without correcting the DNA lesion but avoiding 
the replication fork to stall. 
 
Figure 1. NHEJ repair 
pathway and the main 
proteins involved in the 
function of the pathway. 
When a DSB is repaired by 
this mechanism, 
KU70/KU80 heterodimer 
protein strongly binds at 
both sides of the broken 
DNA. Then the ends of 
broken DNA are 
phosphorylated by the 
enzymatic activity of the 
DNA-PKC to be finally 
ligated by DNA ligase IV 
XRCC4. 
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- Homology directed repair (HDR) 
The homology directed DNA repair mechanism is used to repair DSB originated by ICL. It uses a 
homologous DNA strand as a template to repair the DNA with high fidelity, generating as few 
mutations as possible. After exposure to agents that damage DNA during S-phase, the cellular 
stress response mechanism starts, first arresting the cell cycle to allow its repair and then the FA 
pathway starts functioning, orchestrated by ATR and ATM kinases that by phosphorylation, 
activate key proteins of the pathway required to repair the DNA (Collins et al., 2009). The 
damaged strand is capped by the protein 53BP1 that, if not degraded, the lesion undergoes NHEJ 
repair. If BRCA1 (involvement of FA pathway) and CTIP work properly they degrade 53BP1, 
directing the DNA repair to HDR. Then the MRN complex binds to the DNA resection part of the 
strand. This resected DNA requires to be stabilized by RPA protein and is at this moment when 
RAD51 moves the DNA strand to the sister chromatid and the HDR process starts. Once the 
homologous sequence is found, homologous recombination (HR) starts by the generation of the 
so called “Holliday junction” that is in the end resolved (Wu and Hickson, 2003). This is how the FA 
pathway promotes HDR suppressing NHEJ in order to prevent inappropriate DNA repair (Figure 2). 
 
An alternative DNA repair mediated by HDR is the single strand annealing (SSA) in which one 
strand is shifted and the annealing of the other single strand end is then filled and ligated without 
any cross-over. 
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2.2 FANCONI ANEMIA/BRCA PATHWAY DESCRIPTION 
AND FUNCTIONING 
 
The FA/BRCA pathway  is an early responder of interstrand-crosslink derived (ICL) damage, as it  
works at the initial steps of the ICL repair process, recruiting the endonuclease XPF and its partner 
ERCC1 (important role in the initial steps) to perform the incision on the damaged DNA strand, 
flanking the region where the ICL is located. This incision on the DNA creates a DSB that has to be 
repaired by HDR, using the other DNA strand, that was previously repaired by the low fidelity 
translesion synthesis mechanism (TLS), as a template (Wang et al., 2013). 
 
FA cells that were damaged by DNA crosslinking agents accumulate chromosomal breaks, radial 
and fused chromosomes, due to their inability to repair the damage caused by the ICL. This 
Figure 2. Homology directed 
repair pathway (HDR). The first 
step consists of the capping of 
the damaged DNA strand by the 
protein 53BP1 followed by its 
degradation by BRCA1 in 
collaboration with CTIP. The next 
step is the resection of the 
damaged fragment carried out by 
the MRN complex. The DNA 
resulting from the resection is 
stabilized by RPA protein and is 
moved by RAD51 to the sister 
chromatid to recombine the DNA 
and finish the HDR DNA repair.  
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genomic unstable cellular phenotype vary depending on the affected FA protein, being mutations 
in some proteins located downstream in the FA pathway the ones that show a stronger incapacity 
to respond to ICL-DNA damage because some of these downstream proteins are directly involved 
in the HDR process (Kee and D'Andrea, 2010). 
 
- Core complex 
The proteins located in the FA core complex (FANC-A, B, C, E, F, G, L, M), are essential for the 
activation of the FA pathway. FANCM, together with the associated protein FAAP24, recognize the 
ICL in the DNA (Tischkowitz and Dokal, 2004). The association of FANCM to the chromatin occurs 
thanks to the action of the proteins MHF1 and MHF2 (Histone Fold Protein 1 and 2) and the DNA 
damage signalling mediated by ATR (ataxia telangiectasia and Rad3-related) (Hirsch et al., 2004). 
Once the lesion is recognized, the rest of the core complex proteins associate together. If FANCM 
is not functional, the mismatch repair complex MutS has a redundant activity and is able to 
recognize DNA ICLs and start the activation of the FA pathway (Wagner et al., 2004) (Figure 3). 
 
FANCL is the FA core complex protein that has an intrinsic E3 ubiquitin ligase activity necessary to 
carry out the activation of the ID-complex (FANCD2-FANCI) with the E2 conjugating enzyme 
UBE2T (Kennedy and D'Andrea, 2006; Wang, 2007), once FANCM is phosphorylated, to indicate 
that there is DNA damage. This ubiquitin ligase activity activates the mono–ubiquitination, a post-
translational modification in which an ubiquitin (76 a.a) covalently binds, by an internal amide 
linkage to residues of lysine, in a manner dependent on each other (Ishiai et al., 2008), on lysine 
561 of the FANCD2 protein and on lysine 523 in the FANCI (Kee and D'Andrea, 2010). This makes 
these two highly conserved proteins, FANCD2 and FANCI, to heterodimerize, giving rise to the ID-
complex. As said, several associated proteins, FAAP24, FAAP100, FAAP20, MHF1, MHF2, are 
critical for the correct activation of FANCD2 (Kee and D'Andrea, 2010). 
 
Apart from FA-associated proteins, there are other DNA repair factors with important roles in the 
FA pathway in response to DNA damage, such as DNA damage checkpoint proteins (ATR, ATM, 
CHK1, CHK2, -H2AX), that after DNA damage, arrest the cell cycle in a G2/M phase  (Moldovan 
and D'Andrea, 2009; Wang, 2007). Most of the FA proteins are substrates of ATR or of its effector 
CHK1 like FANCD2, FANCI, FANCA or FANCE (Collins et al., 2009; Wang, 2007) (Zhang et al., 2005) 
(Figure 3). 
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The activation of the core complex is mediated by a previous ATR-dependent phosphorylation 
process that serves as a substrate for the ligase. This process has not been fully elucidated yet but 
it has been proposed that the phosphorylation of FANCI on multiple sites mediated by ATR, 
functions as a switch to turn the FA pathway on, by promoting the mono-ubiquitination of 
FANCD2 and as a consequence its own mono-ubiquitination, being the mono-ubiquitination of 
FANCI dispensable for the function of the FA pathway (Ishiai et al., 2008).  
- ID-complex 
The ID-complex, when activated, translocates and loads onto chromatin, localizing at the nuclear 
repair foci with the DNA repair proteins BRCA1 and RAD51 (Smogorzewska et al., 2007).  
 
Mutations in any of the FA genes located in the core complex, except FANCM (with redundant 
activity found in other proteins) give rise to a deficient mono-ubiquitination of FANCD2 and FANCI 
being this one the most important event in the regulation of the FA pathway (Kee and D'Andrea, 
2012; Kottemann and Smogorzewska, 2013) (Figure 3).  
 
- Downstream proteins 
The activation of the heterodimer FANCD2-FANCI moves FANCD1/BRCA2 protein into chromatin 
complexes and it also interacts with FANCJ/BRIP1, FANCN/PALB2 and BRCA1 facilitating the 
assembly of DNA damage-inducible RAD51 nuclear foci (Howlett et al., 2005). Another recently 
identified associated protein, FAN1, (Fanconi-associated nuclease 1) binds to activated FANCD2 
and provides the necessary nuclease activity during ICL repair, probably restructuring the injured 
DNA (Kee and D'Andrea, 2010). The up-regulation of mono-ubiquitinated FANCD2 during S-phase 
and its localization to RAD51 foci suggests that the FA pathway is required in the DNA replication 
process (Howlett et al., 2005) and represents a good model for studying DNA repair and DNA 
damage response, specially after ICL generation (Kee and D'Andrea, 2010) (Figure 3). 
 
The multiple DNA repair processes involved in the repair of ICL-damaged DNA are catalyzed by 
different structure specific nucleases that are recruited once FANCD2 is mono-ubiquitinated, 
when the DNA needs to be repaired. They are regulated by the highly conserved FA downstream 
protein FANCP/SLX4 that serves as a scaffold. This protein interacts with three different nucleases 
at independent places that do not overlap, regulating them in the DNA repair process. At the N-
terminal region, SLX4 interacts with the nuclease complex XPF/ERCC1, at a central region it binds 
to MUS81-EME1 complex and at the C-terminal it has interaction with the SLX1 nuclease. This 
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protein also interacts with the mismatch repair recognition complex MSH2-MSH3 and with other 
compounds of the telomere protecting complex TRF-RAP1 (Kottemann and Smogorzewska, 2013). 
 
The interaction of SLX4 with both MUS81-EME1 and XPF-ERCC1 promotes the cross-over that 
generates a DSB in the DNA that is repaired by the TLS mechanism by the action of DNA 
polymerases that copy damaged DNA to restore the DNA strand. Finally, the DSB generated is 
repaired by HDR, process in which the proteins located downstream in the FA pathway play an 
important role. HDR also functions in multiple processes outside of the FA pathway. These 
proteins help RAD51 loading into the DNA repair foci and also participate in the resolution of the 
recombination intermediates. Four of these proteins (FANCD1/BRCA2, FANCN/PALB2, 
FANCJ/BRIP1, FANCO/RAD51C) (Kottemann and Smogorzewska, 2013) also confer susceptibility to 
breast and ovarian cancer when mutated in one copy, due to the involvement of these proteins in 
HDR repair. The last step in the DNA repair after the generation of an ICL is the repair of the 
formed adducts, that are restored by the already described NER and the nicks in the DNA are 
filled by DNA polymerases. 
 
 
 
 
 
Figure 3.  FA pathway and the proteins involved in its functioning to repair DNA after ICL damage. The FA proteins forming 
the nuclear complex are represented in red colour (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL and FANCM).  
The accessory proteins FAAP20, FAAP24 and FAAP100 together with the protein UBE2T are represented in grey. The 
proteins FANCI and FAND2 that form the ID-complex, when ubiquitinated have a saxophone shape as is represented in 
the figure. In the complex formed by downstream proteins of the FA pathway the FA proteins are represented in light and 
dark pink (FANCD1/BRCA2, FANCJ/BRIP-1, FANCN/PALB2, FANCO/RAD51C, FANCP/Slx4 and FANCQ/XPF) and proteins 
involved but not considered as FA proteins are represented in grey. 
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This pathway must not always be active, so, there is a de-ubiquinating complex with enzymatic 
activity, named USP1/UAF1 that deactivates the FA pathway removing the ubiquitin both from 
FANCD2 and FANCI (Smogorzewska et al., 2007). This deubiquitination is required for ICL repair as 
it has been reported that the loss of USP1 is associated with ICL sensitivity (Wang and Gautier, 
2010) (Figure 3). 
 
There is an important link between FA pathway and BRCA pathway because it is well known that 
BRCA2 plays an essential role in HDR as it interacts with BRCA1 and with RAD51, a central effector 
in HDR, and promotes its loading to the ssDNA coated by RPA, the protein that stabilizes this 
ssDNA for its repair (D'Andrea, 2013). 
 
3. PHENOTYPE OF FANCONI ANEMIA CELLS 
FA cells have a characteristic response to certain endogenous and/or exogenous agents that 
determines their phenotype. There is controversy about what causes the FA phenotype. While 
some authors support the idea that the phenotype of these cells is consequence of a defective 
ICL-DNA damage repair system that leads to the accumulation of genomic instability and damaged 
DNA, others relate the FA phenotype to an increased oxidative stress and imbalances in the 
oxygen metabolism. It is not clear yet what causes the FA phenotype but it is probable that a 
combination of both mechanisms is responsible for it (Pagano et al., 2013), (Pallardo et al., 2010) 
(Figure 4). 
 
3.1 OXIDATIVE STRESS 
FA proteins are known to work in cooperation between them, although their individual role in the 
cell has not been deeply studied, there are evidences suggesting that some of the FA proteins 
(FANCA, FANCC, FANCG, FANCD2 and FANCJ) participate in redox and detoxification metabolism 
through the interaction with enzymes involved in the sense and response to the damage caused 
by oxygen stress, such as cytochrome p-450 or proteins involved in the metabolism of hydrogen 
peroxide. For this reason it is believed that the deficiency in any of these proteins could be 
responsible for the increase in the level of reactive oxygen species (ROS) in FA cells (Sejas et al., 
2007; Zhang et al., 2007).  
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When exposed to elevated oxygen levels, FA cells alter their cell cycle, leading to an accumulation 
of cells in S and G2/M phases, reducing viability and increasing the number of chromosomal 
aberrations (Joenje et al., 1981). They also present an increase in 8-OxodG, one of the most 
common mutagenic lesions caused by cell rust after exposure to DNA damaging agents (Du et al., 
2012). 
 
Recently, a defective mitochondrial function has been proposed to participate in the oxidant 
sensitive phenotype that characterizes FA cells (Ravera et al., 2013), establishing a relationship of 
mitochondrial functionality with cellular redox balance and energy metabolism. The mechanisms 
that involve mitochondrial alterations with oxidative stress and the role of the different FA 
proteins are not fully elucidated, and only evidences of the role of FANCA protein have been 
studied in detail. It relates the deleterious effects in mitochondrial physiology of FA cells with the 
overproduction of TNF and the increase in ROS levels. The mitochondrial alterations in FANCA 
mutated cells affect complex I of the respiratory chain, resulting in mitochondrial dysfunction at 
the level of structure, cytoskeleton, electron transfer and as a consequence, in a defective cellular 
energy metabolism (Kumari et al., 2013; Ravera et al., 2013). Apart from FANCA, FANCC and 
FANCG there are other FA proteins known to be directly involved in redox homeostasis through 
interactions with cytochrome p450 in response to cellular damage. More recently, FANCD2 was 
Figure 4 . Scheme of the phenomena that could be responsible for the characteristic FA phenotype. 
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found to participate in oxygen damage response, interacting with FOXO3a, ATM and FANCJ to 
inhibit the oxygen damage sensor hemoxigenase 1 (Pagano et al., 2012). 
3.2 SENSITIVITY TO TNF AND IFN 
FA is also known to be closely linked to the overproduction of pro-inflamatory and pro-apoptotic 
cytokines, such as tumour necrosis factor alpha (TNF), interferon gamma (IFNy), interleukin 6 (IL-
6) or interleukin 1 (IL-1). As consequence of an alteration in the balance of redox processes 
these molecules strongly affect the homeostasis of hematopoietic stem cells (HSC) at different 
levels, including cell proliferation and the process of homing in the bone marrow niche (Du et al.). 
 
The overexpression of TNFthat occurs in the bone marrow of FA patients creates an 
inflammatory context of oxygen stress and cell death, related with the deregulated expression of 
molecules, such as p38MAPK, JNK and NFK- This process, together with the genomic instability 
of FA cells, can result in the hyperactivation of clonal proliferation, including leukemic or 
myelodysplastic episodes and also the increase in the apoptotic rate, that can contribute to the 
progression of BMF (Du et al., 2014). Nowadays some attempts to ameliorate BMF are being 
developed with the objective of decreasing the levels of cytokines such as TNF (Dufour et al., 
2003) (Figure 5). 
 
 
  
 
 
Figure 5. Diagram representing the effects that increased levels of TNF have in FA cells through the elevated ROS 
production that leads to clonal proliferation of hematopoietic cells and as consequence, the development of 
myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Another effect of a TNF excess is the 
alteration of the NFK- pathway, increasing the rate of apoptosis that contributes to bone marrow failure (BMF). 
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3.3 CROSS-LINKING AGENTS AND CELL CYCLE ARREST 
FA cells are hypersensitive to DNA crosslinking agents, such as mitomycin C (MMC) or 
dyepoxibutane (DEB) among others. The exposure of FA cells to these agents generates a high 
number of chromosomal aberrations such as chromatid breakages, radial chromosomes or 
chromosomal fusions. It is known that as a consequence of replicative stress and unresolved DNA 
damage, partially due to the high number of replication forks stalled after ICL generation, the 
expression of P53 and of its effector P21, is increased in FA cells. FA cells suffer a G2 cell cycle 
arrest that is usually overcome, but the strong induction of P53 expression gives rise to a new cell 
cycle arrest in G0/G1, as a protective mechanism to keep the integrity of the genome by 
prevention of damaged cells to progress in the cell cycle. This mechanism has been proposed to 
be responsible for the loss of hematopoietic progenitor cells in FA patients that leads to BMF, and 
it is believed to start early during development (Ceccaldi et al., 2012).  
 
Strategies to prevent cell cycle arrest have been developed in FA cells, mainly to evercome the 
blockage of G2 checkpoint and downregulation of P53, with the purpose of rescuing the 
hematopoietic proliferation defects and therefore to recover high numbers of hematopoietic 
progenitor cells. The main limitation of these strategies arise from the fact that allowing damaged 
FA cells to continue their cell cycle, bypassing checkpoint controls, could result in the 
accumulation of genomic damage, thus, with high probability of malignant transformation 
(Ceccaldi et al., 2012; Dumitriu and Young, 2012). 
3.4 DEFECTIVE ADHESION ACTIVITIES THAT AFFECT 
HOMING 
It is known that FA cells have impairment in their cell adhesion and as a consequence in their 
homing to the bone marrow niche. The mechanisms accounting for the inability of FA cells to 
attach to the marrow are still unclear, but two molecules have been observed to be altered in FA 
cells. In FANCA deficient cells, the required CDC42 GTPase activity for cell migration, has been 
reported to be decreased (Zhang et al., 2008b). Furthermore, the characteristic over-expression of 
TNF in FA cells could play a role in the down-regulation of CDC42 (Zhang et al., 2008a). Another 
molecule with a key role in cell adhesion and homing activities, CXCR4 (chemokine receptor 4) 
was observed to be involved in FA LSK cells (Lin-, sca1+, ckit+) from different mouse models, 
limiting their homing capacity. Interestingly, the impaired homing of FA cells  can be circumvented 
by an up-regulation of CXCR4 expression in combination with hypoxic conditions, increasing cell 
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migration activities and decreasing the generation of ROS caused by oxidative damage (Skinner et 
al., 2008). 
4. CLINICAL FEATURES AND MANIFESTATIONS 
As it was previously commented, FA is a very heterogeneous genomic instability syndrome that 
affects mainly the HSCs and in consequence, all the cells of the hematopoietic system. The disease 
is characterized by congenital developmental abnormalities in 60-75% of the cases. Although 
there are several common defects that appear in FA patients, they are variable among patients. 
The most frequent abnormalities found in FA are: low weight at birth (50%),  radius axis defects 
(absent or very small thumbs or short radius), skeletal abnormalities in hips or ribs, 
microphthalmia and microcephalia, imperforated anus and mental retardation disorders (Kaplan 
et al., 1985), (Tischkowitz and Hodgson, 2003). 
 
Skin pigmentation defects are also very frequent (55%), specially the so called “café au lait spots” 
and fertility problems in females (35%). Less frequent are gastrointestinal problems (7%) 
(esophageal or duodenal atresia), defects in the kidney and in the urinary tract (21%), endocrine 
disorders that include defective insulin metabolism or hypothyroidism, ear malformations or 
alterations in the central nervous and in the cardio pulmonary systems such as ventricular septal 
defects or pulmonary and aortic stenosis. It is also frequent that FA patients reach adulthood with 
evidences and features of premature aging (Table 2 and Figure 6). 
  
The main characteristic of the disease is BMF that appears in most of the cases. On the other 
hand, due to the genomic instability of the cells, FA patients have a high predisposition to develop 
MDS, AML and  SCC in head, neck, oral cavities and genitals (Howlett et al., 2005). In many cases, 
patients die at an early age due to the severe affection of the hematopoietic system. 
 
There is a phenomenon that takes place in some cases of FA as a consequence of mutations that 
occur due to the genomic instability of the cells. It is known as “somatic mosaicism” and it was 
first described in 2002. It consists of naturally occurring mutations, that lead, either to the wild 
type (wt) form of the mutated FA gene, or to compensatory mutations that generate a mutated, 
although functional, FA protein. Thus, individuals with somatic mosaicism have a chimeric 
hematopoietic system composed of defective cells and also of cells in which the mutation has 
reverted (Gross et al., 2002). Somatic mosaicism is, to a certain extent a natural gene therapy that 
confers selective advantage to the corrected cell/s, allowing the possibility that only one 
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genetically corrected HSC could restore the hematologic defect, rescuing the patient from BMF. 
This long term restoration of the hematologic parameters will occur only if the cell that 
spontaneously reverts its deficiency is a HSC, because if the genetic correction takes place in a 
mature cell it would not affect all the hematopoietic progeny. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  FA most common pyhysical abnormalities, and the frecuency of occurrence in patients. 
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5. DIAGNOSTIC CRITERIA AND 
 IDENTIFICATION OF FANCONI ANEMIA 
COMPLEMENTATION GROUPS 
 
The detection of FA patients based on clinical features is difficult because the congenital 
malformations are not always present or evident, and because sometimes it is not diagnosed until 
BMF appears. In other cases, the FA patient is diagnosed because of the development of AML. In 
all these cases, it is recommended to carry out a chromosomal breakage test with DEB or MMC 
(Giampietro et al., 1997; Kutler et al., 2003). 
 
Symptoms such as haemorrhagic manifestations, fatigue and paleness caused by anemia, 
petechiae, ecchymosis or epistaxis derived from thrombocytopenia, high temperature or bacterial 
infections are common, although nonspecific manifestations of FA that difficult the diagnosis of 
Figure 6. Representation of the most common clinical features observed in FA patients. In the image 
are represented the characteristic A) “café au lait spots”, B, C) thumb abnormality and D) bone 
marrow hypoplasia.  
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the disease. A complete hematologic cell count in FA patients frequently reveals decreased 
numbers of one or all blood cell lineages.  
 
At the time of diagnosis is of critical relevance to discriminate FA from other diseases with similar 
disease phenotypes, such as Nijmegen Breakage Syndrome (NBS), Bloom syndrome, Seckel 
syndrome, Diamond-Blackfan anemia, Dyskeratosis congenita or Thrombocytopenia Absent 
Radius (TAR). 
 
The differential test for FA is the chromosomal breakage test in presence of interstrand-
crosslinking agents (ICL agents), being the most commonly used diepoxybutane (DEB) and 
mitomycin C (MMC). FA cells present increased numbers of chromosomal aberrations in presence 
of these agents (Carreau et al., 1999). This was first established by Auerbach and Schroeder-Kurth 
in 1982, who observed that FA patient´s cells were positive for DEB chromosomal breakage 
induction,  while non-FA patient´s cells were negative (Auerbach et al., 1989). 
 
Once the diagnosis of FA is confirmed, bone marrow aspirates or biopsies are studied to confirm 
the existence of a BMF syndrome, a MDS or specific clonal aberrations indicative of pre-leukemic 
alterations. Aplastic anemia is associated with hypocellular bone marrow that is occupied by fat 
and stromal cells. The bone marrow failure can be classified in terms of cellularity as moderate 
(30% of cellularity, no severe pancytopenia), severe (25% of cellularity; < 50% of cellularity with 
<30% hematopoietic cells and <4x104 absolute reticulocyte count/µl; <500 absolute neutrophil 
count (ANC)/µl or <2x104 platelet count/µl), or very severe (severe plus absolute neutrophil count 
(ANC) <200/µl (Young, 2002). 
  
The diagnosis of FA can also be screened by a G2/M phase cell cycle arrest that consists of the 
accumulation of  G2/M cells  after treatment with ICL agents (DEB or MMC) due to a cell cycle 
blockage (Akkari et al., 2001). This test is frequently performed in fibroblasts to confirm the FA 
diagnosis in cases of mosaicism, because the standard chromosomal breakage test in peripheral 
blood in these patients can be unclear. In these cases, DEB test must be used as a complementary 
and confirmatory study (Seyschab et al., 1995). These studies should also be performed in any 
apparently healthy FA patient sibling, because the disease can be present without clear 
phenotypic manifestations. It can also be prenatally diagnosed with these tests in amniotic fluid 
cells (amniocentesis), chorion villus cells of fetal blood (cordocentesis) or mutation analysis in 
case the mutation of the affected brother is known (Auerbach et al., 1985). 
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5.1 IDENTIFICATION OF COMPLEMENTATION GROUPS 
The screening of the FA complementation groups has been conducted in a four step algorithm 
represented in Figure 7.  First the FA diagnosis is confirmed and it is discerned if the patient has 
somatic mosaicism, through a DEB and MMC test performed in patient T-cells. The next step is 
directed to define which of the FA genes is causing the disease.   
 
As previously commented, the identification of the FA affected gene in the patient allows the 
assignment to a complementation group. One of the methods that has been widely used in our 
laboratory, consists of the transduction of PB-T-cells, using a battery of vectors, either -retroviral 
(-RV) or lentiviral (LV), each one encoding a different FA gene, analyzing which vector corrects 
the mitomycin C (MMC) hypersensitivity of these cells. The vector that corrects the MMC 
sensitivity determines the FA complementation group to which the patient belongs (Antonio 
Casado et al., 2007; Hanenberg et al., 2002). 
 
 
 
 
 
 
 
 
 
     
          
       
 
   
   
 
   
 
 
Figure 7. Representation of a four-step algorithm proposed for the subtyping of the FA patients. Step1: T-cell 
sensitivity diepoxybutane (DEB) and mitomycin C (MMC). Step2: subtyping of the patient with gamma retroviral 
vectors (-RVs) carrying the most common FA genes. Step 3: detection if the defective protein is upstream or 
downstream of the FA pathway when the most frequent genes do not correct the genetic defect. Step 4: 
detection of the exact mutation of less common FA genes using other existing methods.   
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In case none of the most common FA genes complements the mutation, Western Blot (WB) of 
FANCD2 protein allows defining if the FA affected protein is located upstream or downstream of 
the ID-complex in the FA pathway. The presence of the non-ubiquitinated (FANCD2-S) form of 
FANCD2 indicates that the affected protein is located upstream. On the other hand, the detection 
of the ubiquitinated (FANCD2-L) form of FANCD2 indicates that the mutation is located 
downstream in the pathway. The specific mutated FA protein can be detected by other 
approaches, such as molecular and functional analysis. For example, the generation of RAD51 foci 
is useful to detect functional alterations in FANCD1/BRCA2. The FANCJ/BRIP1 foci formation can 
be useful to detect certain mutations in this protein. The WB of FA proteins is often used to detect 
truncated mutations in these proteins (Figure 7) (Antonio Casado et al., 2007). 
 
Due to the advances in exome sequencing and also to the reduced costs of these techniques, the 
identification of the FA gene responsible for the disease can be efficiently performed through the 
analysis of any of the 16 FA genes described so far.  The analysis of the entire genome by exome 
sequencing also makes possible the detection of new FA genes. This technique allowed the recent 
identification of the XPF/FANCQ as a FA gene (Bogliolo et al., 2013). 
 
6. STANDARD THERAPIES OF THE FANCONI 
ANEMIA HEMATOPOIETIC SYNDROME  
 
Standard therapies of the bone marrow failure are based on the use of androgens, hematopoietic 
growth factors (Stucki et al., 1998), and if possible hematopoietic stem cell transplantation 
(HSCT). HSCT is the only treatment that cures bone marrow failure and it is specially 
recommended when there is a severe or very severe aplasia, because these patients are less likely 
to respond to other therapies, and have a high risk of bleeding and infection (Ades et al., 2004). 
Despite its advantages, HSCT does not solve other manifestations of FA, such as SCC. Additionally, 
it has been discussed wether or not HSCT can increase the risk of head and neck SCC, mainly as a 
consequence of the development of graft versus host disease (GVHD) (Rosenberg et al., 2005) 
(Tolar et al., 2012). HSCT in FA is particularly complicated due to the sensitivity of these patients to 
conditioning regimes used to facilitate the engraftment of transplanted HSCs. 
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6.1 PALLIATIVE TREATMENTS OF THE HEMATOPOIETIC 
ASPECT OF THE DISEASE 
 
The palliative treatments to reduce anemia, trobocytopenia or neutropenia in FA patients include 
the use of androgens, growth factors and transfusions.   
- Androgen Therapy 
Androgen therapy has been used for more than 50 years and is mainly indicated when the patient 
does not have a HLA-identical related donor (Tischkowitz and Dokal, 2004). 
 
The clinical symptoms to prescribe androgen therapy are low haemoglobin (HGb) and platelet 
(PLT) levels. Androgen therapy is known to be more effective when the administration starts 
before there is a complete BMF. Androgens frequently improve the anemia and, at a less extent 
thrombocytopenia and neutropenia. Historically, the androgen most widely used was 
oxymetholone, while in the recent years danazol is more frequently used because it has less 
virilization side effects. In some cases it is combined with prednisolone to reduce the liver toxicity 
and premature epiphyseal closure. About 75% of FA patients respond to androgens in a period of 
2-12 months. In case there is no hematopoietic improvement with this therapy after three 
months, the treatment is not recommended any longer (Tischkowitz and Dokal, 2004).  
 
There are several secondary effects derived from the use of androgens, such as accelerated 
growth followed by an early closure of epiphyses, virilization, changes in the behaviour of the 
patient (hyperactivity), transaminases raise, cholestatic jaundice or hypertension. Less frequent 
are hepatic adenoma or hepatic cystic disease. 
 
Several clinical trials are being performed in patients to evaluate the benefits and risks of using 
different androgens (Scheckenbach et al., 2012). 
 
- Hematopoietic growth factors 
The hematopoietic growth factors tested in FA patients are erythropoietin (EPO), granulocyte 
colony-stimulating factor (rhG-CSF), granulocyte-macrophage colony-stimulating factor (rhGM-
CSF) and interleukin-3 (IL-3), being rhG-CSF (granulocyte colony-stimulating factor) the one in 
which there is more experience (Rackoff et al., 1996).  
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In general, patients suffering from neutropenia improve the ANC, but the PLT and HGb counts 
remain unaltered in most of the cases studied. If no increase in ANC is observed after 8 weeks of 
administration the treatment should be stopped (Rackoff et al., 1996). There is some evidence 
that the treatment with rhG-CSF could contribute to the early development of MDS or AML. 
Therefore, treatment with hematopoietic growth factors is not frequently conducted in FA 
patients. 
 
Blood transfusions are required when BMF is severe. At this stage, HSCT is generally 
recommended if the patient has a convenient donor.   
  
6.2 CURATIVE TREATMENTS OF THE HEMATOPOIETIC 
ASPECT OF FANCONI ANEMIA: HEMATOPOIETIC STEM 
CELL TRANSPLANTATION (HSCT) 
 
As it was previously said, HSCT is the only current treatment to cure BMF (Gupta et al., 2010). 
HSCT is indicated in FA patients with BMF, MDS or AML, being patients suffering from MDS and 
AML the ones with a worse prognosis. It is of great importance to find an appropriate donor for 
HSCT and a good source of HSC cells for HSCT (Figure 8). The ideal donor for FA-HSCT is an HLA-
matched sibling donor to limit risks of graft rejection and GVHD. 
 
Apart from adult donors, umbilical cord blood (UCB) is a new and good alternative for allogeneic 
HSCT. The first successful HSCT using UCB progenitors was performed in the late 80´s by Dr. 
Gluckman in a patient affected by FA (Gluckman et al., 1989).  Since then UCB has emerged as a 
potential source of HSCs for allogeneic HSCT because it is enriched in immature progenitors 
(CD34+ CD38-), although it still remains challenging finding ways of improving rates of engraftment 
and immune recovery after HSCT (Navarrete and Contreras, 2009). 
 
More recently, peripheral blood (PB) mobilized HSCs gained ground as a good stem cell source for 
HSCT. It is based on the administration of hematopoietic growth factors that increase the 
percentage of HSCs circulating in PB and to collect these cells by apheresis (Lemoli et al., 2003). 
HSC mobilization can be based on the blockage of HSC interactions with the niche, releasing 
functional progenitor hematopoietic cells to circulation (Pelus and Fukuda, 2008; Ramirez et al., 
2009). 
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Plerixafor (AMD3100, Mozobil) acts reversibly inhibiting the interaction between SDF-1 in bone 
marrow stromal cells and its receptor CXCR4 (Peled et al., 1999) and has been effective to 
mobilize HSCs in poor mobilizing patients and also in patients suffering from lymphoma (Farina et 
al., 2014) or -thalassemia (Yannaki et al., 2012). There is a sinergy between plerixafor and 
filgrastim (r-metHuG-CSF) that increases the number of mobilized CD34+ cells. This mobilization 
regime has not been clinically tested in FA patients. Thus, a phase II clinical trial in FA is currently 
being developed in Spain to evaluate its efficacy and safety. 
 
- Conditioning regimes of Fanconi anemia patients prior to HSCT 
As FA patients are more sensitive to conditioning drugs administered prior to transplant, the 
conditioning regimes used in FA patients are milder than those used in non FA patients (Gluckman 
et al., 1995; Guardiola et al., 2004).  
 
For patients receiving HLA-identical related/sibling donor HSCT, Dr. Gluckman showed that a low-
dose of cyclophosphamide (CY) (20 mg/kg) with a single dose of thoracoabdominal radiation (TAI) 
(500 cGy) improved the long-term survival after HSCT, although there is controversy about the 
convenience of using radiation combined with CY (Zanis-Neto et al., 2005) (Dufour et al., 2001; 
Farzin et al., 2007; Kohli-Kumar et al., 1994; Medeiros et al., 1999; Socie et al., 1998). Thereafter it 
was observed that the use of fludarabine had less toxicity and reduced GVHD. For this reason 
fludarabine has been widely introduced in conditioning regimes for FA patients (Tan et al., 2006). 
 
Since then, several improvements have been made by Drs. Wagner and McMillan for the 
conditioning of FA patients that tend to limit the dose of radiation, based on the administration of 
low dose of CY, fludarabine and antithymocyte globulin (ATG*) (Pasquini et al., 2008). 
 
In cases in which there is not an HLA-matched donor available, the conditioning regime is 
different.  It was reported that relatively low doses of CY help to decrease the risk of transplant 
failure.  
 
A pilot study carried out by MacMillan et al. to scale down the dose of irradiation in matched 
unrelated donors, partially matched related or unrelated donors consisted of low-dose irradiation, 
fludarabine, CY and ATG*. In this study it was determined 300 cGy to be the minimum dose of 
radiation possible in this conditioning regime and it was observed a survival rate of 96% after a 
three year follow up, with a minimal toxicity and development of GVHD (Yabe et al., 2006). The 
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latest conditioning regime established for unrelated donors consists of the administration of low 
dose of CY and fludarabine, combined with ATG*, 300 cGy of radiation and thymic shielding.   
 
In cases of high-risk transplants, that include FA patients with MDS, leukemia or with BRCA2 gene 
affected, busulfan was also included in the conditioning regimes (Chaudhury et al., 2008) (Mitchell 
et al., 2014). 
 
6.2.1 TRANSPLANT FROM SELECTED EMBRYOS 
 
Within the last years, a reduced number of FA patients have been transplanted, after 
preimplantation genetic diagnosis, with HLA-identical UCB or bone marrow HSCs from a healthy 
sibling. (Bielorai et al., 2004; Grewal et al., 2004; Rechitsky et al., 2004). These transplants were, 
thus similar to those performed with hematopoietic grafts from conventional related donors. 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
Figure 8.  FA treatment algorithm based on the existence or not of bone marrow failure. It 
represents how to proceed in case there is bone marrow failure depending of the 
circumstances of the patient, such as the availability or not of an HLA-identical donor. 
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6.2.2 POST-TRANSPLANT MALIGNANCIES 
FA patients that received a HSCT have an increased risk of developing malignancies such as MDS, 
lymphoproliferative disease, AML or solid tumours, being SCC the most frequent, a side effect 
that is believed to be enhanced by GVHD.  The probability of developing a tumour after the 
transplant depends on factors like age, the dose of radio and chemotherapy, the severity of the 
disease, Epstein-Barr virus infection and also on the genetics of the patient. It is difficult to 
elucidate the contribution of HSCT to the development of malignancies because the 
administration of immunosuppresive therapy (cyclosporine, ATG etc), also used prior to 
transplant may contribute to increase the risk of cancer. In a study performed by the European 
Bone Marrow Transplantation Group it was observed that the incidence of tumour development 
20 years post-transplant was 42% in contrast to the 14% observed in patients with severe aplastic 
anemia with a different aetiology (Dufour et al., 2001). 
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7. NOVEL THERAPIES FOR FANCONI ANEMIA 
 
7.1 GENE THERAPY 
Gene therapy is one of the most promising new therapeutic approaches to overcome BMF in FA, 
because it has already shown its potential to cure other monogenic diseases. It consists of 
modifying the cellular genome by the introduction or substitution of genes mediated by viral 
(integrating or non-integrating) or non-viral vectors. Gene therapy is of special interest in 
monogenic recessive diseases caused by the loss of gene function, because it offers the possibility 
of restoring the defective gene by the introduction and expression of the correct copy of the gene 
(therapeutic gene) in the target cells. The outcome of gene therapy can be improved using 
methods to confer a proliferative or survival advantage to the target cells over non-transduced 
cells to increase the proportion of corrected cells in the patient (Qasim et al., 2007) (Corrigan-
Curay et al., 2012).  
 
In this decade several clinical trials have been initiated with promising results in adenosine 
deaminase-severe combined immunodeficiency (ADA-SCID) (Aiuti et al., 2002b; Thrasher et al., 
2006), Wiskott-Aldrich syndrome (WAS), chronic granulomatous disease (CGH), 
adenoleukodystrophy and hemoglobinopathies, among others. In Table 3 representative HSC 
gene therapy protocols are shown. 
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DISEASE INJECTED CELLS VECTOR REFERENCE 
 X-SCID (X-linked Severe 
Combined Immunodeficiency) 
HSC -RV (Cavazzana-
Calvo et al., 
2000) 
 ADA-SCID   
(Adenosine Deaminase 
Deficiency-Severe Combined 
Immunodeficiency) 
HSC -RV (Aiuti et al., 
2002a) 
 X-CGD (X-linked Chronic 
Granulomatosus Disease) 
HSC -RV (Ott et al., 2006) 
 ALD 
(Adrenoleukodystrophy) 
HSC SIN LV (Cartier et al., 
2009) 
 WAS (Wiskott-Aldrich 
Syndrome) 
HSC -RV (Boztug et al., 
2010), 
 -Thalassaemia HSC SIN LV (Cavazzana-
Calvo et al., 
2010) 
 X-SCID (X-linked Severe 
Combined Immunodeficiency) 
HSC -RV (Cavazzana-
Calvo et al., 
2000) 
 ALD 
(Adrenoleukodystrophy) 
HSC SIN LV (Cartier et al., 
2009) 
 LDM (Metachromatic 
leukodystrophy) 
HSC SIN LV (Biffi et al., 2013) 
 WAS HSC SIN LV (Aiuti et al., 
2013) 
 
 
 
Gene therapy can be classified in three types depending on the strategy followed:  
1- Gene addition: introduces the correct and functional gene to be expressed in the target cells at 
a degree that allows the restoration of the genetic defect. In this type of gene therapy the 
expression of the transgene is usually conferred by an exogenous promoter. 
2- Gene substitution: is based on the replacement of a defective gene by a correct form of it, 
either by substitution of a functional copy of the gene by HR or modifying only the non-functional 
part of the gene by exchanging defective nucleotides by the correct ones, to finally obtain a 
functional gene. 
Table 3. Modified from Kaufmann (2013) (Kaufmann et al., 2013). Table representing the clinical trials carried 
out until now in hematologic and immune diseases, in which hematopoietic stem cells were modified and 
transplanted into patients. 
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3- Gene suppression: consists of the elimination or reduction of the expression of a gene by 
knocking-out or knocking-down strategies, respectively, using techniques such as gene targeting 
or mRNA interference (Davidson and McCray, 2011). 
 
 
          
 
 
 
 
 
 
According to the modality of treatment, gene therapy can be classified as in vivo gene therapy 
and ex vivo gene therapy.  
 
In vivo gene therapy consists of the introduction of the therapeutic gene directly into the patient 
with the therapeutic vector.The ex vivo gene therapy is based on the in vitro transduction of the 
Table 4. Types of gene therapy strategies. 1. Gene addition of the therapeutic gene A) Semi-random 
integration and expression driven by the promoter of the vector introduced. B) Knock-in strategy in which 
the transgene is introduced by homologous recombination (HR) in a determined genomic region and the 
expression is regulated by the cellular promoter. C) Consists of the safe harbour strategy by which the 
vector is introduced in a secure genomic site by HR and the expression is regulated by the exogenous 
promoter. 2.  Gene substitution of the mutation causing the disease by the correct nucleotides by the 
design of arms flanking the therapeutic gene, that have homology with the genomic region flanking the 
mutation and the substitution of the defective nucleotides by HR.  3. Gene suppression is based on the 
design of vectors that can express siRNAs or specific nucleases to knock-out the gene.  
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cells. Once corrected, transduced cells are infused back into the patient, being this strategy more 
efficient and the most widely used in HSC gene therapy (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.1.1 CONSIDERATIONS FOR GENE THERAPY 
Several aspects must be considered for the development of efficient and safe gene therapy.  
 
- Type of gene 
The main limitation of the gene to be expressed is the size of the gene to be introduced in the 
gene therapy vector. The promoter chosen to activate the gene expression is also critical for the 
adequate level and stability of transgene expression, something that can be affected by the 
differentiation state of the cells and epigenetic changes that may occur in vivo (Manilla et al., 
2005). 
 
- Type of vector  
Finding a good system to introduce the DNA of interest in the target cells is another critical aspect 
in the design of a safe and efficient gene therapy strategy.The viral vectors more widely used for 
hematopoietic gene therapy are the γ-retroviral (-RV) and lentiviral vectors (LV). They will be 
Figure 9. Basic diagram representing in vivo and ex vivo gene therapy protocols.  
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described in detail later but in general they present certain limitations of semi-random integration 
and the maximum size of DNA that can be introduced. Relevant recent non-viral systems have 
been developed to deliver DNA into the cell genome using plasmids or transposons  (Ivics et al., 
1997) (Izsvak et al., 1997). 
 
- Ex vivo manipulation 
Ex vivo manipulation in gene therapy protocols allows the isolation of cells from the patient, the 
correction of the genetic defect in the cells and the introduction of the corrected cells back into 
the patient. This manipulation is generally more efficient and safer than the in vivo modification 
of the cells, because it prevents the patient to be directly exposed to the vector, and also allows, 
in some instances, the selection of transduced cells (Kaufmann, Buning et al. 2013). 
 
- Efficiency of transduction and selective advantage 
 One relevant aspect that needs to be considered when performing gene therapy is the number of 
cells available to be transduced. In the case of HSCs, this number is frequently very limited. This 
limitation is particularly relevant if the percentage of transduced cells is low and transduced cells 
do not have a significant survival and/or proliferation advantage over non-transduced cells 
(Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al., 2002).  
 
In some cases, cells corrected by gene therapy can develop a proliferative advantage that allows 
the efficient reconstitution of the affected system, with only a small number of corrected cells 
avoiding, in some cases, the use of conditioning regimes prior to the infusion of corrected cells. 
This was the case of gene therapy trials performed for X1-SCID patients (Kaufmann et al., 2013). In 
FA this selective advantage of cells corrected by gene therapy would be even stronger because in 
this case the affected cells include the HSC. 
 
- Immunogenicity 
It is also important to consider the possible reaction of the immune system to the vector and/or 
the transgene.  To prevent this undesired reaction, different strategies, such as modifications of 
the viral capsid, have been developed to avoid the recognition of the viral capsids by the immune 
system of the recipient (Raper et al., 2003). 
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- Genotoxicity or insertional oncogenesis  
Insertional oncogenesis is an important factor to consider mainly due to two aspects. The so 
called “clonal dominance” by which a determined cell population can grow at a higher rate 
leading to MDS, or leukemia (Kaufmann et al., 2013). Related to the potency of the 
promoter/enhancer element of the vector and the nature of the vector itself, the use of strong 
LTRs from -RVs and the preferential insertion close to the TSS of genes have generated some 
problems. 
 
Due to these undesired events, integrating viral vectors have been modified to prevent them, by 
using self-inactivating LTRs (Sokolic et al., 2008). Weak promoters or promoters with specific 
activity in defined cell lineages are nowadays widely used in HSC gene therapy trials (van Til et al., 
2012) (Vassilopoulos et al., 2001) (Throm et al., 2009). 
7.1.2 GENE THERAPY VECTORS USED IN THIS WORK: 
 
- Gamma-retroviral vectors (-RV) 
-RVs are developed from the genome of -retroviruses that have a diameter of 80-100 nm and an 
encapsidated RNA based genome. Their envelope is formed by the membrane of the host cell and 
glycoproteins from the envelope encoded by the virus. The viral cycle goes from ssRNA through a 
double stranded DNA (dsDNA) intermediate that is able to integrate in the host genome, allowing 
this proviral DNA to replicate with the host DNA. The -RV genome usually has a size of 8-12 kb 
and is composed by two molecules of single stranded RNA (ssRNA) linked by hydrogen bridges, 
with positive polarity and a “capping” region at 5´and a “polyadenylation” region at 3´. There is 
also a transfer RNA that the virus needs for its replication. The complexity of the retroviruses is 
different among retroviral genera, having the simplest ones only the basic information and others 
also have regulatory elements. There are three genes that all -RVs share that are always located 
in the same order: 5´-gag-pol-env-3´ (Figure 10). 
     
 
 
Figure 10. General representation of -RVs used in gene therapy assays, with the principal elements. LTR 
are the long terminal repeats located at both sides of -RVs that control essential activities such as 
transcriptional and post-transcriptional processes. Ψ is the encapsidation signal. gag, pol and env are the 
structural genes needed for vector production. 
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The principal components of integrating -RVs are: 
- gag: this gene encodes the information for core and structural proteins: the proteins that form 
the capsid (CA), the matrix (MA) and the nucleo-capsid (NC). 
- pol: encodes the reverse transcriptase (RT), the integrase (IN) and the protease that are 
essential proteins for viral integration. 
- env: is the gene that encodes for the viral envelope. It is processed by the cellular proteases to 
generate the glycoprotein of its surface and the transmembrane protein. These two proteins form 
the complex that interacts with the cellular receptors and is the specificity of this interaction the 
one that determines the type of cells that the virus can infect (tropism). 
As -RVs tend to integrate in areas both upstream and downstream of the TSS (Wu et al., 2003), in 
this basic structure of -RVs several modifications were introduced to prevent from possible 
adverse effects of integration into the host genome. Some of these modifications are the 
generation of self-inactivating (SIN) -RVs or the -retroviral based protein delivery system that 
was used in this work. This is based on the use of -retroviral particles specifically designed to 
transduce proteins in a targeted, controlled, dose dependent and transient manner into cultured 
cells. Precursors of the protein of interest are inserted into gag-protein precursors from -RVs and 
they assembly into infectious retroviral particles to escape the action of proteases in the 
endosome. They carry nuclear localization signals to facilitate that proteins are released by the 
retroviral protease in the nucleus of transduced cells (Voelkel et al., 2010) (Figure 11). This 
method results useful for vector excision in induced pluripotent stem cells (iPSCs) by the specific 
release of the Cre recombinase enzyme. 
 
 
(Schwarze et al., 1999), (Dalba et al., 2007), (Anton and Graham, 1995), (Miura et al., 2009) 
 
 
 
 
Figure 11. Retroviral based protein delivery system in which the Cre recombinase was cloned to be used as 
a vector removing system for vectors with LoxP sites. 
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- Lentiviral vectors 
These vectors derive from a genus of the Retroviridae family and have the property of being able 
to transduce both dividing and non-dividing cells. They have the basic structure of -RVs (5´-gag-
pol-env-3´) but they are more complex since they have accessory proteins that are involved in the 
regulation of the viral cycle (in human immunodeficiency virus (HIV)-derived vectors: vif, vpr, vpu, 
tat, rev, nef) (Manilla et al., 2005) (Figure 12). 
 
 
 
 
 
 
LVs, particularly the ones that derive from HIV, integrate preferentially in transcriptionally active 
genes. In some instances this can lead to the production of aberrantly spliced transcripts and 
deregulated gene expression (De Palma et al., 2005) (Yang et al., 2008) (Yang et al., 2008) (Cesana 
et al., 2012; Moiani et al., 2012). In contrast to -RVs, LVs do not have a preferential integration in 
regions close to the TSS of genes, something that markedly limits the trans-activation potential of 
LVs. In the so called “Self-Inactivating (SIN) LV vectors” the U3 region of the LTR is inactivated, 
allowing the use of different enhancer-promoters with improved safety properties. The design of 
more sophisticated vectors also includes the option of inserting strong RNA 
termination/polyadelination signals that act as insulators to prevent undesired gene trans-
activation (Richard et al., 2001). 
 
The genetic engineering of gene therapy vectors facilitates the modification of the natural tropism 
of the vector, and in consequence the cell type to be transduced. This can be done by replacing 
the natural viral envelope by other viral envelopes or by chimeric proteins, in a process known as 
vector pseudotyping. The most widely used envelope for lentiviral pseudotyping is the Vesicular 
Stomatitis Virus’ G-protein (VSV-G) that is able to transduce many  cell types (Cronin et al., 2005).  
 
Figure 12. General representation of the lentiviral vectors backbone used in gene therapy with the 
principal elements. LTR are the long terminal repeats located at both sides of LVs that control essential 
activities such as transcriptional and post-transcriptional processes. Ψ is the encapsidation signal. Gag, 
pol and env are the structural genes needed for vector production. vif, vpr, vpu, tat, rev, nef correspond 
to accessory proteins that participate in the regulation of the viral cell cycle. 
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As many LVs derive from HIV, improved packaging systems have been progressively developed in 
which the vector production involves three plasmids (2nd generation LV vectors) or four plasmids 
(3rd generation LV vectors) (Figure 13). 
    
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Several modifications have been made in lentiviral vectors, for example through the development 
of integration defective lentiviral vectors (IDLV) (Figure 14) in which the integrase is mutated to 
block the integration process (Brussel and Sonigo, 2004) and to avoid undesired effects of 
integrating LVs (Kulkosky et al., 1992; Shibagaki and Chow, 1997; Yanez-Munoz et al., 2006) even 
though a residual integration of these vectors has been already reported. IDLV vectors are 
competent at transcription and they efficiently express the transgene of interest for a short 
Figure 13. A) Plasmids used in 2
nd
 generation LV production that involves the use of three plasmids. Plasmid 1 
corresponds to the construct that contains the gene of interest under the control of the adequate promoter. 
Plasmid 2 contains the structural genes gag and pol and some regulatory elements and plasmid 3 contains the viral 
envelope gene. B) Plasmids used in 3
rd
 generation LV production that involves the use of four plasmids to increase 
the biosecurity of the process. Plasmid 1 corresponds to the construct that contains the gene of interest under the 
control of the adequate promoter and 5’ LTR is modified for the expression to be driven only by the internal 
promoter. Plasmid 2 contains the structural genes gag and pol and some regulatory elements, plasmid 3 contains 
the regulatory element rev. Plasmid 4 harbours the envelope gene. 
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period of time given that non-integrated episomes are lost within cell divisions (Philippe et al., 
2006; Yanez-Munoz et al., 2006) (Figure 14).  
 
Another kind of modified LVs are the ones designed to be induced or repressed in response to the 
administration of certain drugs “drug inducible LVs”. 
 
 
 
7.2 NEW TOOLS FOR TARGETED GENE THERAPY BY 
HOMOLOGOUS RECOMBINATION 
 
Recently, more refined strategies of gene modification have been developed that consist of the 
genome modification at specific sites, trying to avoid dangerous genomic localizations with a high 
risk of proto-oncogene activation and other undesired effects.  
 
Tools based on HR have been designed to specifically modify the gene of interest by gene editing. 
As HR occurs at a low frequency in mammalian cells, efforts are directed to increase the HR rate, 
using a donor DNA construct, flanked by regions with homology to the target site. Although many 
studies have been performed to find optimal systems that increase the rate of HR in the cells, it 
Figure 14. Non-
integrating 
lentiviral vectors 
and their 
mechanism of 
action in the cell. 
The different LTR 
conformations that 
take place in the 
cell are 
represented. 1-LTR 
circle is generated 
after intramolecular 
homologous 
recombination 
between the LTRs 
with one single 
final LTR. 2-LTRs 
are generated when 
there is non- 
homologous- end- 
joining of linear 
episomal DNA. 
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seems that the mechanisms that have a stronger effect on the rate of HR are the ones based on 
the generation of DSB in the target site (Vasquez et al., 2001), (Porteus and Baltimore, 2003), 
(Deng et al., 2012). These strategies use specific endonucleases that can recognize unique sites of 
the genome where they are able to generate a DSB and promote its repair by HR, thus improving 
the efficiency to introduce the gene of interest. Several endonucleases are used in gene targeting, 
being  meganucleases, zinc finger nucleases, TALE nucleases  and more recently the CRISPR/CAS 
nucleases, the most widely used (Grizot et al., 2010), (Mussolino et al., 2014; Pabo et al., 2001) 
(Wijshake et al., 2014) 
 
7.3 GENE THERAPY IN FANCONI ANEMIA 
FA constitutes a good candidate disease for being treated by HSC gene therapy strategies.  
The gene therapy approaches proposed for FA aim the introduction of the correct sequence of 
the gene that is defective in the FA patient into his HSC. These corrected HSCs, would have a 
selective advantage over uncorrected cells, and therefore, the transduction of a small number of 
HSCs with the therapeutic vector would give rise to disease-free HSCs and finally to definitive 
differentiated cells. Gene therapy approaches for FA are particularly relevant for patients who do 
not have a HLA-identical donor for bone marrow transplantation (Rio et al., 2008). 
 
So far, two gene therapy trials have been developed for FA patients with -RVs. The first one was 
carried out by Liu and colleagues in 1997 to treat FA patients of the FA-C complementation group. 
In this study the authors observed an increased number of bone marrow cells in treated patients 
but no clinical improvement was observed (Liu et al., 1999). The second study was developed for 
FA-A patients and was performed in 2007 by Dr. Williams. This study neither generated clinical 
improvements in the patients (Kelly et al., 2007). 
 
There are certain obstacles that slowed down the gene therapy for FA to be a reality, like the 
difficulty of obtaining high numbers of HSCs from patients, once BMF was developed. Improved 
vectors were also required to achieve high transduction rates with the therapeutic vector.  
 
The transduction efficiency of vectors carrying the required therapeutic gene was improved by 
reducing the culture time during transduction (Jacome et al., 2006), preventing oxidative stress 
and by the development of more sophisticated vectors, such as SIN LVs (Kee and D'Andrea, 2012) 
(Gonzalez-Murillo et al., 2010). 
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The lack of success observed in previous FA gene therapy trials led researchers to think about 
improvements and considerations that should be taken into account to develop safer and more 
efficient gene therapy trials to treat this disease. Thus, at the International FA Gene Therapy 
Working Group that was held in 2011, worldwide experts in the field, set up the conditions for 
future FA gene therapy trials to reduce genotoxicity and to assure stable expression of the 
transgene (Tolar et al. 2011). In Europe these studies are coordinated by our laboratory, and 
another gene therapy protocol is being conducted at the Fred Hutchinson Center in Seattle, USA. 
In our laboratory a SIN LV vector developed by Gonzalez-Murillo et al. (Gonzalez-Murillo et al., 
2010) was designated as an Orphan drug in 2010 by the European Comission (EU 3/10/822) and 
was approved for a Phase I/II Gene Therapy Trial for FA-A patients, the most common 
complementation group in Spain (Antonio Casado et al., 2007).  The proposed protocol will be 
carried out by multiple centres all over Europe and it is believed to improve the clinical efficacy 
observed in the two protocols previously performed.  
MING 
8. FANCONI ANEMIA MOUSE MODELS 
Mouse models represent a powerful tool in basic and translational research because they allow to 
deeply investigate the mechanisms underlying the disease and also to evaluate the efficacy and 
toxicity of new experimental therapies.   
 
In FA, different mouse models have been generated to improve the understanding of the 
molecular basis of the disease and to mimic the phenotype observed in the affected patients.  In 
the mouse models developed until now, several FA genes have been deleted by knock-out 
strategies, in which one FA gene or part of it was deleted in ESCs by HR, allowing the inheritance 
of the genetic modification by the offspring. With the generation of these models, important 
information was revealed about how FA pathway protects against genomic instability and how to 
develop safer and more efficient therapies for FA. In this respect, it was observed that the 
disruption of FA pathway affects viability in mice, especially in certain backgrounds, being the 
C57/BL6J mouse strain the one that produces more lethality (van de Vrugt et al., 2009).  
 
Most of the mouse models developed so far present some of the typical features observed in FA 
patients, such as cell hypersensitivity to DNA ICL agents (MMC and DEB) and to some cytokines 
like IFN or TNF and also impaired fertility. From the single FA gene mutants, none of these 
models was able to reproduce the BMF observed in patients. Among these models, the 
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Slx4/Fancp-/- (Btbd12-/-) mouse model that presents low white blood cell (WBC) and platelet (PLT) 
counts (Crossan et al., 2011), the Brca2/Fancd1hypomorphic model, with proliferation 
defects in hematopoietic progenitor cells  (McAllister et al., 2002a) (Houghtaling et al., 2003) 
(Navarro et al., 2006) are the ones that more closely resemble the disease observed in FA 
patients. Cells lacking FANCD1/BRCA2 gene are the only ones  from all FA gene deficiencies that 
do not form RAD51 foci after damaging their DNA with ICL agents, although cells deficient in 
BRCA2 partner FANCN/PALB2, also have an impaired capacity to form RAD51 foci (Xia et al., 
2007), thus proving the importance of this protein in repairing the DNA by HDR (Godthelp et al., 
2006). 
 
The most frequent developmental abnormality observed in FA mouse models is microphtalmia 
(Carreau et al., 1998; Crossan et al., 2011; Houghtaling et al., 2003; Wong et al., 2003), although it 
has not been described in all the models. A high percentage of Slx4/Fancp-/- (Btbd12-/-) mice show 
an abnormally shaped and enlarged skull in C57/BL6J strain (Crossan et al., 2011).  
 
The embryonic and perinatal lethality is common to different FA mouse models observed in 
Fancd1, Fancn-/-, Fanco-/-, Fancl-/- Fancd2-/-, Fancm-/-and Fancp-/- (Agoulnik et al., 2002; Bakker 
et al., 2009; Crossan et al., 2011; Houghtaling et al., 2003; Marmorstein et al., 1998; Rantakari et 
al., 2010). FANCD1 and FANCN are lethal in humans as well, and this is the reason why some of 
these mouse models are hypomorphic rather than knock-out (Alter, 2007; Tischkowitz and Xia, 
2010). In some models the embryonic lethality was bypassed by generating conditional models. In 
other cases, genes such as p53 were also deleted to increase viability  (Jonkers et al., 2001). 
 
Apart from the fact that very few models show evidences of BMF, mouse models do not show 
many of the hematologic defects observed in FA patients. Some FA models have a predisposition 
to develop cancer. This is the case of Fancd1 (high incidence of epithelial cancer) (McAllister 
et al., 2006) or Fancm-/-.  Nevertheles, it is very rare that FA mouse models spontaneously develop 
AML. Recently, the hypothesis that aldehydes could contribute to the pathology of FA has been 
supported by studies performed in which double mutants for Fancd2 and Aldh2, one of the 
enzymes in charge of metabolizing aldehydes, were not viable and the very low proportion of 
surviving mice had a high H2AX induction, indicative of DSBs in the DNA (Langevin et al., 2011). 
 
The FA mouse models existing nowadays are described in Table 5.
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FANCONI ANEMIA MOUSE MODELS 
GENE DISRUPTION REFERENCE PHENOTYPE 
Fanca Exons 4-7 replaced by neo 
Cheng et al. (Hum. Mol. Genet., 2000; 9:1805) (Cheng 
et al., 2000) 
 Infertility, hypogonadism, genetically unstable and hypersensitive to ICL agents 
(MMC) fibroblasts. No signs of anemia, although there is a small PLT decrease and 
rise of erythrocytes. 
Fanca Exons 1-6 replaced by LacZ 
Wong et al. (Hum Mol Genet, 2003; 12(16):2063-76) 
(Wong et al., 2003) 
Microphtalmia, infertility and defects in meiosis. Retarded growth, chraneal 
malformations, germ line apoptosis and hypersensitivity to ICL agents. No 
hematologic abnormalities. 
Fancc Exon 8 replaced by neo 
Chen et al. (Nature Genet., 1996; 12:448) (Chen et al., 
1996) 
Infertility, hypersensitivity of spleen cells to ICL agents (DEB and MMC). No 
hematologic or developmental anomalies until 9 months of life. 
Fancc Exon 9 replaced by neo 
Whitney et al. (Blood, 1996; 88:49) (Whitney et al., 
1996) 
Infertility, hypersensitivity to ICL agents. Reduced capacity of forming progenitor 
colonies in vitro from BM cells although no anemia was observed in PB. HPC 
sensitive to IFN 
Fancg Exons 2-9 replaced by neo Yang  et al. (Blood, 2001; 98: 3435) (Yang et al., 2001) 
Reduced fertility. Low repopulating ability. Defects in mobilization and homing. 
Normal telomere length. Spontaneous chromosomal breakage and sensitivity to 
MMC. 
Fancd1 
(Brca2∆27/∆27) 
Exon 27 
McAllister et al. (Cancer Res. 2003; 62: 990) 
(McAllister et al., 2002a) 
Infertility, hypersensitivity to ICL agents (MMC). Light reduction of perinatal 
lethality. Increased probability of cancer and reduced survival. Low short and long-
term repopulating ability and low HPC in vitro proliferation. 
Fancd2 
Replacement of exons 26-27 
with neo 
Houghtaling et al. (Genes & Dev. 2003; 17:  2021) 
(Houghtaling et al., 2003) 
Microphtalmia, infertility, hypersensitivity to ICL agents. Perinatal lethality, 
especially in C57/BL6J strain, deficiencies in meiosis, low repopulating ability. 
Increased cell cycle entry and loss of quiescence. High incidence of epithelial 
tumours and telomere dysfunction. 
 
Fancd2 
Intron 1 replaced by pur Parmar et al. (2010) (Parmar et al., 2010)  
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Usp1  
Kim et al. (Dev. Cell, 2009, 16(2):314-20)(Kim et al., 
2009) 
Male infertility, hypersensitivity to ICL agents (MMC). Increased perinatal 
lethality.Hypoplasia in BM. 
Fancd2/p53  
Houghtaling et al. (Cancer Res, 2005;65:85–91) 
(Houghtaling et al., 2005) 
Infertility, hypersensitivity to ICL agents. Increased tumours in comparison with the 
single Fancd2 mutant. Cells do not stop at S-phase due to genotoxic stress derived 
from p53 suppression. 
Fancc/ Sod1  
Hadjur et al. (Blood, 2001; 98:1003) (Hadjur et al., 
2001) 
Infertility, hypersensitivity to ICL agents. Increased production of superoxide by 
hepatocytes in vitro. Hypocellular bone marrow and decreased WBC and red cells in 
PB. Low number of lineage commited progenitors in vitro. 
Fancc/p53  Freie et al. (Blood, 2003; 102: 4146) (Freie et al., 2003) 
Infertility, hypersensitivity to ICL agents .Tumour development early in life. 
 
 
Fancd2/Mlh1  
van de Vrugt HJ et al. (Cancer Research, 2009, 
69(24):9431-8) (van de Vrugt et al., 2009) 
Infertility, hypersensitivity to ICL agents in fibroblasts (MMC). Delayed growth. 
Fancm Exon 2 replaced by LoxP  neo 
Bakker et al. (Hum Mol Genet, 2009; 18(18):3484-95) 
(Bakker et al., 2009) 
Perinatal lethality; in C57/BL6J background there are less females in the offspring.  
Infertility, hypersensitivity to ICL agents Increased incidence of cancer and reduced 
lifespan. 
Fancc/Fancg  
Pulliam-Leath et al. (Blood, 2010, 116(16):2915-20) 
(Pulliam-Leath et al., 2010) 
Infertility, hypersensitivity to ICL agents. High incidence of bone marrow failure and 
tendency to develop AML and MDS. 
Fancp (Slx4) 
Insertion of b-geo in  intron 3 
and LoxP mediated deletion in 
exon 3 
Crossan et al. (Nat  Genet., 2011, 43(2):147-52) 
(Crossan et al., 2011) 
Infertility, hypersensitivity to ICL agents. Microphtalmia and in some cases 
abnormally shaped and enlarged skull. Prerinatal lethality. Reduced WBC and PLT 
counts. Premature senescence and tendency to accumulate spontaneous DNA 
damage. 
Fancl 
150kb on chr. 1 (exons 4-14) 
replaced by goat b-globin gene 
Agoulnik et al., 2002, Hum. Mol. Genet. (2002) 11(24): 
3047-3053 (Agoulnik et al., 2002) 
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Fancn Intron 1 replaced with b-geo 
Rantakari et al. 2010,  Hum. Mol. Genet. (2010) 
19(15): 3021-3029 (Rantakari et al., 2010) 
Bouwman et al.,2011,  J. Pathol., 224: 10–21 
(Bouwman et al., 2011) 
 
Fandf Exon 1 replaced by neo 
Bakker et all.  J Pathol. 2012 Jan;226(1):28-39 
(Bakker et al., 2012) 
Infertility, hypersensitivity to ICL agents. Reduced capacity to monoubiquitinate 
Fancd2. Compromised survival and high incidence of tumours. 
Fanco 
Introduction of G>A splice-site 
mutation in intron 5 
Smeenk et al., 2010,  Mutat Res. 2010 Jul 7;689(1-
2)(Smeenk et al., 2010) 
 
Fanco 
Exons 2-3 replaced with LoxP 
neo 
Kuznetsov et al.,2007,  J Cell Biol. 
2007February26;176(5) (Kuznetsov et al., 2007) 
 
Fancd2/Aldh2  
Garaycoechea et al. (Nature, 2012, 489(7417):571-5) 
(Garaycoechea et al., 2012) 
Infertility, hypersensitivity to ICL agents. Developmental defects and susceptibility 
to develop AML and to the toxic effects of ethanol. Adults that do not develop 
spontaneous leukemia develop aplastic anemia with accumulated damage in 
CPHs/CMHs.  
Table 5. Fanconi anemia existing  mouse models. 
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The Brca2 hypomorphic mouse model (Fancd1/Brca2) was generated in 2002 by 
McCallister et al. (McAllister et al., 2002a) by a deletion of exon 27, last exon of Brca2 gene. 
This model was characterized in 2006 by Navarro et al. (Navarro et al., 2006) from our 
laboratory and by that time it was the model that more closely resembled the phenotype of 
human FA patients. Importantly, Brca2mice showed spontaneous chromosomal 
instability, even in the absence of DNA damage, and also reduced proliferative potential of 
CFCs and HSCs compared to control mice or to other FA mouse models. Finally, these mice 
showed a defective competitive repopulating potential in vivo, compared to wild type (wt) 
cells. Because of the relevance of this model in the field of FA, this was the model that we 
chose in this PhD work. 
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B. CELL REPROGRAMMING 
 
1. STEM CELLS  
Stem cells have the ability to self-renew, differentiate and to undergo two different types of 
cell division, symmetric division, in which the two daughter cells are either differentiated cells 
or stem cells and asymmetric division, in which the progeny is composed by a stem cell and a 
partially differentiated cell (Morrison and Kimble, 2006; Tajbakhsh et al., 2009). Stem cells can 
be divided in four categories based on their potency to generate different cell types (Figure 15 
and Table 6). 
 
 
 
 
 Table 6. Stem cell classification in terms of their differentiation potential. 
 
Figure 15. Stem cells and the 
differentiation pattern that they can 
follow to maintain the stem 
population and also to generate 
differentiated cells. Stem cells have 
the particularity that they can 
divide simetrically, giving rise to 
new stem cells (self-renew) or to 
differentiated cells and 
assimetrically, differentiating into a 
stem cells and a maturing cell type 
(differentiation). 
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1.1 EMBRYONIC STEM CELLS (ESC) 
Embryonic stem cells are pluripotent cells able to generate cells from all the lineages of the 
individual, including germ cells, with the exception of the extra-embryonary tissues.  
 
ESC isolation dates from the 80´s, when the researchers Evans and Kaufman in the UK and 
Martin (Martin, 1981) in the US, derived ESC from the inner cell mass (ICM) of 2.5 days 
blastocysts. 
 
It is important to mention that ESCs have a high telomerase activity, a ribonucleoprotein 
enzyme in charge of compensating for telomere shortening during cell division by synthesizing 
telomeric DNA, thereby maintaining the telomere length. This activity allows ESCs to self-
renew without undergoing senescence (Hiyama and Hiyama, 2007). 
 
ESCs have the capacity to form teratomas, tumours of embryonic origin that contain cells of 
the three embryonic layers, endoderm, mesoderm and ectoderm. Altough human ESC (hESC) 
and mouse ESC (mESC) are very similar, they differ in their properties. Some molecular and 
functional characteristics of mouse ESCs (mESCs) are represented in Table 7. 
 
 
 
 
Table 7. Main properties of mouse embryonic stem cells. 
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Despite the promising future of hESC to be used in cell therapy, there are several biologic 
limitations, mainly derived from aspects related to allogeneic transplantation that should be 
circumvented for their use. There are also important ethical problems regarding the 
obtainment and use of these cells.  
 
 1.2 HEMATOPOIETIC STEM CELLS (HSC) 
HSCs are adult stem cells with multipotent capacity. These cells are very rare in bone marrow, 
representing only 1/104-1/105 in total bone marrow cells. They cannot be recognizable by 
morphology and have a low rate of renewal. The hematopoietic system is a hierarchical system 
in which HSCs generate committed progenitors that can only be recognizable by cellular 
markers or by in vitro clonogenic cultures (Lemieux et al., 1995). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Diagram of the hematopoietic system with the different cell populations along differentiation of the 
hematopoietic stem cell to give rise to all cell types present in blood.  
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HSCs were identified by the expression of a variety of surface markers. Their functional 
properties could be determined by transplants into lethally irradiated mice (Morrison and 
Weissman, 1994). The assays that best define the HSCs are the in vivo competitive 
repopulating assays in which the functionality of these cells is proven by their ability to restore 
and reconstitute the hematopoietic system of irradiated mice (Harrison, 1980). 
 
The phenotypic characterization of the HSCs has shown that these cells are characterized by 
the lack of expression of lineage markers, either erythroid, monocytic, granulocytic or 
lymphoid, together with an elevated expression of Sca1+ and ckit+ specific markers of 
undifferentiation. This population is known as LSK (Lin-, Sca1+, ckit+) (Figure17).  
 
 
 
Among LSK population, other markers have been found in the long-term HSCs (LT-HSCs -Lin-, 
Sca1+, ckit+, Flk2-, Thy1low, CD34--), in the short term HSCs (ST-HSC - Lin-, Sca1+, ckit+, Flk2-, Thy1, 
CD34+ -) and in the primitive progenitors (MPP - Lin-, Sca1+, ckit+, Flk2+, CD34+) (Ratajczak, 
2008).  
 
More recently, the SLAM code was proposed as a system for HSC characterization based on 
the surface markers CD150, CD244 and CD48. Based on this, the HSC are characterized by the 
CD150+, CD244- and CD48- phenotype, while primitive progenitors  express CD150-, CD244+ and 
CD48-, and most restricted progenitors express CD150-, CD244+and CD48+ (Kiel et al., 2005) 
(Figure 18). 
Figure 17. LSK population 
(Lin
-
, Sca1
+
, ckit
+
) 
represented in green colour 
that is double positive for 
ckit and Sca1. The 
population to which these 
cells give rise when 
differentiated are also 
represented in beige and red 
colours. 
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During embryogenesis, mouse HSCs, follow a differentiation that passes through an 
intermediate stage called hemangioblast defined by the expression of the mesodermal 
markers Flk1+ and Brachyury+, and then they differentiate to hemogenic endothelium (Tie2high, 
ckit+, VE cadherin+ and CD41-) from which cells would differentiate both to endothelium 
(CD31+) and to primitive (CD41+, CD45-) and definitive hematopoiesis (CD41+, CD45+). In this 
transition from endothelial to hematopoietic fate, the cells undergo several changes in their 
expression of adhesion molecules and their pattern of expression of endothelial related genes, 
losing the expression of hemogenic endothelial surface markers and acquiring hematopoietic 
like markers and features (ie; round shape and mobility) (Figure 19) (McKinney-Freeman et al., 
2009), (Lancrin et al., 2012). 
 
 
 
Figure 18. SLAM code for 
the characterization of HSC 
populations based on the 
expression of CD150, CD244 
and CD48. 
 
Figure 19. Model of hematopoietic differentiation through an intermediate hemogenic endothelium that 
gives rise both to endothelial cells and to hematopoietic progenitor cells.  
 60 
 
1.3 INDUCED PLURIPOTENT STEM CELLS (iPSCs) 
In the year 2006, a new horizon of future opportunities in basic and translational research 
opened when Shinya Yamanaka and Kazutoshi Takahashi demonstrated for the first time that 
mouse fibroblasts could be reprogrammed to an embryonic state through the delivery of only 
four pluripotency genes into their genome. These transferred genes were Oct3/4 (encoded by 
the Pou5f1 gene), Sox2 (cooperates with Oct3/4 to regulate the expression of target genes 
involved in pluripotency), Klf4 (Kruppel-like factor 4 highly expressed in undifferentiated cells) 
and c-Myc (a proto-oncogene that regulates genes involved in cell proliferation, differentiation 
and apoptosis) (Figure 20). 
 
The resulting cells had an ESC-like morphology and other properties such as 3D compacted 
colonies, high proliferation rate, teratoma formation capacity etc. In contrast, these cells did 
not reproduce the ESC genetic expression pattern and methylation status (Yamanaka and 
Takahashi, 2006). One year later Yamanaka´s group refined the technique solving that problem 
and being able to generate chimeras (Okita et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jaenish et al. contributed to the very new field of cell reprogramming obtaining similar results 
to the ones published by Okita, without introducing selection markers into the fibroblasts 
(Takahashi et al., 2007). Simultaneously, this approach was improved and extended to human 
cells, both healthy and affected by a variety of genetic defects (Eminli et al., 2009; Hanley et 
Figure 20. Cell reprogramming protocol after correction of the genetic defect by gene therapy. 
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al., 2010), using several cell sources like neonatal and adult fibroblasts (Park et al., 2008a; Park 
et al., 2008b) as well as blood progenitors (Loh et al., 2009). Later on, many different strategies 
were developed for the reprogramming of mouse and human cells. The most commonly used 
methods for the introduction of the reprogramming factors are represented in Figure 21. 
 
Cell reprogramming technology provides an optimal source of cells to investigate embryonic 
development. Furthermore, iPSCs derived from patients or animal models of disease 
constitute important tools for modelling and understanding the pathogenesis of the molecular 
defects underlying the disease. The use of iPSCs is particularly important in BMF diseases, such 
as FA where HSCs are severely affected. They can also serve as a platform to test different 
methods or compounds that can restore the normal phenotype in disease-affected cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Different methods for cell reprogramming based on viral and non-viral systems and the moment in 
which each technology was developed. 
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2. SPECIFIC LIMITATIONS IN CELLULAR 
REPROGRAMMING 
Studies performed since the cell reprogramming technology was developed showed different 
patterns of gene methylation among different cell sources, suggesting that there might be a 
certain epigenetic memory intrinsic to the cell type of origin and that this may condition both 
the reprogramming and the differentiation capacity of these cells (Chin et al., 2009), (Deng and 
Xu, 2009). Another hypothesis supported that these differences could be due to variability 
among different iPS clones (Bock et al., 2011) (Lengner et al., 2010) (Newman and Cooper, 
2010). 
 
So, it seems that there are some critical factors to consider in cell reprogramming that can 
influence the expression of the reprogramming factors. For example, the age of the cells used 
for reprogramming is important and their DNA should be as less damaged as possible. 
 
At a molecular level, it has recently been shown that cells with telomere shortening, with 
deficiencies in DNA repair pathways, or with DNA damage caused by exogenous factors, are 
not able to efficiently reprogram their genome. Similarly, p53 was shown to be critically 
involved in the abrogation of the reprogramming of cells with harmed DNA (Raya et al., 2009) 
(Marion et al., 2009) (Marion and Blasco, 2010) (Muller et al., 2012a).  The studies of Raya et 
al. and Müller et al. showed that cells deficient in FA genes cannot be efficiently 
reprogrammed due to their characteristic phenotype. These last authors reported that this 
impairment in cell reprogramming efficiency could be overcome by using low oxygen 
concentration during iPSC generation (Muller et al., 2012b). 
 
It is also known that cells in which the telomere homeostasis is altered and that have 
mutations in genes of signalling pathways involved in DNA damage repair systems, such as 
signal transducer genes (ATM or 53BP1), nucleotide excision repair genes (XPC and RAD23B) 
are not able to efficiently wind back their genetic program to a pluripotent state (Marion and 
Blasco, 2010).  
 
Prior to our studies, the implication that proteins located downstream in the FA pathway, such 
as FANCD1/BRCA2, had in cell reprogramming was unkown.  
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3. HEMATOPOIETIC DIFFERENTIATION OF iPSC 
The arose of the iPSC technology allowed the envision of a new field in regenerative medicine 
through the generation of iPSCs-derived cells capable of generating a large repertoire of cell 
types.   
 
In the field of hematopoietic diseases, the generation of iPSC-derived hematopoietic 
progenitors has been challenging, due to the difficulties to generate hematopietic repopulating 
cells. 
 
Although many different hematopoietic differentiation protocols have been proposed, the 
most efficient ones were based on the generation of embryoid bodies (EBs) and the sequential 
addition of determined cytokines. This allowed the differentiation of iPSCs towards mesoderm, 
and then to the hematopoietic populations of interest. In some cases the co-culture of iPSC-
derived cells with hematopoietic stromas secreting hematopoietic cytokines and adhesion 
molecules improved the hematopoietic differentiation of iPSCs. It has also been described that 
genes from the LIM homeobox family play an important role in the differentiation and 
expansion of HSCs both in vitro and in vivo. Thus, the ectopic expression of HOXB4 (Sauvageau 
et al., 1995) or LHX2 (Kitajima et al., 2011) has been used to improve self-renewal of HSC cells 
(Kitajima et al., 2013). Strikingly, Hanna´s group engrafted the hematopoietic system of mice 
affected by Sickle cell anemia with gene corrected iPSCs-derived HSCs from a mouse model of 
this disease (Hanna et al., 2007).  
One of the main limitations of HSC gene therapy of FA is the limited number of HSCs that are 
present in most FA patients. Therefore, the possibility of generating HSCs from genetically 
corrected FA iPSCs results of great interest as a new therapeutic approach to treat the BMF 
characteristic of this disease. Our group, in collaboration with Izpisúa-Belmonte’s group and J. 
Surrallés, generated iPSC-derived hematopoietic progenitor cells from two FA 
complementation groups, one located in the FA core complex (FA-A) and the other one, FA-D2 
that belonged to the ID-complex. Significantly, only after correction of the genetic defect, iPSCs 
from these patients could be generated (Raya et al., 2010). Based on this study, in the present 
work we have investigated the generation of iPSC from a FA mouse model with hypomorphic 
mutations in the Brca2 gene. The relevance of correcting the genetic defect of this FA-D1 
model to reprogram and re-differentiate these cells towards the hematopoietic system is 
shown in this work.   
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IV. OBJECTIVES 
FA is a genetic disease associated with developmental abnormalities, bone marrow failure 
(BMF) and cancer predisposition. Nowadays, the only curative treatment of the BMF of FA 
patients is the HSCT from a healthy donor. Novel therapies, such as gene therapy, are being 
investigated to find new therapeutic alternatives for patients without a compatible donor. 
One of the current limitations of FA gene therapy is the limited number of HSCs present in 
many of these patients. As there are no protocols capable of expanding these cells in vitro, we 
have proposed that gene therapy combined with cell reprogramming would facilitate the 
generation of corrected HSCs from non hematopoietic tissues. 
The objective of this thesis was to investigate for the first time the process of cell 
reprogramming in a mouse model of FA-D1 and to explore the feasibility of using this approach 
to generate disease-free HSCs that could rescue the hematological defects that characterize 
these animals. 
To achieve this main objective, three intermediate objectives were investigated: 
1. Study of the relevance of Brca2 in cell reprogramming. 
 
2. Generation and characterization of disease-free iPSCs from Brca2Δ27/Δ27 mouse 
fibroblasts. 
3. Differentiation of gene corrected Brca2Δ27/Δ27 iPSCs towards disease-free HSCs. 
IALS AND METHODS 
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1. ANIMAL MODELS 
 
Several FA mouse models and their correspondent wild type (wt) mouse strains used as 
controls were used in the different experiments performed in this work. 
Fanca-/-: This mouse model was generated by Dr. Arwert (Department of Clinical Genetics 
and Human Genetics, Free University Medical Center, Amsterdam, The Netherlands) (Cheng et 
al., 2000) by the elimination of exons 4 to 7 of the gene and they were substituted by the LacZ-
Neo by homologous recombination in a Fvb/129 background. Wt Fvb/129 litter mates were 
used as controls. 
Brca2 : This mouse model was first generated by Dr. McAllister at Dr. Wiseman 
laboratory (Laboratory of Women’s Health, National Institute of Environmental Health 
Sciences, Research Triangle Park, NC) on a Balb/c background (McAllister et al., 2002a). As 
Brca2 knock-out mice are not viable, the transgenic mice were generated by the deletion of 
exon 27 of the Brca2 gene (Fancd1) resulting in a hypomorphic mutation, that does not 
generate embryonic lethality (Sharan et al., 1997). Wild type Balb/c litter mates were used as 
controls. 
NOD/SCID γcnull: This is an immunodeficient mouse model, which is double 
homozygous for the severe combined immunodeficiency (SCID) mutation and interleukin-2R_ 
(IL-2R_) mutation (γcnull). It was used in the teratoma formation experiments for the 
characterization of iPSCs. 
All experimental procedures and animal maintenance were carried out according to Spanish 
and European regulations (Spanish RD 223/88 and OM 13-10-89 of the Ministry of Agriculture, 
Food and Fisheries; and European convention ETS-123, for the use and protection of 
vertebrate mammals used in experimentation and other scientific purposes). 
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2. PRIMARY CELLS  
 
- Adult fibroblasts (MAFs)  
The first set of reprogramming experiments was performed using mouse adult fibroblasts 
(MAFs) from the ears of two different FA mouse models, Fanca-/- and Brca2Δ27Δ27 (Fancd1) mice 
and their control wt littermates.  
The generation of mouse adult fibroblasts (MAFs) was done by extraction of small biopsies 
from the ears of one mouse from each strain. They were cut in small fragments and then 
digested for 6 hours at 37°C with shaking and 0.25 % collagenase A (0.240 U/mg) lyophilized 
Clostridium histolyticum – Roche, diluted in DMEM + glutaMAX TM-I Dulbeccos’s Modified 
Eagle’s Medium (Gibco 61965-026) with 0.1 µg-U/µl penicillin/streptomycin (Invitrogen). Once 
the tissues were digested the fibroblasts were cultured in F25 flasks (Nunc) in DMEM + 
glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium (Gibco 61965-026) medium 
supplemented with 10 % FBS (Biowhitaker) and 0.1 µg-U/µl antibiotics (penicillin-
streptomycin, Gibco 15140-148) filtered by 0.1 µm. MAFs were maintained in culture for two 
to three passages. 
- Mouse embryonic fibroblasts (MEFs) 
Mouse embryonic fibroblasts (MEFs) were extracted from the chorion of 13.5E pregnant 
females. The procedure was performed by removing the uterus with the embryos. Once the 
embryos were obtained, the head and viscera were removed and the remaining embryonic 
parts were dissociated with 0.05 % trypsin (Gibco) with the help of scissors until complete cell 
dissociation. The big fragments remaining after dissociation were discarded by centrifugation 
and fibroblasts were seeded at a concentration equivalent to two embryos per 145 cm2 plate 
(Nunc), in DMEM + glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium (Gibco 61965-026) 
medium supplemented with 10 % FBS (Biowhittaker) and 0.1 µg-U/µl antibiotics (penicillin-
streptomycin, Gibco 15140-148), filtered by 0.1 µm, and cultured under hypoxic conditions 
(37°C, 5 % CO2, 5 % O2) in 145 cm
2 plates (Nunc). When confluent, MEFs were split 1/5 and 
expanded as required for the experiments. 
MEFs for cell reprogramming were expanded for one passage and were then either 
reprogrammed of frozen for future reprogramming experiments.  MEFs to be used as feeder 
layers were expanded until passage 4 to obtain a high number of cells trying to minimize the 
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number of passages. Mouse embryonic fibroblasts from ATTC (SCRC-1008) from C57BL/6 
males were also used as feeder layers.  
For MEFs inactivation, cells were trypsinized and added into tubes at a concentration 
equivalent to 10 confluent 145 cm2 plates (Nunc) per 50 ml tube in a final volume of 20 ml.  For 
the inactivation, cells were irradiated with X-rays at a dose of 60 Gy and when inactivated with 
MMC, cells were exposed to 12 mg/ml of MMC for 2.5 hours. After inactivation, cells were 
either maintained in culture to use as feeders for ESC or iPSC culture or frozen at -80°C at a 
concentration equivalent to two 145 cm2 plates (Nunc) per cryotube with half a mililitre of 80 
% DMSO freezing solution and half a mililitre of culture medium to obtain a final freezing 
solution concentration of 10 %. 
 
3. CELL LINES   
 
- NXE cell line (ATCC: SD 3444) 
It is a packaging cell line used for -RV production in a transient or stable manner. This cell line 
was generated by modification of the previously described 293T cells in which the retroviral 
proteins (gag-pol, env) required for the packaging of the -RVs had been stably transduced.  
This cell line was cultured in DMEM + glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium 
(Gibco 61965-026) medium supplemented with 10 % FBS (Biowhittaker) and 0.05 µg-U/µl 
(penicillin-streptomycin, Gibco 15140-148). Suplemented medium was filtered by 0.1 µm. 
 
- 293T cell line (ATCC: CRL-11268) 
It is a cell line used to produce non replicative LVs. It is a human embryonic kidney epithelial 
cell line that was modified by the insertion of a temperature sensitive gene codified by the 
simian SV40 T antigen that is constitutively expressed to achieve higher transfection efficiency. 
The inserted sequence allows the episomal replication of plasmids that contain the replication 
origin (ORI) in the early promoter region of the SV40. 
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- NIH/3T3 (ATCC-CRL-1568 TM) 
It is a cell line of embryonic origin from mouse sarcoma derived from the MIH/Swiss strain. The 
NIH/3T3 cell line is highly sensitive to sarcoma virus focus formation and leukemia virus 
propagation and has proven to be very useful for DNA transfection.  
It was cultured in DMEM + glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium (Gibco 
61965-026) medium supplemented with 10 % FBS (Biowhittaker) and 0.05 µg-U/µl antibiotics 
(penicillin-streptomycin, Gibco 15140-148). Supplemented medium was filtered by 0.1 µm. 
This cell line was cultured in DMEM + glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium 
(Gibco 61965-026) medium, supplemented with 10% FBS (Biowhittaker) and 0.05 µg-U/µl 
antibiotics (penicillin-streptomycin, Gibco 15140-148). Supplemented medium was filtered by 
0.1 µm. 
- HT1080 cell line (ATCC-CCL-121) 
It is a human male fibrosarcoma cell line with adherent morphology that contains an activated 
N-RAS oncogene. This cell line was used for vector titration. 
It was cultured in DMEM + glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium (Gibco 
61965-026) medium supplemented with 10 % FBS (Biowhittaker) and 0.05 µg-U/µl antibiotics 
(penicillin-streptomycin, Gibco 15140-148). Supplemented medium was filtered by 0.1 µm. 
- mESJ1 mouse embryonic stem cell line 
This cell line (ATCC (SCRC-1010)) of male mouse of the 129S4/SvJae strain was used as a 
control cell line for the characterization of the iPSCs generated in this study and also in the 
hematopoietic differentiation protocols of iPSCs. mESC and iPSCs were cultured in KO-
DMEMTM medium (Gibco 10829-018) supplemented with 15 % Hyclone  (Thermo Scientific, Sv 
30160.03), 1 % glutamax, 0.1 µg-U/µl antibiotics (penicillin-streptomycin, Gibco 15140-148), 1x 
NEAA (non-essential aminoacids 100x, Biowhittaker, PE13-114C), 50 µM 2mercaptoethanol 
(Gibco 31 350-010), 100 U/ml LIF (Mouse Leukemia Inhibitory Factor) (107 Chemicon, 
CA92590). Supplemented medium was filtered by 0.1 µm. 
- Hematopoietic stromal cell line OP9 (CRL-2749 TM) 
This cell line derives from a mouse hematopoietic stroma with fibroblastic morphology. It was 
obtained from C57BL/6 x C3H F2-op/-op mice. These cells are unable to produce functional 
macrophage colony stimulating factor (M-CSF) due to an osteopetrotic mutation in the gene 
that codifies for the GM-CSF, factor that inhibits the hematopoietic differentiation. This line 
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was grown and amplified one week prior to initiate the differentiation of iPSCs. OP9 cells were 
grown in -MEM medium (MEM-Alpha + glutamax), Minimum Essential Medium 1x, 
supplemented with 10 % FBS, 0.1 µg-U/µl penicillin/streptomicin (Gibco), 1x NEAA (non-
essential aminoacids 100x, Biowithttaker, PE13-114C), 50 µM 2mercaptoethanol (Gibco 31 
350-010) and filtered by 0.1 µm.   
The cells were split 1/5 - 1/8 when confluent to prevent contact self-inactivation and the 
generation of cytoplasmic vacuoles, decreasing the quality of the cells. OP9 were frozen in 10 
% DMSO and stored in liquid nitrogen until needed. 
- AM20.1B4 stromal cell line 
It is a stromal cell line from the aorta-gonada-mesonephro region obtained from mouse 
embryos at day E11 of development. This line was immortalized by transduction of the T 
antigen of the SV40 virus and was used in hematopoietic differentiation protocols. 
AM20.1B4 cell line was kindly provided by Dr. Majlinda Lako’s laboratory. It was amplified in 
culture medium composed of 50 % Myelocult long term medium M5300 (Stem Cell 
Technologies), 30 % -MEM (MEM-Alpha +glutamax), Minimum Essential Medium 1x, 12 % 
Hyclone (Thermo Scientific, Sv 30160.03), 4 mM L-Glutamine and 10 µM -mercaptoethanol 
(Gibco 21350-010 50MM). Cells were amplified and split 1/10 and were frozen when reached 
80 % confluence in 10 % DMSO and were stored in liquid nitrogen. 
- SC1#6: Cre reporter 
Cell line used for the functional titration of the retroviral based protein delivery system, to 
excise the reprogramming cassette (Ma.Cre.prot). This cell line was genetically modified to 
express a vector cassette in which the green fluorescent protein (eGFP) and the red 
fluorescent protein (RFP) were inserted. The vector was designed for eGFP open reading frame 
to be interrupted by LoxP sequences that, in between harboured the RFP. When the Cre 
recombinase was expressed in these cells, the sequence in between the two LoxP sites of 
SC1#6 cells, was removed allowing the eGFP protein to be expressed.  
This cell line was kindly provided by Dr. Melanie Galla from the Experimental Hematology 
Institute, MHH, Hannover. 
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5’ LTR 3’ LTR
 
 
4. VIRAL VECTORS 
4.1 VECTORS FOR PHENOTYPE CORRECTION OF THE 
FA CELLS  
 
- PCL1-BRCA2 
Lentiviral vector in which the expression of the human BRCA2 gene was driven by the SFFV 
promoter (Rio et al., 2008). The BRCA2 fragment had a size of 10,254 base pairs. It was used 
for the genetic correction of Brca2fibroblasts for further generation of disease-free 
Fancd1 iPSC (Figure 23). 
5’ LTR 3’ LTR
10,254 bp
 
 
 
- PGK-hFANCA-wpre (pCCLsin18.ppt.hPGKhFANCAWpre)  
This monocistronic lentiviral vector was also developed in the laboratory and designed for its 
clinical use in FA patients. It carries the human FANCA gene under the control of the 
phosphoglycerate kinase promoter (PGK). In this vector, FANCA expression was stabilized by a 
woodchuck hepatitis virus posttranscriptional regulatory element (wpre) in which the ATG that 
could give rise to a protein and part of the coding sequence were eliminated (Egelhofer y col., 
2004; Schambach y col., 2006).  
                         
 
Figure  23. Schematic representation of the therapeutic PCL1-BRCA2 lentiviral vector used for 
the genetic correction of the Brca2
Δ27Δ27
 mouse cells. 
 
Figure 24. Schematic representation of the therapeutic lentiviral vector pCCLsin18.ppt.hPGKhFANCA.Wpre* 
used for genetic correction of the Fanca
-/- 
deficiency in mouse cells. 
Figure  22. Schematic representation of the construction that SC1#6 cell line harboured to 
perform the functional titration of  Ma.Cre.prot supernatant for reprogramming vector excision.  
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4.2 VECTORS FOR CELL REPROGRAMMING 
 
- Monocistronic -RVs: pMXs.Sox2 (Addgene plasmid 13367), pMXs.Klf4 (Addgene 
plasmid 13370), pMXs.Oct3/4 (Addgene plasmid 13366), pMXs.c-Myc.T58A (Addgene plasmid 
13372). 
 
pMXs based monocistronic 4 RV vectors containing the mouse factors for reprogramming:  
Sox2, Klf4 (Kruppel-like factor 4), Oct3/4 (POU domain, class 5, transcription factor 1) and 
mouse c-Myc (myelocytomatosis oncogene T58A mutant) were used in the first experiments of 
cell reprogramming. They were generated by Dr. Toshio Kitamura from Tokyo University and 
the Institute of Medical Science from Shinya Yamanaka’s laboratory and were obtained from 
Addgene. 
5’ LTR 3’ LTR
950 bp
1420 bp
1150bp
1320bp
 
 
 
-Polycistronic lentiviral vectors for cell reprogramming: 1) 
EF1STEMCCA LoxP (pHAGE - EF1Full-Oct4 .F2a.Klf4.IRES. Sox2. E2A. cMYC. Wpre.LoxP).  2) 
EF1STEMCCA REDLIGHT LoxP (pHAGE - EF1Full-Oct4 .F2a.Klf4.IRES. Sox2. E2A.Cherry. 
Wpre.LoxP) 
Polycistronic vectors carrying the four reprogramming factors (Oct4, Klf4, Sox2 and c-Myc) 
under the control of the EF1 promoter with a F2A and an IRES sequence to allow the 
expression of the four factors at a similar level were kindly provided by Gustavo Mostoslavsky 
(Gianotti-Sommer et al., 2008). 
 
Figure 25. Schematic representation of the monocistronic 4 -RV vectors carrying the Sox2 gene 
(pMXs.Sox2), Klf4 gene (pMXs.Klf4), Oct3/4 gene (pMXs.Oct4) and c-Myc gene (pMXs.c-Myc)  used for cell 
reprogramming. 
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5’ LTR                     3’ LTR
1056bp 1250bp 956bp 1056bp
 
 
 
 
 
 
4.3 VECTORS FOR THE EXCISION OF THE 
REPROGRAMMING CASSETTE  
 
- Integrase deficient lentiviral vector carrying the Cre 
recombinase (pLBid-nlsCre-SF LV: IDLV) 
This vector was used for the excision of the polycistronic lentiviral vector from the iPSC. It is a 
bidirectional, integration deficient lentiviral vector carrying the Cre recombinase under the 
control of the CMV promoter and the cherry fluorescent protein controlled by the SSFV 
promoter. It was built and kindly provided by Drs. Tobias Mätzig and Mellanie Galla from the 
Experimental Hematology Institute, MHH, Hannover. 
 
             
 
 
 
 
Figure 26. Schematic representation of the polycistronic lentiviral vectors carrying either the four 
reprogramming factors (Oct4, Klf4, Sox2 and c-Myc) or three of the reprogramming factors (Oct4, Klf4 
and Sox2)  followed by the fluorescent cherry protein, used for cell reprogramming. The vector 
expression was driven by the EF1 promoter, followed by the Oct4 gene, a F2A sequence that cleaved 
the first polyprotein by a ribosomal skipping mechanism and the Klf4 reprogramming factor. Then there 
was an IRES to continue the expression of the Sox2 and c-Myc or the Cherry protein reprogramming 
genes. The vector contained a stabilizing wpre sequence and a LoxP site to allow the removal of the 
cassette by the Cre recombinase activity. 
Figure 27. Schematic representation of the integration deficient lentiviral vector carrying Cre 
recombinase and cherry protein as a reporter that was used to remove the reprogramming cassette 
from the iPSCs. 
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- Mlv.Ma.prot.nlsCreco 
This vector was generated by Dr. Schambach and Dr. Schedlmeier at the Experimental 
Hematology Institute, MHH, Hannover. It consisted of a retroviral vector specifically designed 
to transfer non-retroviral proteins in a directed, controlled and transient manner. This vector 
was designed to express the Cre recombinase from a MLV structural protein precursor 
harbouring a nuclear localization signal that allowed the protein of interest to be released in 
the nucleus of the target cells. It was produced in a 3rd generation packaging system (described 
in materials and methods). A functional titration was done by FACS using the previously 
described “SC1#6: Cre reporter” cell line. The excision of the reprogramming cassette in the 
iPSCs by this method occurred through a site specific delivery of the DNA Cre recombinase in 
the gag position of the retroviral matrix, after the proteolysis that allowed its release (Voelkel 
et al., 2010). 
5’ LTR                     3’ LTR
1132bp
 
 
 
 
4.4 VECTORS FOR HEMATOPOIETIC 
DIFFERENTIATION PROTOCOLS 
 
- MSCV-HOXB4-IRES-GFP 
A -RV carrying the HOXB4 LIM-homeobox gene was used to promote the expansion of HSCs 
by the obtainment of a selective advantage of transduced cells by the expression of this gene 
during the hematopoietic differentiation process of mESC and iPSCs. 
This vector was kindly provided by Christopher Baum’s laboratory at Experimental Hematology 
Institute, MHH, Hannover, and drove the expression of HOXB4 gene by the MSCV promoter 
followed by an IRES sequence that also allowed the expression of the reporter eGFP protein 
(Zhou et al., 1998) (Mizuguchi et al., 2000).  
 
Figure  28. Schematic representation of the retroviral based protein transfer system used for the 
reprogramming vector excision. 
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4.5 GENERATION OF RETROVIRAL AND LENTIVIRAL 
SUPERNATANTS 
 
The production of -RV and LV was performed both by transient co-transfection of the transfer 
plasmid in Nxe and 293T cells, respectively, and also the plasmids encoding for the VSV-G and 
for the gag/pol structural proteins, and the rev protein in case the production was in 3rd 
generation. 
The viral vector production in 2nd generation was performed as previously commented, using 
three plasmids, the transfer plasmid of interest, the envelope that in all cases was the VSV-G 
and the helper plasmid that was commercial but different in -RVs (Pasmid Factory–pCDNA3) 
or LVs (Pasmid Factory -PCMV.dR.8.74) production. The vector production in 3rd generation 
involved the use of the additional plasmid that encoded for the rev protein.   
For that purpose Nxe/293T cells were seeded the day before transfection on gelatin coated 
(0.1 %) 10 cm2 plates, at a concentration of 5 x106 cells per plate.  The day after 293T cells 
were at 80 % confluence and the medium was changed 2-4 hours before the transfection 
(except for the CaCl2 based transfection method). 
Different transfection methods were used for viral supernatant production that will be 
described, together with the vectors that were produced by each of the methods: 
- FuGENE transfection method 
The vectors that were produced by this method were:   
- pMXs.Sox2 (reprogramming experiments) 
- pMXs.Klf4 (reprogramming experiments) 
- pMXs.Oct3/4 (reprogramming experiments) 
- pMXs.c-Myc.T58A (reprogramming experiments) 
Figure 29. Schematic representation of the MSCV-HOXB4-IRES-GFP vector that expressed the HOXB4 
homeobox gene driven by the MSCV promoter. This vector contained an IRES sequence to express the 
eGFP protein. 
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- Four factor polycistronic excisable lentiviral vector for cell reprogramming. 
EF1STEMCCA LoxP (pHAGE-EF1Full-Oct4.F2a.Klf4.IRES.Sox2.E2A.cMYC. 
Wpre.LoxP) 
- Three factor polycistronic excisable lentiviral vector for cell reprogramming 
EF1STEMCCA REDLIGHT LoxP (pHAGE-EF1Full-Oct4.F2a.Klf4.IRES.Sox2.E2A. 
Wpre.LoxP) 
- MSCV-HOXB4-IRES-GFP (hematopoietic differentiation experiments) 
 
FuGENE (FuGENE HD Transfection Reagent - Roche) is a non-liposomal compound to transfect 
cells with a high efficiency and low toxicity even in non-serum free conditions. It is an 
expensive transfection method that we used in cases in which other methods were not 
successful, due to the size of the transfer vector or to the need of transfecting a high number 
of plasmids. For transfection with FuGENE, 51 µl of FuGENE were diluted in 600 µl of serum 
free DMEM glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium (Gibco 61965-026) DMEM 
added in 10 cm2 plates and incubated for 5 minutes at room temperature. In another tube the 
DNA mix was prepared at a total concentration of 11-12 µg of total DNA per 10 cm2 plates (8 
µg transfer DNA, 2 µg helper 1 DNA, 2 µg helper 2 DNA (3rd generation) and 2 µg envelope-
VSV-G. 
The FuGENE-DMEM mix was added to the DNA mixture drop by drop, avoiding FuGENE to 
touch the tube walls to allow the proper formation of DNA precipitates. This mixture was 
incubated for 15 minutes and then added to the cells (650 µl/plate). Cells were incubated for 
24 hours and then the medium was replaced by 9 ml of IMDM 10 % FBS y 0.05 µg-U/µl 
antibiotics (penicillin-streptomycin, Gibco 15140-148) per 10 cm2 plate and after 24 hours the 
supernatant was collected, filtered by 0,45 µm and  concentrated by ultracentrifugation in 
polypropylen tubes at 25,000 rpm for 2.5 hours in an OptimaTM L-100 XP Beckman Coulter 
ultracentrifuge using a Beckman Culture SW32 Ti S/N 10V 2610 rotor. After centrifugation the 
viral particles were resuspended in PBS or medium and stored at -80°C. The day after, the 
same procedure was repeated by collecting the supernatant 48 hours post-transfection. 
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- PEI transfection method (Polyethylenimine) 
By this method the following vectors already described in materials and methods were 
produced:   
- PCL1-BRCA2 (correction of FA Brca2 cells) 
- PGK-hFANCA-wpre (correction of FA Fanca-/- cells) 
 
Previous to transfection, the culture medium was replaced with 4 ml/10 cm2 plate of DMEM 
glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium (Gibco 61965-026) supplemented with 
10 % Hyclone and without antibiotics. The PEI stock was prepared to obtain a final 
concentration of 40 µM = 1 mg/ml. The transfection was carried out in 10 cm plates and the 
preparation of the transfection mixture was performed in the following proportions per 10 cm2 
plate.  
In one 15 ml tube (Tube1) 20 µL PEI 1 mg/ml were added over 980 µL of non supplemented 
DMEM glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium (Gibco 61965-026) and mixed. In 
a different 15 ml tube (Tube2) 14 µg of total DNA (2nd genereation) or 16.8 µg (3rd generation) 
8.4 µg Transfer DNA and 2.8 µg of each plasmid (helper 1, helper 2 (3rd generation) and 
envelope)- were mixed with 993 µl of non supplemented DMEM glutaMAX TM-I Dulbeccos’s 
Modified Eagle’s Medium (Gibco 61965-026). The PEI-DMEM mixture (Tube 1) was pipetted 
over the DNA-DMEM mix (Tube2), mixed and incubated for 20 minutes at room temperature. 
After the incubation the 2 ml mixture was added per plate, moved and stored in the incubator 
for 24 hours. The day after, the medium was replaced by 9 ml of IMDM 10 % FBS y 0.05 µg-
U/µl antibiotics (penicillin-streptomycin, Gibco 15140-148) per 10 cm2 plate and after other 24 
hours the supernatant was collected from the medium, filtered by 0.45 µm and concentrated 
by ultracentrifugation in polipropilen tubes at 25,000 rpm for 2.5 hours in a Beckman Coulter 
OptimaTM L-100 XP ultracentrifuge in a Beckman Culture SW32 Ti S/N 10V 2610 rotor. After 
centrifugation, the viral particles were resuspended in PBS or medium and stored at -80ºC. The 
day after, the same procedure was repeated collecting the 48 hours supernatant. 
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- CaCl2 transfection method  
The vectors that were produced by this method were the ones used for the excision of the 
reprogramming cassette.   
- Integrase deficient lentiviral vector carrying the Cre recombinase (pLBid-nlsCre-SF LV) 
(excision of the reprogramming cassette) 
 
- Mlv.Ma.prot.nlsCreco. For the production of this vector only the envelope plasmid (VSV-
G) was necessary because gag/pol was already encoded in the vector construction 
(excision of the reprogramming cassette) 
 
For transfection by the HBS and CaCl2 method, plasmids were mixed in a 15 ml tube with 2.5 M 
CaCl2 in the following proportions per plate: 5 µg transfer DNA, 10 µg helper 1.5 µg helper 2 
(3rd generation), 1.5 µg envelope, 50 µl CaCl2 and distilled water in a final volume of 500 µl. In 
another 15 ml tube 500 µl/plate of HBS (HEPES buffered saline solution (274 mM NaCl, 50 mM 
HEPES, 1.5 mM Na2HPO4 y H2O, optimal pH between 6.95 and 7.05) were added. While gently 
bubblig up, the DNA-CaCl2 mixture was added drop by drop with a p20 micro-pipette to allow 
the formation of calcium precipitates. This mixture was incubated at room temperature 
without moving for 20 minutes. While incubating the DNA mixture, the culture medium was 
replaced by the “transfection medium” composed of: DMEM + glutaMAX TM-I Dulbeccos’s 
Modified Eagle’s Medium (Gibco 61965-026) medium supplemented with 10 % FBS 
(Biowhitaker), 1 % Natryum pyruvat, 0.1 µg-U/µl antibiotics (penicillin-streptomycin, Gibco 
15140-148) and 20 mM HEPES. Additionally, just before use, cloroquine was added to the 
medium at a concentration of 25 mM (Chloroquine Diphosphate, Sigma-Aldrich). After 
incubation, the transfection mixture was added to the cells (1 ml/plate) and 6-7 hours post-
transfection, the medium was changed again for “tansfection medium” without cloroquine, to 
avoid the toxicity of this drug. Thirty six hours post-transfection the supernatant  was collected  
from the cell plates and filtered by 0.45 µm to eliminate cellular debris, and was stored at 4°C. 
At 48 hours post-transfection, the supernatant was collected and filtered again and together 
with 36 hour supernatant was concentrated by ultracentrifugation in polypropylene tubes at 
25,000 rpm for 2.5 hours in a Beckman Coulter OptimaTM L-100 XP ultracentrifuge using a 
Beckman Culture SW32 Ti S/N 10V 2610 rotor. After centrifugation, the viral particles were 
resuspended in PBS or culture medium and stored at -80°C. 
 
 80 
 
4.6 TITRATION OF VIRAL SUPERNATANTS BY FACS 
AND RT-qPCR 
 
The titration of vector supernatants was performed by transducing HT1080 cells (human 
fibrosarcoma cells) with serial dilutions of the supernatant. Fifty thousand HT1080 cells per 
well were seeded in p24 well plates, one day before the supernatant collection, in DMEM + 
glutaMAX TM-I Dulbeccos’s Modified Eagle’s Medium (Gibco 61965-026) medium 
supplemented with 10 % FBS (Biowhitaker) and 0.05 µg-U/µl antibiotics (penicillin-
streptomycin, Gibco 15140-148) filtered by 0.1 µm. Once the supernatant was prepared 
HT1080 cells were transduced with serial dilutions of the supernatant, ranging from 10-2 to 10-
7. Just before transduction, the number of cells in one well was counted to use this data for the 
titre calculation. Twenty four hours post transduction, the medium was replaced by fresh 
medium. When vectors carried fluorescent reporter genes, cells were collected 5 days after 
transduction and the percentage of cells expressing the reporter gene was analyzed by flow 
cytometry.  When the vector did not contain a reporter gene, cells were collected 10-11 days 
after transduction. Genomic DNA was extracted (DNeasy Tissue Kit, Qiagen GmbH) and the 
number of viral particles per microlitre was determined by RT-qPCR-Rotor-Gene RG-3000 
(Corbett Research Products), analyzing the number of integrated copies of the provirus, using 
either probes or primers that specifically recognized sequences of the provirus. The 
quantification of the number of viral particles in the samples was performed normalizing the 
data obtained with a standard curve that was performed by 10 fold serial dilutions, starting 
from 106 molecules of a plasmid containing the housekeeping human albumin gene gene 
(hALB)- pRRL.SIN.cPPT.PGK.EGFP.hALB (provided by Fr. Charrier;(Gennethon, Evry, France). 
This plasmid also harboured the ψ (psi) lentiviral encapsidation signal, only present in LV-
transduced cells. Samples were loaded in triplicates with the appropriate negative control 
corresponding to non-transduced cells and DNA of a sample known to contain one 
provirus/cell. The titre of the supernatant was given by the number of infective particles per 
mililiter, accordingly to the formula represented in Table 8. 
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 5. GENETIC CORRECTION AND 
MODIFICATION ASSAYS 
 
5.1 GENETIC CORRECTION OF FANCONI ANEMIA 
CELLS WITH GAMMA-RETROVIRAL VECTORS  
 
The FA cells used were adult or embryonic fibroblasts, either deficient in FA A gene (Fanca-/-) 
gene or in FA-D1 gene (Brca2 Δ27/Δ27). 
In the first set of experiments in which the defective genes were corrected, Fanca-/- and 
Brca2Δ27/Δ27 mouse ear adult fibroblasts were transduced with lentiviral vectors carrying the 
gene of interest and their correspondent control vectors PGK.iGFP, PGK FANCA Wpre 
(Gonzalez-Murillo et al., 2010), PCL1.EGFP, PCL1.BRCA2 (Rio et al., 2002). Viral supernatants 
were produced and titrated following the previously described method. 
 
 
Table 8. T is the titre of the viral supernatant. Nº of cells is the number of cells counted at the moment of 
transduction. Percentage of fluorescent cells corresponds to the percentage of cells expressing the 
transgene, obtained by FACS. DF is the dilution factor that corresponds to the dilution used for the titre 
calculation. CF is the factor used to obtain the titre in UT/mL, when the total volume at infection is not 
higher than 1 ml. (200 µl/well x 5= titre/ml). VCN is the vector copy number value. 
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5.2 CELL REPROGRAMMING ASSAYS 
 
5.2.1GENERATION OF INDUCED PLURIPOTENT STEM CELLS  
The generation of mouse iPSCs from two FA mouse models, Fanca-/- and Brca2Δ27/Δ27, was 
performed using -RVs in a first attempt and LVs only in Brca2Δ27/Δ27 deficient cells.  
- Generation of induced pluripotent stem cells (iPSC) using 
RVs reprogramming vectors 
Fifty thousand mouse adult fibroblasts (MAFs) per well were infected with a 1:1:1:1 proportion 
mixture of Oct3/4, Sox2, Klf4 and c-Myc (T58A) retroviral supernatants with 8 µg/mL of 
polybrene. The plate was centrifuged at 700 g and 32°C for 45 min without brake and then the 
cells were incubated for 24 hours. A second cycle of transduction was repeated following the 
same procedure. The day after, the medium was replaced by fresh DMEM + glutaMAX TM-I 
Dulbeccos’s Modified Eagle’s Medium (Gibco 61965-026) medium supplemented with 10 % 
FBS (Biowhittaker) and 0.1 µg-U/µl antibiotics (penicillin-streptomycin, Gibco 15140-148). 
At day 4 post-transduction, transduced cells were trypsinized and plated at a concentration of 
5x104 cells on irradiated MEFS seeded the day before over 0.1 % gelatine pre-coated 10 cm2 
plates. The day after, the culture medium was replaced for a medium for ESC/iPSC culture 
(mES medium).  mES medium was composed of 15% FBS Hyclone, 1x NEEA (Biowhittaker), 1 % 
Glutamax (Invitrogen), 0.1 µg-U/µl P/S (penicillin-streptomycin, Gibco 15140-148), 50 µM -
Mercaptoethanol (Gibco), 100 U/mL leukemia inhibitory factor (LIF) (Chemicon), KO-DMEM 
(Invitrogen). From this moment the culture medium was replaced daily and between 9-13 days 
post-transduction iPSC colonies arose in the plates showing a compact and round morphology.  
The iPSC colonies were selected and marked for individual colony collection. To pick the 
colonies, 5 ml of 0,25 % trypsin per plate were added and rapidly removed to prevent the 
complete detachment of the cells from the plate, but allowing them not to be too tightly 
attached. Single colonies were picked under the microscope with a p200 micropipette and 
were seeded in new 10 cm2 plates over irradiated MEFs trying to dissociate the cells as much 
as possible. 
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- Generation of induced pluripotent stem cells (iPSC) using an 
excisable polycistronic lentiviral vectors 
To increase the efficiency of reprogramming of Brca2 mouse embryonic fibroblasts 
(MEFs) and polycistronic reprogramming LVs were used. Several conditions were included in 
these experiments: uncorrected fibroblasts, fibroblasts corrected prior to reprogramming and 
fibroblasts that were corrected and reprogrammed at the same time. In each condition, 
2.5x104 mouse embryonic fibroblasts (MEFs) were transduced with supernatants from a 
polycistronic excisable vector (STEMCCA-LV) produced as previously described by Sommer 
(Sommer, Stadtfeld et al. 2009), every 24 h at 37 °C, 5 % CO2 in two cycles of infection.  
Four days after transduction the culture medium was replaced by mES Medium, composed by: 
KO-DMEM (Invitrogen), 15 % FBS Hyclone, 1x NEEA (Biowhittaker), 1 % Glutamax (Invitrogen), 
0.1 µg-U/µl P/S (penicillin-streptomycin, Gibco 15140-148), 50 µM -mercaptoethanol (Gibco), 
100 U/mL leukemia inhibitory factor (LIF) (Chemicon). The medium was replaced daily and 
between 9-11 days post-transduction iPSC arose in the plates showing a compact and round 
morphology. iPSC colonies were expanded as already described.  
 
5.2.2 INDUCED PLURIPOTENT STEM CELL CHARACTERIZATION  
 
- Alkaline Phosphatase 
Two kits were used for alkaline phosphatase (AP) detection: Alkaline Phosphatase Detection 
Kit (Millipore, SCR004) and Vector Blue Alkaline Phosphatase Substrate Kit III Cat. No. SK-5300 
(Vector laboratories). Alkaline phosphatase is a hydrolase enzyme that acts dephosphorylating 
nucleotides and other molecules under alkaline conditions. This activity, together with the 
expression of other surface markers is often used to evaluate the pluripotent state of ESC and 
iPSC, one of the first criteria in the characterization of these cells. Alkaline phosphatase (AP) 
activity was evaluated in the cell membrane of colonies fixed with 2 % paraformaldehyde 
according to the protocol described by the manufacturer (Millipore). Undifferentiated, thus 
pluripotent cells appeared red or purple, whereas differentiated cells appeared colorless. 
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- OCT3/4, NANOG and SSEA1 Immunostaining 
The expression of the pluripotency markers OCT3/4, NANOG and SSEA1 was analyzed by 
immunostaining in the iPSC colonies. Fifty thousand cells per chamber were cultured in gelatin-
coated polystyrene two slide chambers BD Falcon, fixed with 4 % paraformaldehyde and then 
permeabilized for 1 hour by a treatment with 1% BSA, 10 % FBS, 0.3 M glycine, 0.1 % Tween 20 
diluted in PBS.  
Fixed colonies were stained with the corresponding antibody hOCT3/4-FITC (1:20) (R&D, 
Minneapolis, MN). SSEA1-PE (1:200) (R&D Systems) and Nanog-PE (1:20) (R&D), overnight 
incubated at 4ºC together with DAPI (1:500) (Roche). Preparations were mounted with Moviol 
(Fluka) for analysis. 
- Teratoma formation 
iPSCs were cultured under normal conditions and when confluent, one million iPSCs were 
subcutaneously injected into the dorsal flanks of NOD.Cg-Prkdcscid IL2rgtm1Wjl mice 
(NOD/SCID γcnull). 4-8 weeks after injection tumours were extracted and paraffin sections of 
formalin-fixed teratoma specimens were prepared. Teratoma evaluation was performed by 
histological analysis of hematoxilin and eosin (H&E) stained sections. Aditionally, teratomas 
from iPSCs generated by transduction with the four reprogramming RVs were stained for 
specific tissues: AFP (Abcam) for teratoblastoma and mesendoderm cells, FOXA2 (Abcam) for 
endoderm, BRACHYURY (Abcam) and-ASMA (Abcam) for mesoderm and TUJ1-Neuronal 
Class III β-Tubulin (Abcam) and GFAP (Abcam) for ectoderm.  
- Quantitative RT–PCR and transgene expression 
The hBRCA2 relative transgene expression was determined by the 2 Ct method (Livak and 
Schmittgen, 2001), in which Ct corresponds to the cycle threshold. The primers used for 
hBRCA2 gene expression are represented in Table 9. The murine glyceraldehyde-3-phosphate 
dehydrogenase (mGapdh) housekeeping gene was used as an expression control (Table 9). The 
expression of endogenous mouse pluripotency genes was also determined by this method, in 
which Brca2Δ27/Δ27 MEFS were used as a negative control. Primers used for pluripotency gene 
expression analyses are detailed in Table 9. 
- Promoter methylation analyses  
The methylation profile of the internal Oct3/4 and Nanog promoters in the iPSC and their 
original fibroblasts was analyzed by the sodium bisulfite method.  
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This method was based on the conversion of non-methylated cytosine (C) into uracil (U) after 
bisulfite treatment. As this technique produced a high rate of DNA degradation, gDNA from at 
least 1x106 iPSCs, mES cells or fibroblasts was used. DNA was then amplified by RT-qPCR in 
which non-methylated C that became U were read as T, while the methylated ones were read 
as C. For Oct3/4 promoter analyses, a nested PCR was carried out obtaining a 460 bp long 
product with 15 CpG islands and for Nanog promoter analyses a single PCR was carried out 
obtaining a 366 bp long product with 6 CpG islands. Primers used for the amplification of 
Oct3/4 and Nanog promoters are described in Table 9. “Hot start” PCR was performed for 35 
cycles consisting of denaturation at 95°C for 1 minute, annealing at 56°C for 1 minute and 
extension at 72°C for 1 minute for all primer sets.  
The sequence obtained after amplification was run on a 2 % agarose gel and cloned in a TOPO 
vector (TOPO-TA Cloning® Kit for Sequencing; Invitrogen) for DNA sequencing. The result was 
obtained by differences in the amount of C that did not become T, at locations where there 
was a CpG island. 
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Primer/probe Primer/probe sequence
mOct4-F (RV) 5
 
-GGATGCTGTGAGCCAAGG-3
mOct4-R (RV) 5-GAACAAAATGATGAGTGACAGACAG-3
 
mNanog–F (RV) 5
 
-CACCCACCCATGCTAGTCTT-3
mNanog-R (RV) 5
 
-ACCCTCAAACTCCTGGTCCT-3
BRCA2-F 5
 
-CTTATGTTGCACAATGAGAAAAGAAATTAG-3
BRCA2-R 5-CGGAATCGGGCAAAACG-3
 
mNanog–F 5
 
-TTGCTTACAAGGGTCTGCTACT-3
mNanog-R 5
 
-ACTGGTAGAAGAATCAGGGCT-3
mOct4-F 5
 
-TAGGTGAGCCGTCTTTCCAC-3
mOct4-R 5
 
-GCTTAGCCAGGTTCGAGGAT-3
mSox2-5
 
F 5
 
-GAAACGACAGCTGCGGAAA-3
mSox2-R 5
 
-TCTAGTCGGCATCACGGTTTT-3
mMyc-F 5
 
-TAACTCGAGGAGGAGCTGGA-3
mMyc-R 5
 
-GCCAAGGTTGTGAGGTTAGG-3
mUtf-F 5
 
-GTGCACGCACCTCTACCTG3
mUTF-R 5
 
-AGAAAAAGCGGGCAACCT-3
Oct3/4 Promoter F1 5’- GTAAGTAAGAATTGAGGAGTGG-3’
Oct3/4 Promoter R1 5’- TCCAAACCCACCTAAAAACC-3’
Oct3/4 Promoter F2 5’- GATGGTTGAGTGGGTTGTAAGG-3’
Oct3/4 Promoter R2 5’- CCAACCCTACTAACCCATCACC-3’
Nanog Promoter F 5’- GATTTTGTAGGTGGGATTAATTGTGAATTT-3’
Nanog Promoter R 5’- ACCAAAAAAACCCACACTCATATCAATATA-3’
mGapdh-F 5
 
-TCCAAGGAGTAAGAAACCCTGGA-3
mGapdh-R 5
 
-GAAATTGTGAGGGAGATGCTCAG-3
mGapdh-Probe 5
 
-TexasRed-GAGCAAGAGAGAGGCCCTATTCCAACTC-BQH23
B-actin-F 5
 
-ACGGCCAGGTCATCACTATTG-3
B-actin-R 5
 
- ACTATGGCCTCAGGAGTTTTGTCA-3
B-actin-Probe 5
 
-Texas Red-AACGAGCGGTTCCGATGCCCT-BQH2-3
WPRE-F 5′-GGCACTGACAATTCCGTGGT-3′
WPRE-R 5′-AGGGACGTAGCAGAAGGACG-3′
 
 
 
 
 
 
Table 9. Schematic representation of primers and probes used for verification of genetic correction of 
gene complemented Brca2
Δ27/Δ27 
cells and for analysis of pluripotency gene expression in iPSCs. 
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- Excision of the reprogramming cassette and analysis of 
proviral copy number by RT-qPCR  
The excision of the polycistronic reprogramming cassette was carried out with two different 
types of excision vectors. First 10x105 cells from diploid iPSC selected clones were transduced 
with an integration-deficient pLBid-nlsCre-SF LV, either in suspension in a tube or over gelatin-
coated plates where they were maintained for 24 hours on irradiated feeder cells (irr MEFs). 
When cells were confluent, gDNA was extracted from each individual colony derived plates 
and the proviral copy number was quantified by RT-qPCR in a Rotor Gene RG-3000 (Corbett 
Research Products) using primers against wpre sequence present in the reprogramming vector 
(Table 9). The housekeeping gene used to normalize the expression data obtained was mβ-
actin (Table 9). Amplification was performed using SYBR Green Amplification Kit (Applied 
Biosystems) and the determination of the copy number was done by absolute quantification 
using a standard curve of a mouse cell line. Those colonies in which viral copies were still 
detected, were re-infected with the retroviral protein delivery system described in materials 
and methods. After re-excision, the iPSC colonies in which no amplification of wpre signal was 
detected were considered for further characterization and differentiation assays. 
- Southern Blot for detection of the presence of reprogramming 
cassette 
Genomic DNA (5-10 µg) from the samples was digested with PstI and EcoRV restriction 
enzymes (New England Biolabs) and a 0.8 % agarose gel electrophoresis was then preformed. 
The result of the electrophoresis was transferred to nylon membranes (Hybond-N + Amersham 
Biosciences) in a 0.4 M NaOH solution that was overnight hybridized with 32P-P labelled 
IRES and Wpre probes, with the labelling kit Rediprime II (Amersham Pharmacia Biotech) and 
fragments obtained from the digestion of the STEMCCA 4F plasmid with PstI and EcoRV 
enzymes.  
Hybridized filters were washed twice in SSC 2X (0.03 M sodium citrate, 0.3 M NaCl) at room 
temperature.  Filters were then washed again twice with SSC 2X + SDS 0.2 % (v/v) at 65°C for 
20 minutes, followed by a room temperature wash with SSC 2X. For the detection of the 
labelled probe bound to the DNA, the Phosphorimaging system was used (Bio-Rad –molecular 
Imager FX). 
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- GENOMIC STABILITY ASSAYS  
- Cell cycle 
For cell cycle analysis, cells were trypsinized and then transferred to flow cytometry tubes to 
be fixed. For fixation, cells were washed with 300 µl of cold PBS while vortexing and then 800 
µl of pure ethanol, while carefully vortexing, and were stored at -20°C for at least two hours. 
Before analysis, cells were washed with PBS and centrifuged at 4ºC and 600 g for 10 minutes. 
Propidium iodide (5 µg/ml Molecular Probes) and RNase A (100 µg/ml Sigma) were added to 
the samples, incubated for 15 minutes at room temperature and then analyzed by flow 
cytometry (Coulter XL) with linear fluorescence of propidium iodide or DAPI,  indicating the 
DNA content and eliminating doublet cells. 
- Chromosomal stability studies 
These studies were performed in actively dividing iPSCs at 70 % confluence in cultures, either 
treated or not with 1-3 butadiene diepoxide DEB (Sigma) to damage the cells, three hours 
before starting the cell cycle arrest treatment. To determine structural chromosomal 
abnormalities, cells were incubated with 10 μg/ml colcemid (Invitrogen) for 4 h at 37 °C after 
the incubation for 2 hours with or without 0,1 μg/mL of diepoxybutane (Sigma). Cells were 
then treated with 0.56 % KCl for 15 min at 37°C and fixed in methanol:acetic acid (3 : 1). Cell 
suspensions were dropped onto clean slides and air-dried for 24 h before hybridization. FISH 
was carried out as described by Samper, E. et al. 2002, using a Cy3-labeled LL (CCCTAA) 3 PNA 
telomeric probe and a FITC-labeled LL (ATTCGTTGGAAACGGGA) PNA centromeric probe 
(Eurogentec). The post-hybridization washes (3 x 10 min; each one) were performed in PBST 
0.1 % Tween 20 at 60 ºC and dehydrated in ethanol (70 %, 90 % and 100 %; 5 min each). Slides 
were then counterstained and mounted in Vectashield H-1200 mounting medium with DAPI 
(Vector Laboratories, CA, USA). Fluorescence images were acquired with a Nikon 90i 
microscope (Nikon Instruments, Melville, NY, USA) fitted with a 100 × planfluor 1.3 N/A 
objective, appropriate filters, and an Hg Intensilight fluorescence unit. Digital images were 
acquired with Cytovision Genus software (Genetix, Boston, MA, USA). At least 20 metaphases 
of each cell line and condition were analyzed.  
Chromosomal aberrations were identified as follows: chromatid or chromosomal breakages: 
gaps in one or two chromatids whose corresponding centromere was identified or loss of 
telomere signal in case of terminal breakage; chromosomal fusions: two chromosomes joined 
without telomere signals at the fusion point with one centromeric signal; dicentrics: 
chromosomal fusions between two chromosomes joined without telomere signals at the 
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fusion point with two centromeric signals, radials: a structure thought to result from the fusion 
of the broken arms of non-homologous chromosomes that can form trirradials, tetrarradials. 
The percentage of each type of aberration in each cell line and condition was used for 
statistical analysis. 
- Comparative Genomic Hybridization arrays (aCGH) 
A whole genome analysis was conducted by the company NIMGENETICS, in selected iPSC 
clones to determine the existence of more detailed chromosomal abnormalities. This 
technique combined genome-wide screening for copy number variations (CGH) with 
microarrays in which slides were arrayed with small DNA fragments as targets. A control DNA 
sample (wt-Balb/c mouse MEFs) and the DNA samples to be tested (wt iPSC and A16Ex7 iPSC) 
were differentially labelled and competitively hybridized  with  a commercial 180 kb 
oligonucleotide mouse array-CGH (AMADID 027411, Agilent Technologies, Santa Clara, CA), 
following manufacturer’s protocol 1 (Barrett et al., 2004).  
Relative fluorescence intensity data from the microarray were extracted and visualized using 
Feature Extraction software v10.7 and Agilent Genomic Workbench v5.0 (Agilent 
Technologies). Copy number altered regions were detected using ADM-2 (set as 6) statistic, 
provided by DNA Analytics, with a minimum number of 5 consecutive probes. Genomic 
build UCSC mm8 (NCBI36) was used for the experiment (Barrett et al., 2004).  
 
5.2.3 STUDY OF THE FANCONI ANEMIA PHENOTYPE 
REVERSION  
- BRCA2 expression 
In corrected Brca2 iPSC clones, the expression of human BRCA2 was analyzed by RT-
qPCR to verify if upon gene complementation, the expression of this gene had been restored.  
When cells were confluent, RNA was extracted from each of the iPSC pellet samples (Qiagen 
kit) and it was retro-transcribed to cDNA to analyze the expression of BRCA2 by RT-qPCR in a 
Rotor Gene RG-3000 (Corbett Research Products) with the primers and probes designed to 
detect the expression of this gene (Table 9). The housekeeping gene used to normalize BRCA2 
expression was the glyceraldehyde-3-phosphate dehydrogenase mGapdh (Table 9). 
Amplification was performed using PCR Taqman (Universal PCR Master Mix. Roche) and the 
data obtained were analysed by the 2 Ct method (Livak and Schmittgen, 2001).  
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- RAD51 foci formation studies  
RAD51 foci formation assays were performed in fibroblasts and in iPSCs as a functional test to 
verify that the genetic defect of Brca2 cells that had been gene complemented with the 
therapeutic PCL1-BRCA2 vector, restored their ability to recruit RAD51 to the DNA repair foci, a 
sign that BRCA2 protein functioned properly and therefore, the HDR pathway. 
To detect RAD51 foci, cells were cultured in gelatin-coated polystyrene two-slide chambers BD 
Falcon (5x104 cells/chamber). Two conditions from each sample were performed: one with 
mitomycin C (MMC) 40 nM (Sigma), to activate the DNA repair pathway that involves the 
generation of RAD51 foci, and another one without MMC, as a control. After 16 hours cells 
were fixed for 15 minutes with 3.7 % paraphormaldehyde and cell membranes were 
permeabilized for 5 minutes with 0.5 % Triton X-100.  After washing up the permeabilizing 
solution with Tris-buffered saline (TBS, 50 mmol/l Tris-HCl, pH8, 150 mmol/l NaCl) samples 
were blocked for 30 minutes with blocking solution (10 % FBS,0,1 % NP-40 diluted in PBS) to 
prevent non-specific binding of the antibody. The primary antibody used for cell staining was 
anti RAD51 Rabbit polyclonal antibody (Calbiochem) diluted 1:250 in blocking solution and 
overnight incubated in a humid and dark chamber. The primary antibody was washed with TBS 
and the preparation was then incubated for 30 minutes at room temperature in the dark with 
a fluorescent secondary antibody (anti-mouse Alexa 488- FITC (Molecular Probes, Leiden, 
Netherlands), diluted 1:1,000) and with DAPI (4,6-diamidino-2phenylindole, diluted 1:1,000) to 
stain the nuclei. Finally, preparations were mounted with Moviol and air dried in the dark. The 
analysis of RAD51 foci formation was performed by fluorescence microscopy. 
 
5.2.4 STUDY OF APOPTOSIS DURING THE REPROGRAMMING 
PROCESS  
 
- Annexin V based apoptosis study 
To analyze apoptosis during the reprogramming process, cells were transduced with the 
polycistronic excisable lentiviral vector harbouring the reprogramming factors Oct3/4, Klf4 and 
Sox2 and the reporter cherry protein. Apoptosis studies were performed only in the cherry 
positive population by Annexin V and DAPI staining. Cells were analyzed by flow cytometry at 
day 9 after transduction with the reprogramming vector. Freshly obtained cells were washed 
with cold PBS and were resuspended in binding buffer 1x. Cells were then incubated with FITC-
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annexin V (BD Pharmigen) antibody together with DAPI (1/300) for 15 minutes at room 
temperature in the dark. After incubation cells were analyzed by flow cytometry in a maximum 
period of one hour. Control cells were wild type (wt) fibroblasts. 
Analyses performed by annexin V, together with DAPI staining allowed the detection of four 
different cell populations that are represented in Figure 30, based on the principle that 
annexin V binds to residues of phosphatidilserine that start appearing in the cell membrane in 
the first steps of apoptosis. Within the advance of the apoptotic process, apoptotic cells 
became positive for annexin V and DAPI.  In dead necrotic cells the binding of annexin V to PS 
residues is lost and only DAPI staining is detected.  
 
 
 
 
 
 
Figure 30.  Representation of the flow cytometry analysis strategy used to study apoptosis during 
the cell reprogramming process by annexin V and DAPI staining. This strategy allowed the 
identification of four populations. I: Living cells that do not have phosphatidilserine (PS) residues 
exposed in the membrane to bind annexin V and do not allow DAPI entrance across the cellular 
membrane. II: Early apoptotic cells that have PS residues exposed in their membrane being 
possible to bind and detect annexin V fluorescence but not DAPI. III: Late apoptotic cells in which 
annexin V could be detected and DAPI was able to enter the cellular membrane. IV: corresponds to 
necrotic cells that lost their ability to bind annexin V to PS residues but DAPI entered the nucleous. 
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6.-HEMATOPOIETIC DIFFERENTIATION 
ASSAYS OF MOUSE iPSC AND mESC 
 
To achieve the hematopoietic differentiation of mouse embryonic stem cells (mESC) and 
genetically corrected iPSCs from Brca2fibroblasts, several protocols were carried out 
with the objective of promoting hematopoietic differentiation (Table 10). 
6.1 IN VITRO HEMATOPOIETIC DIFFERENTIATION 
PROTOCOLS   
- In vitro hematopoietic differentiation of HOXB4 transduced 
cells on OP-9 stroma.  
This hematopoietic differentiation protocol was a serum free method that consisted of 
transducing mESC and iPSC with a retroviral vector carrying the HOXB4 LIM homeobox gene 
(MSCV.HOXB4.IRES.GFP). Forty eight hours before embryoid body generation, the medium in 
which cells were normally cultured (DMEM) was exchanged by IMDM medium (Biowhittaker, 
Walkersville, MD USA) for the cells to adapt to the medium used for embryo body generation. 
 
Embryoid bodies were generated by natural aggregation (48 hours) of transduced cells after 
trypsinization with Trypsin/EDTA 0.25 % 1X (Gibco). Cells were seeded onto 10 cm2 bacterial 
petri dishes at a final volume of 9 mL per plate (1.8x105 cells/plate) or ultralow-attachment 6 
well plates (Corning, Costar) at a final concentration 106 cells/mL to prevent the cells to be 
attached to the surface. Cells were plated carefully, avoiding bubble generation that could 
alter the good condition of the cells, and were incubated at 37°C in a low percentage of O2 (3 
%) and high percentage of CO2 (7 %) atmosphere, protected by a plastic box and a plate of 
sterile water to provide humidity to the environment. The medium used for embryo body 
formation was StemPro34-medium (500ml) (Gibco) + Nutrient Mix (~13 ml), 1 % Glutamax 
supplemented with 0.1 µg-U/µl P/S, 200 µg/ml Holotransferrin, monothioglycerol (MTG) (4,5 
mM),  50 µg/ml ascorbic acid (added just before use due to its instability).  
 
At this time, recombinant human bone morphogenetic protein (rhBMP4), at a final 
concentration of 4 ng/mL, was the only cytokine added to induce the differentiation of the 
cells towards mesoderm. Forty eight hours after aggregation, half of the medium was replaced 
by StemPro34 enriched with nutrient supplement and cytokines, to induce the differentiation 
towards hemangioblast and hematopoietic progenitors, added at a final concentration of 5 
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ng/mL mouse fibroblast growth factor (mFGF) (Prepotech), 5 ng/mL mActivin (R&D Systems), 5 
ng/mL human vascular endothelial growth factor (hVEGF) 20 ng/mL (Prepotech), 20 ng/mL 
human thrombopoietin (hTPO) (Prepotech), 100 ng/mL mouse stem cell factor (mSCF) (R&D 
Systems). Embryoid bodies were maintained for 4 more days in this medium and at day 6, 
embryo bodies were collected and dissociated by Tryple Select treatment (Invitrogen). The 
resulting cells were counted and seeded at a concentration of 2x105 cells/mL in a final volume 
of 2 mL over an irradiated OP9 stroma, in 6-well plates (Nunc, New York, USA).  
Co-cultures were maintained for 14 days in OP9 co-culture medium: Iscove medium 
(Biowhittaker, Walkersville, MD USA) 20 % FBS (Gibco), 2 mM Glutamax (Invitrogen) , 2 mM 
P/S (penicillin-streptomycin, Gibco 15140-148), 100 ng/mL Flt-3, 100 ng/mL mSCF (R&D), 40 
ng/mL TPO (Prepotech) and 40 ng/mL VEGF (Prepotech). Every other day, half of the medium 
was replaced until the final analysis by FACS (Figure 31).  
 
 
 
- In vitro hematopoietic differentiation on AM.20 stromas 
For hematopoietic differentiation in stromas derived from aorta-gonada-mesonephros region 
(AGM) AM20.1B4, mESJ1 and iPSCs clones were differentiated to embryo bodies (EBs) by 
natural aggregation at a concentration of 106 cells/mL in Iscove medium (Biowhittaker, 
Walkersville, MD USA) supplemented with 15% FBS (Gibco), 4.5 mM monothioglycerol (Sigma), 
Figure 31. Schematic representation of the hematopoietic differentiation protocol, based on transduction of 
mESC and iPSCs with HOXB4 and embryo body generation combined with co-culture on an OP-9 stroma.   
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50 g/mL ascorbic acid (Sigma) and 200g/mL iron-saturated holotransferrin (Sigma) at 37°C, 
5 % CO2, 21 % O2. During the period of EB formation that lasted 6 days, hematopoietic 
cytokines were sequentially added as follows (Figure 32): at day 0, 4 ng/mL Bmp4, at day 2.5, 5 
ng/mL hFGF and 5ng/mL Activin A and at day 4.5 ng/mL VEGF.  At day 6, EBs were dissociated 
with Tryple Select (Invitrogen), counted and seeded at a concentration of 1.5x104 cells/cm2 in 
6-well plates over a mitomycin C (MMC)-inactivated and confluent AM20.1B4 stroma. Cultures 
were maintained up to 21 days removing cellular debris and changing the culture medium 
every 3 to 4 days. By day 21, the expression of hematopoietic markers was evaluated by flow 
cytometry. 
 
 
 
 
- Transplantation of iPSC derived hematopoietic progenitors 
into sub-lethally irradiated Brca2mice 
 
Cells from wt iPSCs and also from the A16Ex7 Brca2iPSC clone were obtained after in 
vitro differentiation, following the protocol based on HOXB4 transduction. After cell collection 
for FACS analysis at day 10 of differentiation, cells were collected and dissociated passing them 
through a syringe and were counted with Trypan blue. 
Figure 32. Schematic representation of the hematopoietic differentiation protocol, based embryo body 
generation combined with co-culture on an aorta-gonada-mesonephros region (AGM) stroma.   
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One million cells per mouse were intravenously injected, into sub-lethally irradiated (3Gy) 
Brca2mice, in a total number of two mice per condition, due to the limited number of 
cells.  
The percentage of chimerism and expression of eGFP was analyzed by FACS since day 15 after 
transplant.  
 
 
 
6.2 FLOW CYTOMETRY ANALYSES OF PLURIPOTENCY 
AND HEMATOPOIETIC MARKERS  
 
The phenotype of iPSCs was analyzed by flow cytometry (FACS), using surface and intracellular 
antibodies linked to different fluorophores. The analysis of pluripotency by FACS was 
performed using SSEA-1 antibody (RyD Systems) linked to phycoerythrin (PE) fluorochrome. To 
analyze the phenotype of hematopoietic progenitors the antibodies used were: anti-SCA1-PE 
(BD Pharmigen), that binds to pluripotent cells, anti-FLK1-PE (BD Pharmigen), marker of 
hemangioblast, anti-CD31-PE (BD Pharmigen) that marks hemogenic endothelial cells, anti-cKit 
(BD Pharmigen), anti-CD41-PE (BD Pharmigen), anti-CD45-PE (BD Pharmigen), anti-CD34-biotin 
(eBioscience), anti-AA4.1-FITC (BD Pharmigen), all markers of hematopoietic stem cells at 
different stages. Gating was done with matched isotype IgG1-PE, FITC and -PE-Cy5 monoclonal 
antibodies used as controls, all from Pharmigen. Cells were washed with PBA (PBS with 0.1% 
BSA and 0.01% sodium azide), resuspended in PBA plus 2 µg/ml propidium iodide and analyzed 
using an EPICS ELITE-ESP cytometer (Beckman Coulter Inc). Off-line analysis was done with CXP 
Analysis 2.1 software. 
Figure 33. Schematic representation of the in vivo differentiation protocol, based on intravenous injection of EB-
derived differentiated cells into sub-lethally irradiated Brca2

mice. 
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7. STATISTICAL ANALYSIS 
 
Data obtained from the different experiments represented the mean and standard error of the 
mean (SEM). The significance of differences was determined by two non-parametrical tests. 
For comparisons between two groups we applied Mann-Whitney test. When comparing more 
than two groups we applied Kruskal-Wallis test.  Differences were considered significant at  
p<0 .05. All statistical analyses were performed using GraphPad Prism Software, Version 5.0 a. 
Table 10. A) Representation of the different in vitro hematopoietic differentiation protocols performed. 
Protocol 1 and protocol 2 involved the embryo body generation and culture with hematopoietic differentiation 
cytokines in a semisolid methylcellulose culture medium and co-culture over hematopoietic stromal cells. The 
differences between protocol 1 and 2 were that protocol 1 involved the transduction of the mESC and iPSCs 
with HOXB4 prior to the EB generation and co-culture over OP-9 stroma while protocol 2 employed the aorta-
gonada-mesonephros (AGM) stroma for cell co-culture. B) Specific surface markers that sequencially appear in 
the cells during the embryonic hematopoietic development.  
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1. INDUCED PLURIPOTENT STEM CELLS 
GENERATED BY TRANSDUCTION WITH 
RETROVIRAL VECTORS HARBOURING SINGLE 
REPROGRAMMING FACTORS  
 
1.1 STUDY OF THE RELEVANCE OF FANCA AND BRCA2 
IN CELL REPROGRAMMING  
To investigate the relevance of two important members of FA/BRCA pathway (FANCA and 
BRCA2 proteins) in cell reprogramming and to search for new sources of HSCs in FA gene and 
cell therapy, we standardized the reprogramming method in wt mouse adult fibroblasts 
(MAFs) to then generate induced pluripotent stem cells (iPSC) from two FA mouse models 
(Fanca-/- and Brca2Δ27/Δ27). 
   
1.1.1  CELL REPROGRAMMING OF WILD TYPE CELLS 
 
Three reprogramming attempts were performed using wt adult ear fibroblasts from C57BL/6 
mice with -RVs harbouring the reprogramming factors Oct3/4, Sox2, Klf4 and c-Myc described 
by Yamanaka. Cells were transduced with these -RVs, in two rounds of infection with either 
three (Oct3/4, Sox2 and Klf4) or four of these factors (Oct3/4, Sox2, Klf4 and c-Myc). Four days 
after transduction, cells were split and 5 x 104 cells were cultured over an irradiated mouse 
embryonic fibroblast (MEF) feeder layer, in the presence of mES medium (materials and 
methods). At day 11-13 the colonies arising in the culture were identified by their mESC-like 
morphology and were individually picked. 
Despite it is described in bibliography that the transduction with the three reprogramming 
factors Oct3/4, Sox2 and Klf4 is sufficient to generate completely reprogrammed cells 
(Nakagawa et al., 2008), in our hands, colonies with a good ESC-like morphology could only be 
obtained when cells were transduced with the four reprogramming factors Oct3/4, Sox2, Klf4 
and c-Myc. In the condition that lacked c-Myc, colonies that arose did not perfectly resemble a 
mESC-like morphology as a consequence of being only partially reprogrammed. 
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Our results showed that the iPSC clones had a mESC-like morphology as can be observed in 
representative images of iPSC colonies in the upper part of Figure 34, where the characteristic 
3D and compact shape of mESCs was observed. The lower part of Figure 34 shows the alkaline 
AP activity (red colour) that we obtained in the iPSC colonies where a high AP enzymatic 
activity was observed.  
From the three experiments performed, seven iPSC clones were selected and characterized by 
AP activity detection. The proof of concept that this protocol allowed the reprogramming of wt 
adult fibroblasts let us standardize a reprogramming protocol for future experiments in FA 
deficient cells. 
1.1.2 CELL REPROGRAMMING IN Fanca-/- AND Brca2Δ27/Δ27 
DEFICIENT CELLS 
 
To investigate the comparative role that Fanca and Brca2 play in cell reprogramming process, 
MAFs from Fanca-/- (Cheng et al., 2000) and Brca2Δ27/Δ27 (Fancd1/Brca2) (McAllister et al., 
2002b) mice were reprogrammed with -RVs carrying the four reprogramming factors (Oct3/4, 
Sox2, Klf4 and c-Myc).   
Figure 34. Representative images of wt iPSCs-like colonies generated with -RVs. A) Images obtained 
in bright field of mESC-like morphology of the colonies cultured on irradiated MEFs feeder layer: 
round/tear 3D shape forming syncitia and supportive stroma B) Images of alkaline phosphatase 
activity (AP) in iPSC like colonies captured at 4x.  
  Results 
99 
 
To compare the reprogramming efficiency in both FA models with respect to the 
corresponding complemented cells, two days before reprogramming, Fanca-/- and Brca2Δ27/Δ27 
cells were transduced with the correspondent therapeutic lentiviral vector (PGK.FANCA and 
PCL1.BRCA2, respectively).  
In the case of Fanca-/- MAFs, a total number of 45 iPSC-like starting colonies could be 
generated while only one iPSC colony could be isolated and maintained. In the Brca2Δ27/Δ27 
condition, eight iPSC-like colonies appeared, only in the condition in which the cells had been 
corrected with the therapeutic gene, while in the uncorrected cells one single colony was 
obtained. This colony could only be maintained with good mESC morphology for a few 
passages and was used as a control in different experiments. Significantly, iPSC colonies from 
corrected Brca2Δ27/Δ27 cells appeared in the culture at day 13 post-transduction, while in the 
case of corrected Fanca-/- cells, iPSC-like colonies appeared two days earlier.  
 
 1.2 CHARACTERIZATION OF CORRECTED Fanca-/- 
AND Brca2Δ27/Δ27 iPSCs  
 
iPSCs from these two models were characterized  according to well established criteria that 
assured the generation of “bona fide” iPSCs. 
- Morphology 
The first sign of having iPSCs was obtained by selecting colonies with a mESC-like morphology. 
These mESC-like features were a round/tear shape with defined borders, more than one 
nucleus forming syncytia and the formation of a surrounding stroma that fed the colony with 
required factors. 
Our results showed the typical morphology of mESC colonies used as the reference cell 
population, to compare with the iPSCs generated (Figure 35). Based on this morphological 
criteria, four clones from Fanca-/- corrected cells (C1, C8, C8*, C11, C15, C23 and C35) and five 
from the Brca2Δ27/Δ27corrected cells (C1, C2, C11, C14, C15, C20) were selected. The 
representative pictures in Figure 35 correspond to some of the iPSC clones with mESC-like 
morphology. The representative colony of uncorrected Fanca-/- iPSC-like cells, shown in the 
figure did not show such a 3D shape, demonstrating a limitation in the complete 
reprogramming of the cells.  
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- Immunofluorescence and FACS analysis 
Next we studied the AP enzymatic activity in the iPSC clones that were selected. All iPSC-like 
clones selected by morphology criteria were positive for this staining, although different levels 
of AP activity could be observed among them, being slightly lower in uncorrected Fanca-/- and 
cBrca2Δ27/Δ27 iPSC-like clones (Figure 36). 
 
 
 
Once the AP activity was determined, the expression of the pluripotency markers SSEA1 and 
OCT3/4 was analyzed in corrected Fanca-/- and Brca2iPSCs, either by FACS or by 
immunofluorescence, compared with mESC, used as control.  
Figure 35. Representative images of the cell morphology observed in the iPSCs-like colonies generated 
from Fanca
-/-
 deficient ear adult fibroblasts, genetically corrected Fanca
-/-
 and corrected Brca2
Δ27/Δ27 
iPSCs 
generated with the four reprogramming -RVs. Images obtained at 40x in bright field. 
Figure 36. Representative images of AP activity in iPSC-like colonies generated from gene corrected 
Brca2
Δ27/Δ27 
mouse adult fibroblasts (MAFs). 
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In Figure 37, the percentage of SSEA1 expression by FACS analysis is represented. In Fanca-/- 
corrected iPSC-like clones, it reached an average level of 10 %. These expression levels were 
not as high as the ones observed in the control population of mESC (60 %). The level of SSEA1 
expression in Brca2Δ27/Δ27 corrected iPSCs was even lower than that of Fanca-/- corrected cells, 
with an average of 2 % of cells positive for this marker.  
 
 
 
 
 
The OCT3/4 expression in Fanca-/- corrected iPSCs was also determined by FACS. As shown in 
Figure 38, higher percentages of cells positive for this pluripotency marker were observed, as 
compared to SSEA1 in Brca2Δ27/Δ27 corrected cells. All selected clones were positive for this 
marker at equivalent levels to the ones obtained in mESCs. 
 
 
Figure 37. A) Representative dot-plots of the flow cytometry analysis of the percentage of cells positive for 
SSEA1 expression in Fanca
-/-
 corrected iPSCs and in gene corrected Brca2
Δ27/Δ27 
iPSCs, compared with the same 
study in mESC. B) Corresponds to the SSEA1 expression obtained in all the iPSC clones analyzed, both in Fanca
-/-
 
corrected iPSCs and gene corrected Brca2
Δ27/Δ27 
iPSCs.  
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- Teratoma formation 
The capacity to form teratomas is a functional assay that is considered one of the essential 
tests in the characterization of iPSCs in terms of pluripotency. For this assay, 1 x 106 cells from 
each iPSCs selected clone were subcutaneously injected into NOD/SCID γcnull mice. 
One month after injection of the iPSCs, a tumour mass could be observed in mice flanks. After 
dissection, histological analyses were performed to detect the presence of cells from the three 
germ layers. The histological samples were first stained with H&E. As shown in Figure 39, cells 
Figure 38. A) Representative dot-plots of the FACS analysis of the percentage of cells positive for the OCT3/4 
expression in Fanca
-/-
 corrected iPSCs compared with the same study in mESC. B) Corresponds to the OCT3/4 
expression obtained from all the Fanca
-/-
 corrected iPSCs clones analyzed, compared with the expression of this 
marker in mESC. C) Immunofluorescence of representative clones for the expression of OCT3/4 pluripotency 
marker in gene corrected Brca2
Δ27/Δ27 
iPSCs. 
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belonging to the endoderm, mesoderm and ectoderm layers were detected, both in corrected 
Fanca-/- and Brca2 27/Δ27 iPSC clones, similar to the structures observed in the control mESCs. 
Additionally, in the four cBrca2Δ27/Δ27clones obtained, immunofluorescence staining with 
specific markers of the three germ layers showed that all the clones were positive for the alpha 
fetoprotein (AFP) endodermal marker (Figure 39). Furthermore, 3 out of 4 analyzed teratomas 
resulted positive for the FOXA2 marker. The specific mesodermal markers analyzed were 
BRACHYURY and ASMA. The expression of ASMA was detected, confirming the presence of 
cells of mesodermal origin. Finally, the staining with TUJ1 and GFAP ectodermal specific 
markers resulted positive in the clones that were analyzed, demonstrating that these iPSC 
clones were pluripotent. 
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Figure 39. A) Representative images  of teratoma formation in iPSCs derived from Brca2
Δ27/Δ27 
MAFs and mESC 
control line. Images obtained at 40x and details at 200x  A.1) Endodermal cell types corresponding to respiratory 
epithelium. A.2) Mesodermal cells of different tissues such as bone, cartilage or muscle. A.3) Epithelial cells 
corresponding to ectoderm. B, C and D) Representative images of specific immunofluorescence assays of each of 
the three germ layers, performed in the teratoma derived from the Brca2
Δ27/Δ27
derived iPSC teratoma. B) 
Endodermal markers AFP (alpha feto protein) in green and FOXA2 in red. C) Specific mesodermal markers 
BRACHYURY in green and ASMA in red. D) Ectodermal markers Tuj1 in green and GFAP in red. 
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- Expression of endogenous pluripotency genes 
In the cBrca2Δ27/Δ27 iPSC clones that were selected to characterize, the expression of the 
endogenous pluripotency genes was analyzed, to verify if these cells had been effectively 
reprogrammed. In Figure 40 we can observe that the expression of the endogenous 
pluripotency genes was nearly undetectable when compared with the high pluripotency gene 
expression detected in mESCs.  
 
 
 
 
 
 
 
 
 
 
Figure 40. RT-qPCR analysis of endogenous pluripotency gene expression relative to mouse Gapdh in cBrca2
Δ27/Δ27 
iPS clones. Purple colour corresponds to the expression of Oct3/4 gene, aubergine colour bars represent the 
expression of Nanog, light pink corresponds to Sox2 expression. The expression of Klf4 is represented in green 
colour, Utf1 in dark blue and c-Myc is represented in dark pink. 
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- Expression of exogenous pluripotency genes 
We also analyzed, by RT-qPCR, the exogenous pluripotency genes Oct3/4, Klf4, Sox2 and c-
Myc, using specific primers for these exogenous genes.  
Our results showed that clones 2, 14 and 15 were the ones with higher expression of these 
exogenous pluripotency genes, while in the others we could only observed a modest 
expression of these genes (Figure 41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Graph representing the RT-qPCR analysis of exogenous pluripotency gene expression in 
cBrca2
Δ27/Δ27 
iPS clones. Green colour corresponds to the expression of Klf4 gene, purple bars represent the 
expression of Oct3/4, dark pink corresponds to c-Myc expression and the expression of Sox2 is represented 
in light pink. 
 
- The reprogramming of uncorrected Fanca-/- and Brca2Δ27/Δ27 cells, showed that these two genes 
play important roles in cell reprogramming. However, compared to Fanca, Brca2 was more 
critical, as no activation of the endogenous pluripotency genes could be reproducibly detected in 
Brca2Δ27/Δ27cells.   
- The reprogramming of gene-corrected Fanca-/- and Brca2Δ27/Δ27 cells with -RVs carrying four 
reprogramming genes generated iPSCs-like cells that did not fulfill all the criteria of “bona fide” 
iPSCs. 
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2. GENERATION OF CORRECTED iPSCs USING 
POLYCISTRONIC EXCISABLE LENTIVIRAL 
VECTORS  
 
2.1  RELEVANCE OF BRCA2 IN CELL REPROGRAMMING 
WITH POLYCISTRONIC EXCISABLE LENTIVIRAL 
VECTORS  
 
To improve the efficiency and safety associated to reprogramming of corrected Brca2Δ27/Δ27 
cells, in the next set of experiments, MEFs, instead of MAFs, were used. Additionally, an 
excisable polycistronic lentiviral vector carrying the four reprogramming factors under the 
control of the EF1 promoter and a LoxP site to remove the reprogramming cassette, once the 
cells were reprogrammed, was used instead of the four reprogramming -RVs. In this 
experiment Brca2Δ27/Δ27 deficient MEFs were transduced with the reprogramming vector, either 
after 48 hours, or simultaneously to transduction with the therapeutic vector (Figure 42).   
MEFs from each condition were transduced with the polycistronic reprogramming LV in two 
rounds of infection. Four days later (day 6), infected cells were seeded on irradiated MEF-
coated plates, when mESC-like colonies arouse, between day 11 and 13, clones were 
individually selected and expanded. 
 
 Figure 42. Cell reprogramming process in uncorrected and genetically corrected Brca2
Δ27/Δ27 
MEFs
 
with an excisable 
polycistronic lentiviral vector (STEMCCA-4F.OKSM). Selection, expansion and characterization once the iPSCs were 
established are also represented.  
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As shown in Figure 43, when Brca2Δ27/Δ27 cells were not corrected from their genetic defect, no 
iPSC colonies could be obtained while in the two other conditions evident iPSC-like clones 
were generated and no significant differences in their respective numbers were observed. 
The efficiency of cell reprogramming was evaluated in the three conditions, corresponding to 
uncorrected Brca2Δ27/Δ27 cells, Brca2Δ27/Δ27 corrected previous to cell reprogramming and 
Brca2Δ27/Δ27 cells that were corrected simultaneously to the transduction with the 
reprogramming vector. Four different independent experiments were performed (mean value 
of 80 colonies in the condition in which the cells were first corrected and then reprogrammed 
and mean value of 150 colonies in the condition in which correction and reprogramming were 
performed simultaneously). In our hands, the efficiency of reprogramming was slightly higher, 
although not significant, in the condition in which Brca2Δ27/Δ27 MEFs were gene complemented 
and reprogrammed at the same time (71.25 ± 31.75 and 197 ± 90.29, respectively). 
From these experiments, a total number of 96 colonies were picked, and 26 colonies were 
further characterized.  
 
 
 
 
 
 
 
Figure 43. Analysis of the reprogramming efficiency of Brca2
Δ27/Δ27 
mouse embryonic fibroblasts 
(MEFs), transduced with a polycistronic lentiviral vector harbouring the four reprogramming factors 
(Oct3/4, Klf4, Sox2 and c-Myc). The graph corresponds to the three conditions studied: Uncorrected 
Brca2
Δ27/Δ27 
cells; Brca2
Δ27/Δ27 
cells corrected prior to or simultaneously to transduction with the 
reprogramming vector.  
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2.1.1  STUDY OF THE HOMOLOGY DIRECTED REPAIR 
PATHWAY DURING THE REPROGRAMMING OF COMPLEMENTED 
AND NOT COMPLEMENTED Brca2Δ27/Δ27 CELLS 
 
Due to the relevance of Brca2 in cell reprogramming we wondered to which extent HDR could 
be playing a role during the process of cell reprogramming as described by Marion et.al. 
(Marion et al., 2009). The HDR during cell reprogramming was investigated and analyzed in 
uncorrected Brca2Δ27/Δ27 cells, in genetically corrected Brca2Δ27/Δ27 cells (cBrca2Δ27/Δ27) and in 
their correspondent wt cells (Balb/c), as well as in Fanca-/- cells.   
Our results showed that reprogramming of wt and genetically corrected cells Brca2Δ27/Δ27 was 
associated with the generation of RAD51 foci.  In Brca2Δ27/Δ27 cells, although there was a basal 
percentage of RAD51 foci of around 5 % in non reprogrammed cells, the number of RAD51 foci 
during reprogramming was significantly lower than the basal ones (Figure 44).   
This study confirms that HDR is activated during the process of cell reprogramming.  However, 
in the case of Brca2Δ27/Δ27 cells, this process was interfered, while gene complementation with 
BRCA2 restored the HDR process during cell reprogramming of these cells. 
             
 
 
 
  
 
 
 
 
 
 
Figure 44. Study of the HDR during the cell reprogramming process by the analysis of the recruitment of RAD51 to 
DNA repair foci. The graph represents the percentage of cells with RAD51 foci in wt, in Fanca-/-, Brca2 and in 
genetically corrected Brca2MEFs (cBrca2). Grey bars correspond to the mock condition in which the cells 
were not transduced with the reprogramming vector. Pink bars represent cells transduced with the polycistronic 
reprogramming lentiviral vector. Data represent mean value of three independent experiments and standard 
error. 
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2.1.2  APOPTOSIS STUDIES DURING THE REPROGRAMMING 
OF CORRECTED AND UNCORRECTED BRCA2Δ27/Δ27 CELLS  
To study the reasons accounting for the extremely low reprogramming of Brca2Δ27/Δ27cells, we 
analyzed the level of apoptosis in these cells during the process of cell reprogramming. 
To ensure that the cells that we analyzed had been transduced with the reprogramming 
vector, in these three independent experiments, we used an excisable polycistronic lentiviral 
reprogramming vector harbouring three reprogramming factors (Oct3/4, Klf4 and Sox2) and 
also the red fluorescent protein (RFP) as a reporter, to select the transduced population. At 
day 9 of reprogramming the parameters of viability, apoptosis and necrosis were analyzed by 
FACS.  
Our results showed that the viability was reduced in reprogrammed cells both in wt and 
Brca2Δ27/Δ27 with a percentage of dead cells that ranged from 50 to 70 %, in contrast with the 
10 to 30 % observed in the cases in which reprogramming had not been induced. However, the 
results shown in Figure 45, demonstrated that there was an increase in the percentage of early 
and late apoptosis during the reprogramming of Brca2Δ27/Δ27 cells, in contrast to the lower 
number of apoptotic cells observed during the reprogramming of wt cells. 
         
  
 
 
             
 
 
 
 
 
 
 
Figure 45. A) FACS analysiss of 
apoptosis in cherry positive cells by 
Annexin V assay. Annexin V binds to 
phosphatidylserine (PS) residues that 
are exposed in the cell membrane in 
the first steps of apoptosis. L: living 
cells (Annexin V negative); EA: Early 
apoptosis (Annexin V positive, DAPI 
negative); LA: Late apoptosis 
(Annexin V positive, DAPI positive); 
N: Necrosis (Annexin V negative, 
DAPI positive). Left panel 
corresponds to reprogrammed wt 
cells, while right panel represents 
reprogrammend Brca2
Δ27/Δ27
 cells. B) 
Graph representing the distribution 
of the different populations analyzed 
in cherry positive cells. Pink bars 
correspond to wt cells during 
reprogramming and grey bars 
correspond to Brca2
Δ27/Δ27
 cells 
during the process of cell 
reprogramming. 
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-  The reprogramming of uncorrected and corrected Brca2Δ27/Δ27 MEFs by transduction with a 
polycistronic lentiviral excisable vector confirmed that BRCA2 is essential for pluripotency induction.  
 
- Studies of homology directed repair (HRD) demonstrated that this DNA repair mechanism is activated 
during the reprogramming of wild type or FA-A cells. However, this mechanism is not activated during 
the reprogramming of Brca2Δ27/Δ27 cells. After correction of the genetic defect, the HDR capacity of 
Brca2Δ27/Δ27 cells is restored.  
- Apoptotic studies performed during the reprogramming of Brca2Δ27/Δ27 cells revealed an increase in 
the early and late apoptosis of these cells, accounting – at least in part - for their extremely low 
efficiency of reprogramming. 
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2.2 CHARACTERIZATION OF COMPLEMENTED 
Brca2Δ27/Δ27 iPSCs GENERATED FROM MOUSE 
EMBRYONIC FIBROBLASTS BY TRANSDUCTION WITH 
PLOYCISTRONIC EXCISABLE REPROGRAMMING LVs 
 
The characterization of the iPSC from Brca2Δ27/Δ27 corrected cells was done in two blocks, the 
first one corresponded to reprogrammed cells prior to the excision of the reprogramming 
cassette, and the other one was performed after the excision of the reprogramming vector.  
- Morphology 
The characterization of Brca2Δ27/Δ27 iPSCs generated with the polycistronic lentiviral vector was 
first performed by the evaluation of their mESC-like morphology. When Brca2Δ27/Δ27 cells were 
not genetically corrected, no iPSC colonies could be isolated.  
 
Figure 46 shows representative images of the 26 clones that were selected by a morphology 
that resembled the morphology of mESCs. 
 
 
 
- Immunofluorescence and FACS analysis of pluripotency 
markers 
 
The AP staining showed that the number of colonies positive for AP had increased in the 
reprogramming with the polycistronic lentiviral vector (Figure 47). 
Figure 46. Representative images obtained at 40x in bright field, of iPSCs-like colonies generated from gene 
corrected Brca2
Δ27/Δ27 
MEFs after transduction with the excisable reprogramming LV (STEMCCA-4F.OKSM). The 
mouse ESC line J1 was used as a control.  
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The presence of SSEA1 in Brca2Δ27/Δ27 corrected MEFs was determined by FACS. As it can be 
observed in Figure 48, all the clones expressed a very high proportion of SSEA1 (between 60 
and 90%), equivalent to the percentage observed in the mESC used as a control. SSEA1 
expression was confirmed by immunofluorescence analyses (Figure 49). 
After the first screening of iPSC clones by AP activity and expression of the SSEA1 pluripotency 
marker, we analyzed the expression of other pluripotency markers, such as OCT3/4 and 
NANOG (Figure 49 and 50). 
 
 
Figure 47. Images of AP staining of a 
representative cBrca2
Δ27/Δ27 
iPSC clone 
generated by STEMCCA-4F.OKSM, 
cultured over a feeder layer of 
irradiated MEFs. A and B correspond to 
images of the cultured plates obtained 
after fixation and staining. A) Control 
mESC line B) A16 cBrca2
Δ27/Δ27 
iPSC 
clone. C and D correspond to 40x 
images obtained in bright field 
obtained under a magnifying glass. C) 
Control mESC line. D) A16 cBrca2
Δ27/Δ27 
iPSC clone. 
Figure 48. Graph representing the percentage of SSEA1
+
 cells analyzed by FACS in cBrca2
Δ27/Δ27 
iPSC 
clones generated with STEMCCA-4F.OKSM. Mean values and standard error are represented by a grey 
bar. 
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Figure 50. Images of the immunofluorescence analysis of the pluripotency marker NANOG in corrected A16 
Brca2
Δ27/Δ27 
iPSCs. A) DAPI staining and NANOG expression detected in texas red in the mESJ1 control line. B) 
DAPI staining and NANOG expression detected in texas red in the A16 Brca2
Δ27/Δ27 
corrected clone.  
 
Figure 49. Immunofluorescence analysis of the pluripotency markers SSEA1 and OCT3/4 and the correspondent 
DAPI staining of the cellular nucleus in A12 and A16 Brca2
Δ27/Δ27 
corrected clones and in control mESC line. A) DAPI 
staining, SSEA1 expression detected in texas red and OCT3/4 detected in FITC in the mESJ1 cell line. B) DAPI 
staining, SSEA1 expression detected in texas red and OCT3/4 detected in FITC in the A12 Brca2
Δ27/Δ27 
corrected 
clone. C) DAPI staining, SSEA1 expression detected in texas red and OCT3/4 detected in FITC in the A16 Brca2
Δ27/Δ27 
corrected clone. 
 
  Results 
115 
 
 
- Cell cycle and karyotype analyses  
 
 
 
 
Due to the chromosomal instability inherent to Brca2Δ27/Δ27 cells and also to the iPSC 
generation process, we studied the cell cycle status of 26 clones (passage 17) using a reference 
population of diploid splenocytes. The results showed that at late passage number, only clones 
A12 and A16 were diploid, while all the other clones were aneuploid and polyploid (Figure 51).  
Karyotype analyses of A12 and A16 clones were performed at passage 17, showing a normal 
karyotype in both cases (Figure 52A).   
When karyotype analyses were performed in early in vitro passages, most of the iPSC clones 
had a normal karyotype, suggesting that many of the chromosomal abnormalities and 
aneuploidies took place during the in vitro growth of the iPSCs. 
Figure 51. Cell cycle analysis of representative cBrca2
Δ27/Δ27 
iPSC clones and the spleen cells used as a 
control. A12 and A16 show a diploid DNA content, while clone B0 was tetraploid.  
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- Teratoma formation 
 Selected iPSC clones, based on DNA content and karyotype analyses, were subcutaneously 
injected into NOD/SCID γcnull mice to analyze the capacity of the cells to generate teratomas, 
containing cells of the three embryonic germ layers. One million cells per mice were injected in 
the right flank and after one month the tumours generated were analyzed by expert 
pathologists. 
These analyses showed that cells forming the tumoral masses did not contain cells of the three 
germ layers and they rather consisted of cells with an expansive growth (Figure 53). This 
Figure 52. A) Karyotype analysis of two selected cBrca2
Δ27/Δ27 
iPSC clones A12 and A16 at late passage number 
(p17). B) Karyotype analysis performed in these two clones and in other clones at an early passage number (p4).   
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implied high mitosis rates and also necrotic and apoptotic cells due to the lack of blood supply 
to support the tumour growth.  
 
 
            
2.2.1 MOLECULAR CHARACTERIZATION OF CORRECTED iPSC 
GENERATED WITH POLYCISTRONIC EXCISABLE LENTIVIRAL 
VECTORS  
- Expression of endogenous Nanog pluripotency gene 
 
All iPSC clones were analyzed for Nanog expression relative to the housekeeping gene 
mGapdh. As shown in Figure 54 most of these clones showed a high endogenous expression of 
this gene and only A12 and A16 clones had a lower Nanog expression, similar to the one of 
mESCs. Significantly, these were the clones that best maintained the iPSC morphology and 
chromosomal stability.  
 
 
Figure 53. Image of an undifferentiated tumour mass obtained one month after subcutaneous 
injection of the A16 iPSC clone into NOD-SCID γcnull mice. Representative images 40x of H&E staining 
of undifferentiated cellular mass formation by cBrca2
Δ27/Δ27 
A16 iPSC clone. Black arrow indicates a 
necrotic area with apoptotic cells.  
 
 
 
Figure 54. Graph representing the Nanog expression relative to Gapdh housekeeping gene in iPSCs 
determined by RT-qPCR. Standard error was determined and represented. 
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2.3 EXCISION OF THE REPROGRAMMING CASSETTE 
IN CORRECTED Brca2Δ27/Δ27 iPSC CLONES 
To prevent the unlimited expression of the reprogramming genes in corrected Brca2Δ27/Δ27 
iPSCs we decided to excise the reprogramming LV vector from iPSCs. 
2.3.1 EXCISION WITH AN INTEGRATION DEFICIENT 
LENTIVIRAL VECTOR HARBOURING THE CRE RECOMBINASE 
(IDLV-CRE) 
 
Taking advantage of the LoxP sequence contained in the polycistronic reprogramming LV 
(materials and methods) we excised the reprogramming cassette from A12 and A16 iPSC 
clones, using an integration deficient lentiviral vector vector carrying the Cre-recombinase. 
To induce the excision process, 5 x 104 cells from each clone were transduced with the IDLV-
Cre excision vector at a multiplicity of infection (MOI) of 100 in two rounds of infection. After 4 
days, when iPSC colonies arose in the culture, individual colonies were picked, based on 
morphological criteria and were expanded in culture.  
- Vector copy number determination 
For the analysis of the reprogramming vector copy number (VCN) content we focused on A16 
derived sub-clones, because they grew better in culture. We observed that in several A16 sub-
clones the copy number of the reprogramming cassette, determined by RT-qPCR was less than 
one copy per cell (<0.4 copies/cell) (Figure 55). Among these sub-clones, A16Ex7 sub-clone was 
selected for further studies.  
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A16Ex7 cells were then analyzed by Southern Blot, using a mESC line, wt iPSCs and A16 iPSC 
clone as controls. Figure 56 shows that a band corresponding to the reprogramming vector 
was detected, with a size equivalent to the one observed in A16 clone, when hybridized with 
the wpre probe.  
 
 
 
 
 
 
 
 
 
 
Figure 55. Analysis of the vector copy number after excision of the reprogramming cassette in A16 
derived sub-clones that were selected after excision. Pink bar corresponds to the parental clone before 
the excision and grey bars represent the vector copy number analysis in the sub-clones obtained after 
excision of the reprogramming cassette with IDLV-Cre.  
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Due to the limited efficacy of the reprogramming cassette excision with IDLV-Cre, these sub-
clones were re-excised with a Ma.cre.prot system, based on the delivery of the Cre 
recombinase directly into the cellular nucleus (materials and methods). After excision with 
Ma.Cre.prot, the vector copy number was again determined by RT-qPCR. Now, no 
amplification of the reprogramming cassette was detected in A16Ex7 cells, implying that cells 
were free from the reprogramming cassette. Figure 57 represents the morphology of the cells 
after excision, showing that they still had the characterstic round/tear 3D shape, with defined 
borders and nucleus forming syncytia. 
 
 Figure 57. Representative images obtained at 40x in bright field, of re-excised A16Ex7 sub-clone 
obtained from cBrca2
Δ27/Δ27
. 
 
 
 
Figure 56. Southern Blot analysis of excised A16Ex7 iPSCs for the detection of inserted reprogramming provirus. 
1) Corresponds to the original A16 iPSC clone prior to excision that was used as control 2) Wt iPSC cells. 3) 
Excised A16Ex7 iPSC sub-clone 4) corresponds to the mESC line of reference. The image corresponds to the 
hybridization with a wpre probe that recognizes the reprogramming provirus. The first four lanes represent the 
digestion with the restriction enzyme PstI and the second block of lanes corresponds to the digestion with the 
EcoRV enzyme. 
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 2.4 CHARACTERIZATION OF CORRECTED Brca2Δ27/Δ27 
iPSC AFTER EXCISION OF THE REPROGRAMMING 
CASSETTE  
2.4.1  PHENOTYPIC CHARACTERIZATION STUDIES IN 
EXCISED iPSC CLONES  
 
- Morphology 
After excision of the reprogramming cassette, new sub-clones were individually selected 
and expanded for deeper characterization. Around 40 sub-clones were picked, although 
only the clones that maintained the morphological criteria of round/tear 3D colony shape 
and that grew properly in the plate were maintained in culture for further studies. Figure 
58 shows the morphology of several sub-clones generated from A12 and A16 clones that 
resembled the characteristics of control mESCs. 
 
 
 
 
Figure 58. Representative images (40x) of the morphology of iPSC sub-clones obtained from A12 and A16 
cBrca2
Δ27/Δ27 
iPSC clones after the excision of the reprogramming cassette (STEMCCA-4F.OKSM).  
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- Immunofluorescence of pluripotency gene expression 
In selected excised sub-clones, AP activity was measured and compared with the control mESC 
and with non-excised clones. The AP staining pictures of Figure 59 show a generalized 
increased AP activity in excised versus non-excised clones.  
 
 
In two A16 excised sub-clones that showed a higher AP activity, the expression of the 
pluripotency markers SSEA1, NANOG and OCT3/4 was analyzed by immunofluorescence. In 
panel A from Figures 60 and 61, the expression of these markers in the A16Ex7 sub-clone is 
shown. Panels B form these two figures correspond to the A16Ex 10 sub-clone, which was also 
positive for the three markers. 
 
 
 
Figure 60. Representative images of the immunofluorescence analysis of the intracellular pluripotency 
marker, NANOG (in texas red) and the correspondent DAPI staining of the nucleus in two selected sub-
clones derived from A16 cBrca2
Δ27/Δ27 
iPSC. A) A16Ex7 sub-clone. B) A16Ex10 sub-clone. 
 
 
Figure 59. Images of AP staining of two representative excised cBrca2
Δ27/Δ27 
iPSC clones, A16Ex7 and 
A16Ex10 obtained in bright field 40x. Cells were cultured over a feeder layer of irradiated MEFs. A) Control 
mESC line B) A16Ex7 cBrca2
Δ27/Δ27 
iPSC clone. C) A16Ex10 cBrca2
Δ27/Δ27 
iPSC clone. 
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- Teratoma formation 
After excision, some of the selected sub-clones were subcutaneously injected into NOD/SCID 
cnull mice to evaluate their ability to generate teratomas. As it happened with non-excised 
cells, tumours appeared one month after injection. 
The results obtained showed that teratomas from the excised A16Ex7 sub-clone, contained 
cells of the three germ layers (Figure 62). Ectodermal structures, such as neuronal rosettes and 
keratinized epithelium, resembling the skin were found in these teratomas (panel A and B of 
Figure 62). Panels C and D in figure 62 correspond to cilial epithelium, either cuboidal or 
stratified with globet cells, similar to the ones present in the respiratory tract with an 
endodermal origin. Mesodermal cells detected in this tumour were a cartilaginous matrix with 
isogeneic groups with pale pink cells inside the matrix and are represented in panels E and F. 
Figure 61. Representative images of the immunofluorescence analysis of the pluripotency markers SSEA1 
(in texas red), OCT3/4 (in FITC) and the correspondent DAPI staining of the nucleus in two selected sub-
clones derived from A16 cBrca2
Δ27/Δ27 
iPSC. A) A16Ex7 sub-clone. B) A16Ex10 sub-clone. 
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2.4.2 MOLECULAR CHARACTERIZATION STUDIES IN EXCISED 
iPSC CLONES  
 
Similarly to the characterization studies performed in iPSCs prior to the excision of the 
reprogramming cassette, we analyzed the expression of pluripotency marker genes, VCN and 
reversion of the disease phenotype in excised clones. 
 
- Study of expression of endogenous pluripotency genes 
After excision of the reprogramming cassette we analyzed the expression of endogenous 
pluripotency genes in A16Ex7 cells compared with a mESC line (mESJ1) as well as with the 
original Brca2MEFs and the only iPSC-like clone that was generated without gene 
Figure 62. Analysis of histologic sections stained with H&E from teratomas generated by A16Ex7 excised sub-
clone. A and B correspond to ectodermal structures. A) neuronal rosettes B) keratinized epithelium. C) and D) 
correspond to endodermal cell types C) Cuboidal cilial epithelium D) stratified cilial epithelium. E and F 
represent cartilaginous matrix that corresponds to a mesodermal structure.  
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correction.  As shown in Figure 63, the excised A16Ex7 clone expressed elevated levels of 
Oct3/4 that were even higher than the levels observed in the control mESC. With respect to 
the other pluripotency genes analyzed, all of them were expressed in these cells, meaning that 
these pluripotency genes had been activated.  
 
 
 
 
- Study of the hypomethylation of the pluripotency gene 
promoters 
 
To verify that the excised iPSCs retained their pluripotency genes hypomethylated we carried 
out methylation analyses of the Oct3/4 and Nanog promoters (as described in materials and 
methods) in A16Ex7 cells. As shown in Figure 64, both Oct3/4 and Nanog promoters were 
hypomethylated in cBrca2Δ27/Δ27 A16Ex7 iPS clone, as it happened in the positive mESC control 
and contrasting with the highly methylation of these promoters in the original Brca2Δ27/Δ27 
MEFs. 
 
Figure 63. Endogenous expression of the pluripotency markers Utf1, Sox2, c-Myc and Klf4 relative to Gapdh 
housekeeping gene expression, in excised A16 cBrca2
Δ27/Δ27 
iPSC cells compared with the mouse ESC line 
mESJ1 and with the expression in the only uncorrected Brca2
Δ27/Δ27 
iPSC that we could generate. 
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2.4.3  GENOMIC STABILITY STUDIES  
Based on the chromosomal instability observed in non-excised clones we studied the ploidy 
and genomic stability in clones selected after excision. 
 
- Ploidy and karyotype analysis 
The analysis of the DNA content in A16Ex7 and A16Ex10 excised sub-clones showed a diploid 
content, similar to the one observed in the control mESC line to the diploid population of 
spleen cells and to the original clone A16.  
 
Figure 64. Analysis of the methylation status in cBrca2
Δ27/Δ27 
iPSC clone A16 performed by the bisulfite 
method. A) Methylation status of the Oct3/4 and Nanog promoters in the original Brca2
Δ27/Δ27 
MEFs. B) 
Methylation status of the Oct3/4 and Nanog promoters in the cBrca2
Δ27/Δ27 
iPS clone A16Ex7 C) 
Corresponds to the methylation status observed in the control mESC line. 
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To investigate if the excision of the reprogramming cassette modified the chromosomal 
stability of the iPSCs, karyotype studies before and after excision, were represented. Figure 66 
represents the chromosomal counts in the non-excised A16clone, as well as in excised A16Ex7 
clone and in another clone with low copy number of the reprogramming vector (A16Ex10). In 
panel A of Figure 66, representative images of the karyotype before excision can be observed 
and Panel B represents chromosomal numbers per cell in A16 clone and in the two excised 
clones (A16Ex7 and A16Ex10). As shown in the figure, A16Ex7 cells showed a normal 
karyotype. 
Figure 65. Analysis of the DNA content of two selected excised sub-clones obtained from A16 
cBrca2
Δ27/Δ27 
iPSCs (A16Ex7 and A16Ex10). Also analyses of the control cell populations are shown. A) 
Control cells consisting of diploid splenocytes; a mouse ESC line; wt iPS cells and the original A16 
clone prior to excision. B) Represents the DNA content of the two excised sub-clones. 
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- Comparative Genomic Hybridization array analysis (aCGH) 
aCGH analyses were performed in wt iPSC and in the A16Ex7 sub-clone to study more in detail 
the chromosomal changes present in these cells. 
Figure 67A represents the aCGH analysis in parental Brca2Δ27/Δ27 MEFs, compared with 
genetically corrected Brca2Δ27/Δ27 MEFs. These analyses revealed a duplication of 0.4 
megabases, located in the cytobands 3qA3 at the genomic coordinates of chr3: 35052807-
35453655. Also, a deletion of 0.46 megabases with 4 genes detected in cytobands 17qA3.3 at 
genomic coordinates of chr17:30586087-31049614. These alterations were observed both in 
Brca2Δ27/Δ27 MEFs prior and also after correction of the genetic defect. 
Figure 67B corresponds to aCGH results obtained in the A16Ex7 sub-clone, compared with 
genetically corrected Brca2Δ27/Δ27 MEFs from which iPSCs were generated. In this case, several 
abnormalities could be observed, such as an amplification of 1.84 megabases detected in 
cytobands 4qD1 that affects chromosome 4 at coordinates 111725814-113561350. Another 
amplification of 0.12 megabases at cytoband 11qB4 at coordinates 70989662-71107244 was 
observed in chromosome 11. There was also a deletion of 0.06 megabases in cytoband 13qD1 
Figure 66. Karyotype study in the cBrca2
Δ27/Δ27 
A16 iPSC clone, and in two excised clones, A16Ex7 and A16Ex10. 
Control populations were, the only uncorrected Brca2
Δ27/Δ27
 iPSC colony, wt iPSCs and the mESC line mESJ1. A) 
Representative image of the karyotype of A16Ex7 iPSC cells. B) Respresents the quantification of chromosomes per 
methaphase. 
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at genomic coordinates of chr13:101149708-101211197. In cytoband 19qA, at genomic 
coordinates of chr19:9227197-9312496, a 0.46 megabase amplification was observed. Finally 
the same deletion previously observed both in uncorrected and corrected Brca2Δ27/Δ27 MEFs 
was observed in chromosome 17 at cytobands 17qA3.3 at coordinates 30586087-31049614, 
indicative of the identity of this iPSC clone.  
Importantly, the results obtained in a wt excised also showed significant numbers of  genomic 
alterations, such as a duplication 16.6 megabase at cytobands 1qG3qH3 and coordinates 
chr1:156776790-173369079; a 23.7 megabase deletion located at 1qH3qH6 of 
chr1:173405837-197141847; and a duplication of 43.9 megabases at cytoband 12qC3qF2 of 
chromosome 12 at cordinates of 77339996-121241789. 
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Figure 67. Comparative whole genome gene hybridization in uncorrected and gene corrected Brca2
Δ27/Δ27 
MEFs and 
corrected Brca2
Δ27/Δ27 
iPSCs compared to wt MEFS, considered as a reference population. A) Similar genetic aGCH 
footprint in uncorrected and gene-corrected Brca2
Δ27/Δ27 
MEFs. B) Additional genetic alterations in cBrca2Δ27/Δ27 iPSCs 
with respect to parental cBrca2
Δ27/Δ27 
MEFs. C) Genetic alterations in wt cells.  
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2.5 CHARACTERIZATION OF THE FANCONI ANEMIA 
PHENOTYPE REVERSION IN cBrca2 Δ27/Δ27 iPSC  
Additional phenotype analyses of gene corrected Brca2Δ27/Δ27 iPSCs were investigated to verify 
that the FA phenotype characteristic of Brca2Δ27/Δ27 cells had been reverted after gene therapy 
and cell reprogramming.  
- BRCA2 expression 
To analyze if Brca2Δ27/Δ27 MEFs that had been transduced with the therapeutic BRCA2 LV had 
reverted the FA phenotype, we analyzed the expression of BRCA2 protein by RTq-PCR. 
Additionally, BRCA2 expression was investigated in corrected Brca2Δ27/Δ27 iPSCs, prior and after 
excision of the reprogramming cassette. Our results showed that, in contrast to the null 
hBRCA2 expression observed in the original uncorrected MEFS, hBRCA2 expression could be   
detected both in corrected MEFs and in derived iPSCs. 
 
 
 
- Re-establishment of the capacity to generate RAD51 foci 
after DNA damage 
To determine if BRCA2 was functional in corrected Brca2Δ27/Δ27 MEFS, the capacity of these cells 
to recruit RAD51 to DNA repair foci after DNA damage, induced by mitomycin C (MMC) was 
investigated. Figure 69 shows representative images of RAD51 foci formation revealing that, 
while uncorrected Brca2Δ27/Δ27 MEFs were not able to form RAD51 foci (only a basal percentage 
of 5 % was detected),  corrected cells showed a restored capacity to recruit RAD51 to the DNA 
repair foci. In genetically corrected MEFs and iPSCs, 60 % of the cells generated RAD51 foci 
Figure 68. RT-qPCR analysis of hBRCA2 expression relative to Gapdh, in cBrca2
Δ27/Δ27 
MEFs and cBrca2
Δ27/Δ27 
iPSCs, 
before and after excision (A16 and A16Ex7 respectively). Uncorrected Brca2
Δ27/Δ27 
MEFs were used as a control 
cell population. 
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after MMC exposure. This value was similar to the percentage of wt cells with RAD51 foci, 
confirming the functionality of BRCA2 both in corrected Brca2Δ27/Δ27 MEFS and in corrected 
iPSCs. 
 
 
 
 
 
 
Figure 69. RAD51 foci in cells exposed to 40nM MMC treatment. The white bar corresponds to wt MEFs. 
Coloured bars correspond to uncorrected and corrected MEFs and to corrected Brca2
Δ27/Δ27 
iPSCs, prior to and 
after excision of the reprogramming provirus.  
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- Analysis of the chromosomal stability of corrected Brca2Δ27/Δ27 
iPSCs to diepoxibutane  
In these experiments we wanted to evaluate if corrected Brca2Δ27/Δ27 iPSCs had reverted the 
chromosomal instability generated by DNA ICL drugs, a characteristic phenotype of FA cells.  
Chromatidic breakages, chromosomal fragmentations as well as radial fragmentations were 
quantified in the uncorrected iPSCs-like clone that was generated (positive control) and in the 
excised cBrca2Δ27/Δ27 A16Ex7 iPSC clone. Figures 70 A and C show that excised cBrca2Δ27/Δ27 
A16Ex7 iPSC clone had less chromatidic breakages and radial fragmentations than uncorrected 
iPSCs. The number of chromosomal fragmentations detected in the excised clone was also 
lower than the one observed in uncorrected iPSCs (Figure 70 B). These results show that the 
chromosomal instability of A16Ex7 iPSCs was significantly reduced in corrected versus 
uncorrected iPSCs, thus demonstrating the reversion of the FA phenotype, characteristic of 
cBrca2Δ27/Δ27 cells. 
 
 
 
 
 
 
 
 
 
Figure 70. Chromosomal stability upon exposure to DEB in excised Brca2Δ27/Δ27 A16Ex7 iPSCs compared with 
uncorrected Brca2Δ27/Δ27 iPSCs. A) Chromatidic breakages B) Chromosomal fragmentations and C) Radial 
fragmentations. Error bars correspond to standard error and * to p< 0.05. 
 
- The reprogramming of genetically corrected Brca2Δ27/Δ27 MEFs with a polycistronic excisable 
lentiviral reprogramming vector restored the FA/BRCA pathway and generated bona fide iPSCs after 
the complete excision of the reprogramming cassette. 
 
-  At late passage numbers only one clone maintained a diploid karyotype. Even in this clone, several 
chromosomal anomalies were revealed by CGH analysis. Thus, high chromosomal instability was 
associated to the obtainment of cBrca2Δ27/Δ27 iPSCs which could be due either to the reprogramming 
process, to the in vitro culture of the iPSCs, or to the excision of the reprogramming cassette. 
 
- Gene corrected and excised bona fide Brca2Δ27/Δ27 iPSCs were characterized by a FA reverted 
phenotype.  
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3. ESTABLISHMENT OF HEMATOPOIETIC 
DIFFERENTIATION PROTOCOLS FROM 
cBrca2Δ27/Δ27 CELLS 
 
One of the objectives proposed in this work was to investigate different sources of HSCs once 
we obtained phenotypically corrected Brca2Δ27/Δ27 iPSCs. For this reason we focused on the 
differentiation of these disease-free pluripotent cells to restore the hematopoietic system of 
sub-lethally irradiated Brca2Δ27/Δ27 mice. 
Previous to the performance of hematopoietic differentiation protocols in iPSCs, different 
protocols were established using mESCs. These protocols allowed the determination of the 
optimal conditions and timing for the different steps needed to go through during the in vitro 
hematopoietic differentiation (MOLEIRO, 2010). The in vitro hematopoietic differentiation 
protocols developed, tried to reproduce protocols already established by other groups 
(Lesinski et al., 2012) (Ledran et al., 2008), introducing modifications to adapt them to the cells 
that we were using. These protocols were based on the use of cytokine cocktails and co-
culture over hematopoietic derived stromas. 
First, we evaluated in mESCs the effect of the cell culture medium and cytokine addition on the 
hematopoietic differentiation of the cells, the best method for EB and the kinetics of 
expression of a higher percentage of mesodermal markers, to establish the time point at which 
they had to be dissociated to continue with the differentiation (MOLEIRO (2010).  
Once we observed that we could obtain specific hematopoietic markers after the 
differentiation of mESCs, we carried out in vitro and hematopoietic differentiation protocols in 
cBrca2 iPSCs and we then evaluated the capacity of those in vitro differentiated cells to 
repopulate the hematopoietic system in an in vivo context. 
3.1 IN VITRO HEMATOPOIETIC DIFFERENTIATION OF 
CORRECTED Brca2Δ27/Δ27 iPSCs  
 
Several attempts were performed trying to differentiate mESC and cBrca2 iPSCs towards the 
hematopoietic lineage, based on the generation of EBs and the sequential addition of 
hematopoietic cytokines to the co-cultures on hematopoietic stromas. Stromas were either 
obtained from bone marrow (OP9 cells) or from the embryonic region aorta gonada 
mesonephros (AGM -AM20.4). Prior to co-culture, iPSCs were transduced with LIM homeobox 
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transcription factor HOXB4 known to contribute to the in vitro and in vivo expansion of 
hematopoietic differentiating cells. In Table 10 the different hematopoietic differentiation 
methods used are described. 
- Hematopoietic differentiation of iPSCs based on the 
transduction with HOXB4 -RV and co-cultures with 
hematopoietic stromas (OP9 cells) 
 
 
 
  
 
 
 
The hematopoietic differentiation protocol shown in Figure 71 was performed in gene-
corrected cBrca2Δ27/Δ27 iPSCs (A16Ex7), control mESCs (mESJ1) and wt iPSCs. Cells transduced 
with HOXB4.2aGFP-RV were used for EBs generation. Thereafter, mesodermal differentiation 
was induced by the sequential addition of BMP4 for two days, and then to the hematopoietic 
lineage with activin A, VEGF, TPO and SCF. EBs were maintained for six days, after which they 
were dissociated and co-cultured on OP9 hematopoietic stromas for 10 days. During OP9 co-
culture the same hematopoietic cytokines were added to the medium, only replacing activin A 
for Flt3 to induce a more differentiated stage of the cells. 
After 10 days of hematopoietic differentiation, cells were analyzed by FACS for the expression 
of CD41, CD34, CD45 and c-Kit. As shown in the representative experiment of Figure 72, the 
Figure 71. Schematic protocol to differentiate iPSCs towards the hematopoietic system based on the 
transduction with HOXB4, the generation of EBs and co-cultures on OP9 stromas.  
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expression of hematopoietic markers in iPSCs, both wt and cBrca2Δ27/Δ27 was more modest, 
than the expression obtained in mESJ1 cells. We also observed that, among the cells that 
expressed hematopoietic markers only a small fraction of them was double positive for HOXB4 
and for hematopoietic markers. We can highlight the high proportion of CD41+ cells (47.61 %) 
obtained after the differentiation of mESCs from which 13.91 % corresponded to HOXB4+ cells. 
Within these cells we found cells positive for other markers such as CD45, c-kit and CD34 that 
ranged from 10 to 15 %. In the case of A16Ex7 iPSCs, a 5.5 % of these cells were CD41+, most of 
which were negative for HOXB4. In the case of CD34 marker, a relatively high proportion of 
CD34+ cells (30 %) was observed. In wt iPSC a 3.9 % CD41+ cells was obtained, again most of 
them negative for HOXB4 and around 15 % c-kit+ and CD34+.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72. Representative hematopoietic differentiation experiment showing the expression of hematopoietic markers 
from iPSCs and mESC. Experiments were performed with mESJ1 cells, wt iPSCs and cBrca2 iPSC (A16Ex7). A. 
Representative images of day 6 embryo bodies generated from A16Ex7 iPSCs expressing HOXB4. B. Percentage of cells 
positive for differentiation markers (white bars) and both for differentiation markers and HOXB4/EGFP (black bars) and C. 
Histograms of FACS analysis in which the expression of different hematopoietic differentiation markers was analyzed.  
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- Hematopoietic differentiation of iPSCs by co-cultures on 
aorta-gonada mesonephros (AGM) stromas 
 
With the objective of improving the hematopoietic differentiation of the iPSCs we tested 
another protocol based on the co-culture of the cells with stromas derived from the aorta-
gonada-mesonephros region (AGM), as described in materials and methods.  
We performed this experiment in A16Ex7 iPSC clone and in the control cell line (mESJ1). EBs 
were generated by natural aggregation, and sequential addition of cytokines, to induce 
differentiation to mesoderm (BMP4) followed by hematopoietic cell induction with FGF, activin 
A and VEGF. After 6 days, EBs were dissociated and co-cultured on the AGM derived stromas 
(AM.20) cells.   
During the differentiation process, different hematopoietic markers were analyzed at day 21 of 
differentiation. Representative data shown in Figure 73, illustrate that the marker expression 
was very low, both in mESJ1 (between 0-4%) and in A16Ex7 cells (between 0 and 2%). 
       
 
Figure 73. Flow cytometry 
analysis of cBrca2 iPSC 
derived embryo bodies, co-
cultured with aorta-gonada 
mesonephros (AGM) 
stromas at day 21 after 
embryo body generation.  
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3.2  IN VIVO HEMATOPOIETIC REPOPULATING 
ABILITY OF iPSC-DERIVED HEMATOPOIETIC 
PROGENITORS OBTAINED IN VITRO  
 
To investigate if A16Ex7 cBrca2derived cells could generate functional HSCs, able to 
reconstitute the hematopoiesis of Brca2recipients, one million cells, derived from wt 
iPSC and from A16Ex7 cBrca2iPSCs (day 10 of in vitro differentiation) were transplanted 
in each recipient mouse.   
As shown in Figure 74, only very low levels of exogenous reconstitution could be detected at 
day 15 post-injection.  
 
 
 
 
Figure 74. Representation of the percentage of chimerism observed in the in vivo differentiation protocol based on 
intravenous injection of EB-derived differentiated cells into sub-lethally irradiated Brca2

mice. The upper 
panel corresponds to the analysis performed in peripheral blood from the mice injected with wt iPSC derived cells 
and the two lower panels correspond to blood from the mice injected with A16Ex7 iPSC derived cells. 
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- These results show that either mESCs, wt iPSCs or cBrca2Δ27/Δ27 iPSCs can be differentiated 
towards the generation of cells expressing characteristic hematopoietic markers. However, a more 
modest hematopoietic differentiation was observed in iPSC-derived cells, as compared with mESC-
derived populations.  
 
- The transplantation of cBrca2Δ27/Δ27 iPSC-derived populations into irradiated Brca2Δ27/Δ27 mice, did 
not result in significant hematopoietic engraftments, at least under the experimental conditions 
used in these studies. 
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VII. DISCUSSION 
The discovery made by Shinia Yamanaka and colleagues in 2006 in which pluripotency was 
induced in adult somatic cells, unwinding their genetic program towards an embryonic stem 
cell-like stage (Takahashi et al., 2007) (Yamanaka and Takahashi, 2006) (Yu et al., 2007), 
opened a new horizon that is facilitating the understanding of the physiological processes 
involved in the differentiation, of healthy cells as well as in different disease models. Cell 
reprogramming is also helping to develop new potential therapeutic approaches based on 
gene and cell therapy (Daley, 2007) (Tiscornia et al., 2011). Along these years, many advances 
have been achieved in which different pluripotency induction techniques were developed to 
increase the efficiency and the safety of cell reprogramming and to unveil the molecular 
processes underlying reprogramming (Banito et al., 2009) (Batista et al., 2011) (Fong et al., 
2011) (Hong et al., 2009; Li et al., 2009; Marion et al., 2009; Muller et al., 2012a; Raya et al., 
2009; Utikal et al., 2009; Yung et al., 2013).  
In the field of FA, the FA pathway actively participates in DNA repair after the generation of 
deleterious lesions during replication and after DNA damage with genotoxic agents. As already 
exposed in the introduction, the principal function of the FA pathway is to maintain the 
integrity of the genome. In particular, members of the lower part of the FA pathway constitute 
the key players in HDR, while proteins of the core and I-D complex mainly participate at the 
initial steps of the DNA damage response. 
The main limitation for the development of gene therapy protocols in FA is the scarcity of 
hematopoietic stem cells in the bone marrow of these patients, the target population to 
perform gene therapy. A previous collaborative work of our group with CMRB and the 
Autonoma University of Barcelona, showed for first time the possibility of generating disease-
free hematopoietic progenitors from skin cells obtained from FA patients, of the FA-A and FA-
D2 complementation groups (Raya et al., 2009). Other studies have also shown the 
reprogramming of human and mouse cells from the FA-A and FA-C complementation groups 
(Ledran et al., 2008; Tulpule et al., 2010). 
However, the role of BRCA2 in cell reprogramming had not been investigated so far, despite its 
important participation in DNA repair by HDR. Thus, to understand the involvement of HDR in 
cell reprogramming we took advantage of the Brca2Δ27/Δ27 mouse model, that is one of the 
models that better recapitulates the phenotype of FA patients (McAllister et al., 2002b; 
Navarro et al., 2006). This issue, together with the possibility of having an in vivo model of FA 
iPSC-derived cell and gene therapy, tempted us to explore the possibility of restoring the 
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hematopoietic system of these animals, by the transplantation of disease-free Brca2 
iPSC-derived HSCs.   
 
1. INVOLVEMENT OF FANCA AND BRCA2 IN CELL 
REPROGRAMMING 
  
In a first instance we were interested in discerning the involvement of these two FA proteins, 
FANCA and BRCA2 in the process of somatic cell reprogramming to generate iPSCs.   
As previously observed in human FA-A cells, our results showed that only after gene 
complementation, iPSCs could be generated and maintained (Raya et al., 2009). As we 
observed in a mouse model deficient in Fanca (Cheng et al., 2000), iPSC-like starting colonies 
arose without correction of the genetic defect, but only one iPSC colony could be maintained, 
which is in agreement with our previous studies in which FANCA was needed to preserve 
human FA-A iPSC colonies in vitro (Raya et al., 2009).  With respect to the relevance of FANCA 
in cell reprogramming, Müller et al. described that FA-A cells were resistant, but not 
completely refractory to be reprogrammed (Muller et al., 2012a), since uncorrected iPSCs 
could be obtained using low oxygen concentrations. Lako et al. also confirmed the relevance of 
FA proteins from the FA core-complex in cell reprogramming (Ledran et al., 2008). 
The stronger phenotype observed in FA-D1 patients when compared with patients 
corresponding to other complementation groups led us think that BRCA2 could have a more 
relevant implication in cell reprogramming as compared to other FA proteins.  
The generation of iPSC clones from Fanca-/- and Brca2cells by transduction of the four -
RVs described by Yamanaka (Takahashi et al., 2007), showed that only after cell correction 
with the therapeutic vectors (PGK-hFANCA-Wpre for Fanca-/- cells and PCL1-BRCA2 for 
Brca2 cells) iPSC-like colonies could be established.  
Considering that the use of four independent vectors to reprogram FA cells might have 
collaborated to the low efficiency of reprogramming, we used embryonic fibroblasts and an 
excisable polycistronic vector (Sommer et al., 2012a) to increase the efficiency of the process. 
However, once again an extremely low reprogramming efficacy of Brca2 hypomorphic 
cells was observed, that prevented the generation of any iPSC colony. In contrast with this 
observation, a significant number of Fanca-/- iPSCs could be generated. The observation that 
Brca2 is critical for the generation of iPSCs, together with publications showing the 
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involvement of Brca2 with HDR and cell reprogramming (Banito et al., 2009; Blasco et al., 
2011; Marion and Blasco, 2010; Marion et al., 2009) allowed us to propose the involvement of 
HDR in iPSC generation (Navarro et al., 2014).  
The analysis of the capacity of Fanca-/- and Brca2 cells to recruit RAD51 to the DNA repair 
foci (Esashi et al., 2007) during cell reprogramming revealed that Fanca deficient cells were not 
impeded in their capacity to activate HDR, in contrast with the impossibility observed in 
Brca2cells. Upon correction of the genetic defect, either simultaneously or previous to 
reprogramming, Brca2 cells had restored their ability to respond to the DNA damage 
caused by the reprogramming process. This functional test further supported that HDR was 
induced during the reprogramming process. 
The correction of the genetic defect in Brca2cells allowed us to efficiently generate 
disease-free iPSC colonies that had restored their capacity to recruit RAD51 protein to the DNA 
repair foci, supporting again that a correct HDR function is needed during cell reprogramming 
and that Brca2 gene is essential in this process (Gonzalez et al., 2013). 
This conclusion was highly consistent with the results obtained by other authors that published 
these data in parallel with our observations (Gonzalez et al., 2013). The important role of 
BRCA2 protein and its homologous protein from other organisms in cell reprogramming, 
oogenesis, telomere maintenance and response to genotoxic substances or pathogen 
infections (Badie et al., 2010; Dumont et al., 2011; Rodriguez-Mari et al., 2011; Singh et al., 
2012; Wang et al., 2010; Wang and Dai, 2006), supports the importance of this highly 
conserved protein in stress and DNA damage response. 
Several studies have stressed the involvement of cellular senescence episodes or P53 
overexpression, to be directly related with the low efficiency of reprogramming. Due to these 
observations we decided to study if the low efficiency of reprogramming observed in 
Brca2 cells could be due to increased apoptosis. The study of the level of apoptosis 
induction during the early stages of reprogramming revealed that there was an increase in 
early and late apoptosis in Brca2cells. It is at these stages when the silencing of tissue 
specific genes takes place to activate their endogenous pluripotency genes (Brambrink et al., 
2008), and it constitutes a period that is critical for the generation of iPSCs (Banito et al., 
2009). Our observation of increased apoptosis during the reprogramming of Brca2cells 
contrasts with the results obtained by Gonzalez who did not observe any increase in the 
apoptosis of the same cell type during cell reprogramming. In contrast to our study, these 
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authors analysed apoptosis induction at much later stages after cell reprogramming (Gonzalez 
et al., 2013).  
The use of FA cells to study cell reprogramming made possible to understand how this DNA 
repair pathway influences the process of iPSC generation, being at least partially responsible 
for the low efficiency that characterizes this process in FA cells.  
 
2. GENERATION AND CHARACTERIZATION OF BONA FIDE 
CORRECTED Fanca-/- AND Brca2 iPSC 
 
Once we studied the importance of FANCA and BRCA2 proteins in cell reprogramming, our 
next interest was the generation of bona fide gene corrected Brca2 iPSCs. We explored 
different methods to increase the efficiency and safety of reprogramming. 
The phenotypic characterization of the iPSCs cells generated by transduction with the four -
RVs, revealed that iPSC-like cells generated from corrected Fanca-/- and Brca2 cells 
fulfilled most of the phenotypic criteria to be bona fide iPSCs, in terms of pluripotency marker 
expression and teratoma formation capacity. In Fanca-/- corrected cells we observed that the 
expression of the SSEA1 and OCT3/4 pluripotency markers was higher than that observed in 
corrected Brca2 iPSC, although both Fanca-/- and Brca2 corrected iPSCs generated 
teratomas (Takahashi et al., 2007). 
Due to our interest in exploring the role of Brca2 in reprogramming we decided to continue 
the molecular characterization of the iPSC clones generated from this model. The study of the 
expression of the endogenous pluripotency genes revealed that most of the clones expressed 
nearly undetectable levels of these markers, in contrast with the high endogenous expression 
observed in the control mouse ESC line. On the other hand, the exogenous expression of these 
genes was very high in the clones that were analyzed. These analyses showed that iPSC clones 
generated by -RV transduction were not fully reprogrammed, despite the generation of 
teratomas in immunodeficient mice. This phenomenon could be due to a persistent over-
expression of the exogenous pluripotency factors that could be limiting the reactivation of the 
endogenous machinery (Ji et al., 2013). Another possibility could be that not all the cells had 
integrated the four reprogramming factors. The recently reported requirement of telomere 
reprogramming, simultaneous to the induction of pluripotency, to achieve a correct 
  Discussion 
145 
 
maintenance of iPSCs (Ji et al., 2013) could be another cause of the incomplete reprogramming 
of the cells, although we did not study the telomere status in cBrca2 iPSCs. 
The characterization of iPSC cells generated from cBrca2 mouse embryonic fibroblasts 
(MEFs) by transduction with an excisable polycistronic lentiviral vector (Sommer et al., 2012a) 
revealed that the selected clones fulfilled the criteria of iPSCs in terms of morphology and 
pluripotency (Takahashi et al., 2007). However, unless the reprogramming cassette was 
excised, teratomas were not generated, but only undifferentiated tumoral masses, probably 
generated due to the exacerbated and permanent expression of the reprogramming factors,  
such as c-Myc  (Deb-Basu et al., 2006).  
At early passages, many of the clones were diploid. However, most of them became polyploid 
at later passages, probably due to the acquisition of new copy number variations and other 
genetic abnormalities that led to changes in the genetic content of the cells, as also reported 
both in mouse (Gonzalez et al., 2013) and human iPSC lines (Mills et al., 2013). 
Since the generation of iPSCs from genetically corrected Brca2cells was based on the use 
of a reprogramming cassette that could be removed with the Cre-recombinase, (Sommer et 
al., 2012b), we excised it to prevent that a residual expression of the reprogramming genes 
could be affecting the epigenetic print of the pluripotency genes (Sommer et al., 2012b) and 
thus, the ability of non-excised iPSCs to generate teratomas (Ji et al., 2013).  
RT-qPCR and Southern Blot studies showed that the excision of the reprogramming vector with 
an integrase deficient LV harbouring the Cre recombinase (IDLV) did not allow a complete 
removal of the reprogramming cassette (Banasik and McCray, 2010) (Sommer et al., 2012b). 
The re-excision based on the delivery of the Cre-recombinase enzyme directly into the target 
iPSCs, allowed us to remove the reprogramming vector to undetectable levels. After this re-
excision, several clones of corrected Brca2iPSCs showed morphological and phenotypic 
characteristics of bona fide iPSCs (Takahashi et al., 2007), conserved a stable karyotype and at 
this point they were able to form teratomas. These observations are consistent with the 
hypothesis that a residual activity of exogenous reprogramming genes could interfere with the 
expression of the endogenous pluripotency genes required for the complete reprogramming 
of the cells (Sommer et al., 2012b) (Ji et al., 2013). In this respect, since the expression of c-
Myc is only required during the initial steps of cell reprogramming (Sridharan et al., 2009), the 
removal of this gene might have been critical to facilitate the generation of teratomas, instead 
of rapidly growing tumoral masses.  
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The excised clones that better fulfilled the bona fide iPSC criteria were the ones in which a 
lower Nanog expression had been observed before excision. This is consistent with the 
previously commented notion that the long-term expression of the exogenous pluripotency 
factors could interfere with the activation of the endogenous pluripotency machinery (Sommer 
et al., 2012b). In fact, our observations showed that once the reprogramming vector was 
excised, a high expression of the endogenous pluripotency genes Oct3/4 and Utf1, as well as a 
significant expression of Klf4 and c-Myc, was observed. In agreement with other observations 
that reported that the endogenous Oct3/4 and Nanog promoters should be hypomethylated 
when the endogenous pluripotency machinery is active (Polo et al., 2012), we observed that 
these promoters were strongly hypomethylated in the A16Ex7 clone after excision, in contrast 
to the methylation status of these genes in parental mouse embryonic fibroblasts (Sommer et 
al., 2012b).  
Karyotype studies performed after excision revealed that all the excised clones had an 
abnormal karyotype except cBrca2A16Ex7 iPSC clone that maintained a normal 
karyotype even after extensive passage numbers. In this clone we observed that after excision 
all the cells that were analyzed were diploid, while before excision a little deviation in ploidy 
was observed. The explanation to this observation could underlay in the possibility of the 
preferential survival of karyotypically normal cells as recently described by Bershteyn in human 
cells (Bershteyn et al., 2014). 
In spite of the normal karyotype of the excised cBrca2 iPSC clone, a deeper study of the 
genome of these cells, by Comparative Genomic Hybridization arrays (aCGH), showed 
chromosomal abnormalities that were not present either in parental Brca2MEFs or in 
corrected MEFs (cBrca2. We cannot discern whether these defects were due to the  
reprogramming process or to the preferential expansion of an abnormal starting cell 
population during iPSC culture, as other authors have described (Blasco et al., 2011; Hussein et 
al., 2011; Laurent et al., 2011; Lister et al., 2011; Mayshar et al., 2010; Pasi et al., 2011; Young 
et al., 2012). Additionally the excision process might also have had a role in these observations. 
Despite these chromosomal abnormalities, the selected cBrca2 iPSC clone did not show 
the characteristic FA phenotype (Rio et al., 2008). We observed that this clone efficiently 
expressed the human BRCA2 gene, and also recovered the capacity to recruit RAD51 to the 
DNA repair foci, meaning that the FA pathway was functional and that homology directed 
repair worked properly in these cells. 
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An additional confirmation of the functional correction of cBrca2  iPSCs was deduced 
from the increased genomic stability of cBrca2A16Ex7 iPSC clone after DNA damage with 
diepoxybutane (DEB).  
 
3. EVALUATION OF HEMATOPOIETIC DIFFERENTIATION IN 
CORRECTED Brca2 iPSC  
The last part of our work consisted of the evaluation of the hematopoietic differentiation 
ability of corrected Brca2Δ27/Δ27 iPSCs, with the final objective of exploring their potential 
therapeutic use in Brca2Δ27/Δ27 mice.  
Several hematopoietic differentiation protocols were performed in our studies. Most of the 
existing in vitro hematopoietic differentiation protocols are based on the transduction with 
hematopoietic progenitor cell-promoting transcription factors from the LIM homeobox family, 
such as HOXB4 (Bonde et al., 2008) (Chan et al., 2008) (Hanna et al., 2007) (Pilat et al., 2005), 
Cdx (Wang et al., 2005) or LHX2 (Kitajima et al., 2013). In these protocols, the hematopoietic 
differentiation is completed by co-culture over hematopoietic tissue-derived stromas, such as 
OP9 or aorta-gonada-mesonephros (AGM) stromas.  
The hematopoietic differentiation of our cBrca2Δ27/Δ27 iPSCs based on transduction with HOXB4 
(Bonde et al., 2008) (Chan et al., 2008; Hanna et al., 2007; Lesinski et al., 2012; Pilat et al., 
2005) and followed by co-cultures with OP9 or AGM derived stromas, allowed us to obtain 
cells with a modest hematopoietic phenotype. We found that the hematopoietic 
differentiation observed in these co-cultures was not efficiently reproduced in the different 
experiments conducted in our laboratory.  
In our hands, the protocol based on transduction of iPSCs with HOXB4, followed by embryo 
body generation and co-culture on OP9 stromas was one of the most efficient ones in 
promoting hematopoietic differentiation. This protocol showed that wt and cBrca2Δ27/Δ27 
A16Ex7 iPSCs became positive for hematopoietic markers of different stages of hematopoiesis. 
However, only a very small proportion of these cells were double positive for the 
hematopoietic markers and HOXB4 (Bonde et al., 2008; Chan et al., 2008; Pilat et al., 2005). In 
contrast, in mESC the percentage of cells that were double positive for both hematopoietic 
markers and HOXB4 was significantly higher. Some promoter interference could be occurring 
within the HOXB4 -RV, that did not allow the efficient expression of the second protein of the 
construction (eGFP) (Zhou et al., 1998) despite the efficient initial transduction of the cells. 
However, since the outcome of hematopoietic differentiation is highly dependent on the iPSC 
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clone, and given that we did not select a cell clone that stably expressed HOXB4 (Lesinski et al., 
2012), we cannot assure that a vector silencing process had occurred in our cells.  
The hematopoietic differentiation obtained in co-cultures with AGM stromas, both in mESC 
and in cBrca2Δ27/Δ27 A16Ex7 iPSCs clone, showed percentages of expression of primitive 
hematopoietic markers under 4 %, either in mESC or in cBrca2Δ27/Δ27 A16Ex7 iPSCs clone. In our 
hands, this procedure did not result to be an efficient hematopoietic differentiation system in 
mouse cells, as Ledran proposed for human embryonic stem cells (Gordon-Keylock et al., 2010; 
Ledran et al., 2008). 
In humans, in vitro hematopoietic differentiation of ESC and iPSC has been shown to be more 
efficient and has advanced more rapidly. Nowadays, a relatively efficient production of 
hematopoietic cells from healthy donors and patient cells has been achieved (Ramos-Mejia et 
al., 2012; Schenke-Layland et al., 2008; Woods et al., 2011) (Jiang et al., 2012; Raya et al., 
2009; Xu et al., 2012)(Kyba et al., 2002) (Amabile et al., 2013; Daley, 2007; Suzuki et al., 2013). 
However, the efficient engraftment of iPSC-derived HSCs into sub-lethally irradiated mice 
remains challenging (Kaufman, 2009), (Kennedy et al., 2007; Ledran et al., 2008) (Zambidis et 
al., 2008) (Klimchenko et al., 2009).  
Our interest on evaluating the repopulating ability of in vitro differentiated cBrca2Δ27/Δ27 iPSCs 
cells was based on the results obtained in a mouse model of sickle cell anemia (Hanna et al., 
2007) (Kitajima et al., 2011). However, in contrast with the results obtained by these authors, 
the transplant of cBrca2Δ27/Δ27 A16Ex7 iPSCs-derived cells into sub-lethally irradiated 
Brca2Δ27/Δ27 mice did not result in any significant engraftment of the cells.  More recently, 
Müller and collaborators generated chimeras in which contribution of the iPSC-derived cells to 
fetal liver was observed, showing the potential of these cells to reconstitute a hematopoietic 
system in vivo (Muller et al., 2012a). However, in this study, the long-term hematopoietic 
differentiation in the chimeric animals was not analyzed.  
Several publications have recently arisen, in which the hematopoietic differentiation capacity 
of iPSCs was said to be conditioned by the expression or repression of factors involved in the 
regulation of the differentiation process. For example, it has been shown that BRD4 regulates 
c-Myc expression during hematopoietic differentiation (Rodriguez et al., 2014). Similarly, A20 
was shown to be essential for hematopoietic development (Nagamachi et al., 2014Nagamachi 
et al., 2014). Some of these proteins that interact with related signalling pathways could 
account for the blockage of the differentiation process of iPSCs. The hematopoietic 
differentiation of mESCs or iPSCs seems to be highly dependent on the cellular line. 
  Discussion 
149 
 
Additionally, the reprogramming process, together with the elevated genomic instability 
observed in iPCS cells currently limits the generation of iPSC clones for hematopoietic 
therapeutic purposes.  
Our study in a relevant disease mouse model has shown that iPSC differentiation is an 
inefficient process in which the generation of hematopoietic stem cells (HSC) as a new source 
of cells, to be used for the hematopoietic reconstitution of FA recipients is still an objective to 
be achieved. More efficient in vitro culture systems that may mimic the physiological 
conditions should be developed (Park et al., 2011). 
Taken together, our studies of gene therapy and cell reprogramming of Brca2iPSCs have 
shown new achievements and also current limitations in the application of reprogramming 
approaches in hematopoietic stem cell therapies.   
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VIII. SUMMARY OF RESULTS 
1. The FANCA/BRCA pathway plays an important role in the process of cell reprogramming, 
being BRCA2 critical for the generation of mouse iPSCs.  
 
2. The process of cell reprogramming activates the homology directed DNA repair, measured 
by the recruitment of RAD51 to DNA repair foci in response to cell reprogramming.  
 
3. Increased apoptosis during the first stages of cell reprogramming should account, at least in 
part, for the limited reprogramming of Brca2Δ27/Δ27cells.  
 
4. Gene complementation of Brca2Δ27/Δ27 cells restores the capacity of these cells to recruit 
RAD51 to DNA repair foci and allows the reprogramming of these cells.  
 
5. The transduction of genetically corrected Brca2Δ27/Δ27 fibroblasts with four gamma-retroviral 
vectors carrying the Oct4, Sox2, Klf4 and c-myc reprogramming genes was unable to 
generate bona fide iPSCs. 
 
6. The transduction of genetically corrected Brca2Δ27/Δ27 fibroblasts with a polycistronic 
lentiviral reprogramming vector efficiently generated iPSCs-like cells. 
 
 
7. At late passage numbers only one clone maintained a diploid karyotype, although 
contained several chromosomal anomalies, as revealed by CGH analysis. Thus, a high 
chromosomal instability was associated to the generation of corrected Brca2Δ27/Δ27 iPSCs.   
 
8. The reprogramming of genetically corrected Brca2Δ27/Δ27 fibroblasts with a polycistronic 
excisable lentiviral reprogramming vector, followed by the complete excision of the 
reprogramming cassette generated bona fide iPSCs with a disease-free phenotype. 
 
9. In vitro hematopoietic differentiation protocols based on iPSC transduction with HOXB4, 
followed by embryo body generation and co-cultures over hematopoietic stromas, 
modestly differentiated cBrca2Δ27/Δ27 iPSCs towards the hematopoietic system.   
 
10. In vitro differentiated cells from cBrca2Δ27/Δ27 iPSC were not able to engraft into irradiated 
Brca2Δ27/Δ27 mice, indicating a deficient generation of hematopoietic repopulating cells in 
these cultures.   
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IX. CONCLUSIONS 
Our study in a model defective in HDR supports that: 
 
1. Fanconi anemia/BRCA pathway actively participates in the process of cell reprogramming 
activating the homology directed repair mechanism through BRCA2. 
 
2. Stem cell therapy applications based on combined gene therapy with cell reprogramming 
requires improvements to enhance the genetic stability and the in vivo repopulating 
properties of iPSC-derived cells. 
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